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A B S T R A C T
Background
Early accurate detection of all skin cancer types is essential to guide appropriate management, reduce morbidity and improve survival.
Basal cell carcinoma (BCC) is usually localised to the skin but has potential to infiltrate and damage surrounding tissue, while cutaneous
squamous cell carcinoma (cSCC) and melanoma have a much higher potential to metastasise and ultimately lead to death. Exfoliative
cytology is a non-invasive test that uses the Tzanck smear technique to identify disease by examining the structure of cells obtained from
scraped samples. This simple procedure is a less invasive diagnostic test than a skin biopsy, and for BCC it has the potential to provide
an immediate diagnosis that avoids an additional clinic visit to receive skin biopsy results. This may benefit patients scheduled for either
Mohs micrographic surgery or non-surgical treatments such as radiotherapy. A cytology scrape can never give the same information as
a skin biopsy, however, so it is important to better understand in which skin cancer situations it may be helpful.
Objectives
To determine the diagnostic accuracy of exfoliative cytology for detecting basal cell carcinoma (BCC) in adults, and to compare its
accuracy with that of standard diagnostic practice (visual inspection with or without dermoscopy). Secondary objectives were: to
determine the diagnostic accuracy of exfoliative cytology for detecting cSCC, invasivemelanoma and atypical intraepidermalmelanocytic
variants, and any other skin cancer; and for each of these secondary conditions to compare the accuracy of exfoliative cytology with
visual inspection with or without dermoscopy in direct test comparisons; and to determine the effect of observer experience.
Search methods
We undertook a comprehensive search of the following databases from inception up to August 2016: Cochrane Central Register of
Controlled Trials; MEDLINE; Embase; CINAHL; CPCI; Zetoc; Science Citation Index; US National Institutes of Health Ongoing
Trials Register; NIHR Clinical Research Network Portfolio Database; and the World Health Organization International Clinical Trials
Registry Platform. We also studied the reference lists of published systematic review articles.
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Selection criteria
Studies evaluating exfoliative cytology in adults with lesions suspicious for BCC, cSCC or melanoma, compared with a reference
standard of histological confirmation.
Data collection and analysis
Two review authors independently extracted all data using a standardised data extraction and quality assessment form (based on
QUADAS-2). Where possible we estimated summary sensitivities and specificities using the bivariate hierarchical model.
Main results
We synthesised the results of nine studies contributing a total of 1655 lesions to our analysis, including 1120 BCCs (14 datasets),
41 cSCCs (amongst 401 lesions in 2 datasets), and 10 melanomas (amongst 200 lesions in 1 dataset). Three of these datasets (one
each for BCC, melanoma and any malignant condition) were derived from one study that also performed a direct comparison with
dermoscopy. Studies were of moderate to poor quality, providing inadequate descriptions of participant selection, thresholds used to
make cytological and histological diagnoses, and blinding. Reporting of participants’ prior referral pathways was particularly poor,
as were descriptions of the cytodiagnostic criteria used to make diagnoses. No studies evaluated the use of exfoliative cytology as a
primary diagnostic test for detecting BCC or other skin cancers in lesions suspicious for skin cancer. Pooled data from seven studies
using standard cytomorphological criteria (but various stain methods) to detect BCC in participants with a high clinical suspicion of
BCC estimated the sensitivity and specificity of exfoliative cytology as 97.5% (95% CI 94.5% to 98.9%) and 90.1% (95% CI 81.1%
to 95.1%). respectively. When applied to a hypothetical population of 1000 clinically suspected BCC lesions with a median observed
BCC prevalence of 86%, exfoliative cytology would miss 21 BCCs and would lead to 14 false positive diagnoses of BCC. No false
positive cases were histologically confirmed to be melanoma. Insufficient data are available to make summary statements regarding the
accuracy of exfoliative cytology to detect melanoma or cSCC, or its accuracy compared to dermoscopy.
Authors’ conclusions
The utility of exfoliative cytology for the primary diagnosis of skin cancer is unknown, as all included studies focused on the use
of this technique for confirming strongly suspected clinical diagnoses. For the confirmation of BCC in lesions with a high clinical
suspicion, there is evidence of high sensitivity and specificity. Since decisions to treat low-risk BCCs are unlikely in practice to require
diagnostic confirmation given that clinical suspicion is already high, exfoliative cytology might be most useful for cases of BCC where
the treatments being contemplated require a tissue diagnosis (e.g. radiotherapy). The small number of included studies, poor reporting
and varying methodological quality prevent us from drawing strong conclusions to guide clinical practice. Despite insufficient data
on the use of cytology for cSCC or melanoma, it is unlikely that cytology would be useful in these scenarios since preservation of the
architecture of the whole lesion that would be available from a biopsy provides crucial diagnostic information. Given the paucity of good
quality data, appropriately designed prospective comparative studies may be required to evaluate both the diagnostic value of exfoliative
cytology by comparison to dermoscopy, and its confirmatory value in adequately reported populations with a high probability of BCC
scheduled for further treatment requiring a tissue diagnosis.
P L A I N L A N G U A G E S U M M A R Y
How accurate is exfoliative cytology (’skin scrape’ cytology) for diagnosing basal cell carcinoma and other skin cancers in adults?
Why is improving the diagnosis of skin cancer important?
There are a number of different types of skin cancer. The most common is basal cell carcinoma (BCC). BCC is a localised cancer that
can grow and destroy the skin around it. They rarely spread into the body like other cancers can. Very small or superficial low-risk
BCCs can generally be treated with treatments such as creams rather than surgery, while it is better to surgically remove BCCs that are
more likely to grow and spread. Radiotherapy (a treatment where radiation is used to kill cancer cells) can also be used if BCCs are very
large or cannot be removed by surgery. Cutaneous squamous cell carcinoma (cSCC) is also usually a localised skin cancer. In a small
proportion of cases it can spread to other parts of the body, so the best treatment is to remove it using surgery. Melanoma is one of the
most dangerous forms of skin cancer as it has a higher potential to spread to other parts of the body, and so it is vital to recognise it and
remove it early. If people with BCC do not receive the correct diagnosis (known as a false negative test result), their treatment can be
delayed, making the surgical procedure more complicated. Diagnosing BCC when it is actually something else (a false positive result)
may result in unnecessary treatment, surgery or other investigations and can cause the patient stress and anxiety. If BCC is incorrectly
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diagnosed in an individual who actually has an cSCC or melanoma, effective treatment can be delayed and this might lead to a greater
chance that the cSCC or melanoma spreads to other organs in the body, which can be very serious.
What is the aim of the review?
The aim of this Cochrane Review was to find out how accurate a technique called ’exfoliative cytology’ is for diagnosing skin cancer.
Researchers in Cochrane found nine studies to answer this question. Nine studies were concerned with the diagnosis of BCC, two with
the diagnosis of cSCC and one with the diagnosis of melanoma.
What was studied in the review?
Exfoliative cytology means scraping the surface of a possible skin cancer with a knife and then spreading a small layer of the scrape
onto a glass slide so that the cells in the scrape can be stained and looked at under a microscope. It is less invasive than skin biopsy and
quick to perform, with results available immediately. This could save patients an additional clinic visit to receive skin biopsy results.
What are the main results of the review?
The review examined nine studies with a total of 1655 lesions (a mole or area of skin with an unusual appearance in comparison with
the surrounding skin) that were given these final diagnoses*: 1120 BCCs, 41 cSCCs and 10 melanomas.
For identifying BCC, seven studies show the effect of using exfoliative cytology to confirm BCC in lesions that doctors already suspected
were BCCs. In a group of 1000 such lesions, of which 860 (86%) actually do have BCC, then:
- an estimated 853 people will have an exfoliative cytology result confirming that a BCC is present. Of these 14 (1.6%) will not actually
have a BCC (false positive result);
- of the 147 people with an exfoliative cytology result indicating that no BCC is present, 21 (14%) will in fact actually have a BCC
(false negative result).
One study compared the accuracy of exfoliative cytology to using a hand-held microscope (dermoscopy) for making a diagnosis of
BCC but used a different method of removing cells and included patients with a higher risk of melanoma than found in the other eight
studies.
There was not enough evidence to determine the accuracy of exfoliative cytology for diagnosing cSCC or melanoma.
How reliable are the results of the studies of this review?
The small number of studies included in this review, poor description of how patients were selected to be included in the study, and
limited information on how the test results were used to make diagnoses, reduces the reliability of our results.
The studies did not explain how patients had been referred to have the exfoliative cytology test. Most important of all, the test was only
used in people in whom doctors had already diagnosed a BCC just by looking at the skin lesion. In other words, the test was being
used to confirm a doctor’s diagnosis. Most studies did not include enough people with skin lesions that are similar in appearance to a
BCC to be sure that this test correctly identifies a BCC. This may cause exfoliative cytology to appear more accurate than it would be
in actual practice.
Who do the results of this review apply to?
Studies were conducted in the UK, across Europe and in Australia. Study authors rarely described patient characteristics, such as age
and location of the lesion. The percentage of people included in the studies with a final diagnosis of BCC ranged from 18% to 90%
(nine studies). For cSCC it was 4% and 18% (two studies), and for melanoma it was 5% (one study). It was not possible to tell from
the studies how clinicians had decided that study participants had lesions that could be a skin cancer.
What are the implications of this review?
No research has been done using exfoliative cytology to diagnose a skin cancer when a patient is first seen by a doctor. The results of
this review suggest that exfoliative cytology can help to confirm BCC in patients with skin lesions that a doctor already suspects of
being a BCC. This test could be useful for patients with BCCs that need non-surgical treatments, such as radiotherapy, where a tissue
diagnosis is needed before the treatment can be given.
How up-to-date is this review?
The review authors searched for and used studies published up to August 2016.
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*In these studies, biopsy was the reference standard (means of establishing the final diagnosis).
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Question: What is the diagnostic accuracy of exfoliative cytology for detecting BCC, cSCC or cutaneous invasive melanoma and atypical intraepidermal
melanocytic variants in adults?
Population Adults with lesions suspicious for BCC, cSCC or for melanoma
Index test Exfoliat ive cytology
Comparator test Dermoscopy
Target condition BCC
Reference standard Histology, any method
Action If accurate, posit ive diagnosis by exfoliat ive cytology would reduce the need for biopsies in suspected BCC and help to appropriately select
lesions for excision
Quantity of evidence
Number of studies 9 Total lesions
with test results
1655 Total with BCC 1120a
Total with cSCC 41b
Total with melanoma 10c
Limitations
Risk of bias High risk for pat ient select ion due to case-control study design (2/ 9) or inappropriate exclusion of lesions (1/ 9), and unclear due to poor report ing
of recruitment and exclusion criteria (3/ 9). Unclear risk for the index test due to lack of report ing diagnost ic thresholds and blinding f rom the
reference standard diagnosis (7/ 9). Unclear risk of bias due to inadequate report ing of blinding the reference standard (7/ 9) or the index test (7/
9). High risk of bias in f low and tim ing domain f rom dif ferent ial verif icat ion (2/ 9) and exclusion of slides f rom analysis (1/ 9); t im ing of tests was
not mentioned in 7/ 9
Applicability of evidence to
question
High concern due to narrowly def ined populat ions and mult iple lesions per pat ient (6/ 9), and unclear concern due to poor report ing of pat ient
groups (2/ 9), so may not be representat ive of populat ions eligible for exfoliat ive cytology. High concern for clinical applicability of exfoliat ive
cytology f rom lack of report ing cytodiagnost ic criteria in adequate detail (5/ 9). Lit t le information was given concerning the expert ise of the
cytopathologist or histopathologist
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Detection of BCC: pooled analysisd
Datasets Lesions BCCs Sensitivity (95% CI) Specificity (95% CI)
7 1264 1045 97.5% (94.5 to 98.9) 90.1% (81.1 to 95.1)
Numbers observed in a cohort of 1000 people being testede
True positive False negative False positive True negative
(Appropriately do not re-
ceive excision)
(Inappropriately receive ex-
cision or undertreated)
(Inappropriately
do not receive excision, or
overtreated)
(Receive appropriate management - excision or other)
At prevalence 63% 614 16 37 333
At prevalence 86% 839 21 14 126
At prevalence 88% 858 22 12 108
Detection of BCC: pooled analysisf
Datasets Lesions BCCs Sensitivity (95% CI) Specificity (95% CI)
7 1264 1045 97.3% (93.5 to 98.9) 94.2% (88.7 to 97.1)
Detection of cSCC, melanoma, any skin cancer
Findings Studies also evaluated cSCC (2 studies), melanoma (1 study) or any skin cancer (6 studies)
• cSCC - studies could not be pooled due to dif ferent diagnost ic approaches; sensit ivity ranged f rom 89% to 100%and specif icity f rom 75% to
99%
• melanoma - only study (10 melanomas) conducted in 185 pigmented skin lesions, also providing a comparison with dermoscopy: sensit ivity
and specif icity 100%
• any skin cancer - 4 studies pooled 573 suspicious lesions, with 495 malignant lesions (476 BCCs, 13 cSCCs, 1 melanoma, 4 carcinomas of
unspecif ied histological type, 1 apocrine carcinoma). Pooled sensit ivity 97.3% (95%CI 93.5% to 98.9%) and specif icity 86.0% (95%CI 73.5% to
93.1%) (uncertain diagnoses classif ied as test posit ives). When uncertain diagnoses classif ied as test negat ives, pooled sensit ivity became 96.
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6% (95% CI 90.3% to 98.9%) and specif icity 94.7% (95% CI 80.2% to 98.7%).
BCC: basal cell carcinoma; cSCC: cutaneous squamous cell carcinoma; CI: conf idence interval.
aTotal of 1122 BCC cases, of which 2 excluded due to absence of exfoliat ive cytology result (’test fails’).
bTotal of 55 cSCC cases, of which 14 excluded: 3 due to absence of exfoliat ive cytology result (’test fails’) and 11 due to
insuf f icient cSCC lesion numbers in individual studies (< 5 cSCCs per study).
cTotal of 11 cases, of which 1 excluded due to insuf f icient melanoma lesion numbers in individual studies (< 5 melanomas
per study).
d ’Possible BCC’ cases classif ied as index test posit ive.
eNumbers for a hypothet ical cohort of 1000 lesions are presented for three examples represent ing dif ferent prevalences of
BCC, est imated at 25th, 50th (median) and 75th percent iles of BCC prevalence observed across the 9 included studies.
f ’Possible BCC’ cases classif ied as index test negat ive.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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B A C K G R O U N D
This review is one of a series of Cochrane Diagnostic Test Ac-
curacy (DTA) reviews on the diagnosis and staging of melanoma
and keratinocyte skin cancers conducted for the National Insti-
tute for Health Research (NIHR) Cochrane Systematic Reviews
Programme. Appendix 1 shows the content and structure of the
programme. Appendix 2 provides a glossary of terms used and a
table of acronyms used is provided in Appendix 3.
Target condition being diagnosed
The commonest skin cancers inwhite populations are keratinocyte
skin cancers, namely basal cell carcinoma (BCC) and cutaneous
squamous cell carcinoma (cSCC) (Gordon 2013; Madan 2010).
BCC is the more common of the two keratinocyte carcinomas,
and approximately one third of people with a BCC will develop at
least one other BCC over time (Flohill 2013). In 2003, theWorld
Health Organization (WHO) estimated that between 2 and 3
million ’non-melanoma’ skin cancers occur globally each year (of
which BCC and cSCC are estimated to account for around 80%
and 16% of cases, respectively) and 132,000 melanoma skin can-
cers occur globally each year (WHO 2003). Rather than defining
BCC and cSCC by what they are not (i.e. non-melanoma skin
cancer), we collectively refer to these conditions using the pre-
ferred and more accurate term of ’keratinocyte carcinoma’ in this
DTA review (Karimkhani 2015).
Exfoliative cytology is a simple procedure designed to detect
the presence of malignancy through analysis of cell structure.
Since its main benefit would be to replace histology, basal cell
carcinoma has been chosen as the primary target condition
for this review since this is the condition for which exfoliative
cytology could potentially have the clearest role (see Role of
index test(s) and Rationale below). Secondary target conditions
include: cSCC,invasive melanoma and atypical intraepidermal
melanocytic variants, and any other skin cancer, including ker-
atinocyte skin cancer, invasive melanoma and atypical intraepider-
mal melanocytic variants.
Basal cell carcinoma
BCC can arise from multiple stem cell populations, including
from the bulge and interfollicular epidermis (Grachtchouk 2011).
Growth is usually localised, but it can infiltrate and damage sur-
rounding tissue, and if left untreated it can cause considerable de-
struction and disfigurement, particularly when located on the face
(Figure 1). The fourmain subtypes of BCCare superficial, nodular,
morphoeic or infiltrative, and pigmented. They typically present
as slow-growing asymptomatic papules, plaques, or nodules that
may bleed or form ulcers that do not heal (Firnhaber 2012). Peo-
ple with a BCC often present to healthcare professionals with a
non-healing lesion rather than specific symptoms such as pain.
Clinicians frequently make the diagnosis incidentally rather than
as a result of people presenting with symptoms (Gordon 2013).
Figure 1. Sample photographs of BCC (left) and cSCC (right). Copyright © 2012 Dr Rubeta Matin:
reproduced with permission.
8Exfoliative cytology for diagnosing basal cell carcinoma and other skin cancers in adults (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
BCCs most frequently occur on sun-exposed areas of the head
and neck (McCormack 1997), and they are more common in
men and in people over 40 years of age. A rising incidence of
BCC in younger people has been attributed to increased recre-
ational sun exposure (Bath-Hextall 2007a; Gordon 2013; Musah
2013). Other risk factors include Fitzpatrick skin types I and II
(Fitzpatrick 1975; Lear 1997; Maia 1995); previous skin cancer
history; immunosuppression; arsenic exposure; and genetic pre-
disposition, such as in basal cell naevus (Gorlin) syndrome (Gorlin
2004; Zak-Prelich 2004). Annual incidence is increasing world-
wide; Europe has experienced an average increase of 5.5% per year
over the last four decades, the USA 2% per year, while estimates
for the UK show incidence appears to be increasing more steeply
at a rate of an additional 6/100,000 person-years (Lomas 2012).
Some authors have explained the rising incidence by an ageing
population, changes in the distribution of known risk factors, par-
ticularly ultraviolet radiation, and improved detection due to the
increased awareness amongst both practitioners and the general
population (Verkouteren 2017). Hoorens 2016 points to evidence
for a gradual increase in the size of BCCs over time, with delays
in diagnosis ranging from 19 to 25 months.
According to the National Institute for Health and Care Excel-
lence (NICE) guidance (NICE 2010), low-risk BCCs that may
be considered for excision include nodular lesions occurring in
patients older than 24 years old who are not immunosuppressed
and do not have Gorlin syndrome. Furthermore, lesions should
be located below the clavicle; should be small (diameter of less
than 1 cm), with well-defined margins; not recurrent following
incomplete excision; and not in awkward or highly visible loca-
tions (NICE 2010). Superficial BCCs are also typically low risk
and may be amenable to medical treatments such as photody-
namic therapy or topical chemotherapy (Kelleners-Smeets 2017).
Assigning BCCs as low or high risk influences the management
options (Batra 2002; Randle 1996).
It is recognised that basosquamous carcinoma (more like a high
risk SCC in behaviour and not considered a true BCC) is likely
to have accounted for many cases of apparent metastases of BCC,
hence the spuriously high reported incidence in some studies of
up to 0.55%, which is not seen in clinical practice (Garcia 2009).
Advanced locally destructive BCC can arise from long-standing
untreated lesions or froma recurrence of a basal cell carcinoma after
primary treatment (Lear 2012). Very rarely, BCC metastasises to
regional and distant sites resulting in death, especially cases of large
neglected lesions in those who are immunosuppressed or those
with Gorlin syndrome (McCusker 2014). Rates of metastasis are
reported at 0.0028% to 0.55% (Lo 1991), with very poor survival
rates.
Squamous cell carcinoma of the skin (cSCC)
Primary cSCC arises from the keratinising cells of the outermost
layer of the skin. People with cSCC often present with an ulcer
or firm (indurated) papule, plaque or nodule (Firnhaber 2012;
Griffin 2016), sometimes with an adherent crust and poorly de-
fined margins (Madan 2010). cSCC can arise in the absence of a
precursor lesion or it can develop from pre-existing actinic kerato-
sis, with an estimated annual risk of progression of anywhere from
under 1% to 20% (Alam 2001), or Bowen’s disease (squamous
cell carcinoma in situ), with about a 5% risk of progression (Kao
1986). It remains locally invasive for a variable length of time but
has the potential to spread to the regional lymph nodes or via the
bloodstream to distant sites, especially in immunosuppressed in-
dividuals (Lansbury 2010). High risk lesions are those arising on
the lip or ear, recurrent cSCC, lesions arising on non-exposed sites,
scars or chronic ulcers, tumours more than 20 mm in diameter
and depth of invasion more than 4 mm and poor differentiation
on pathological examination (Motley 2009).
Chronic ultraviolet light exposure through recreation or occupa-
tion is strongly linked to cSCC occurrence (Alam 2001). It is par-
ticularly common in people with fair skin and in rare genetic dis-
orders of pigmentation, such as albinism, xeroderma pigmento-
sumand recessive dystrophic epidermolysis bullosa (RDEB) (Alam
2001). Other recognised risk factors include immunosuppression;
chronic wounds; arsenic or radiation exposure; certain drug treat-
ments, such as voriconazole and BRAF inhibitors; and previous
skin cancer history (Baldursson 1993; Chowdri 1996; Dabski
1986; Fasching 1989; Lister 1997; Maloney 1996; O’Gorman
2014). In transplant recipients, cSCC is the most common form
of skin cancer, with estimates of the risk of developing cSCC 65 to
253 times that of the general population (Hartevelt 1990; Jensen
1999; Lansbury 2010). Overall, local and metastatic recurrence of
cSCC at five years is estimated at 8% and 5%, respectively. Five-
year survival rate following metastatic recurrence is only 25% to
40% (Rowe 1992).
Melanoma
Melanoma arises from uncontrolled proliferation of melanocytes
- the epidermal cells that produce pigment or melanin. Cuta-
neous melanoma refers to skin lesions withmalignant melanocytes
present in the dermis, and includes superficial spreading, nodu-
lar, acral lentiginous, and lentigo maligna melanoma variants.
Melanoma in situ describes malignant melanocytes that lay within
the epidermis without invasion of the dermis, but they are at risk
of progressing to melanoma if left untreated. Lentigo maligna, a
subtype ofmelanoma-in-situ in chronically sun-damaged skin, can
progress to invasive melanoma if its growth breaches the dermo-
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epidermal junction during a vertical growth phase (when it be-
comes known as ’lentigo maligna melanoma’), however its malig-
nant transformation is both lower and slower than for melanoma
in situ (Kasprzak 2015). Melanoma in situ and lentigomaligna are
both atypical intraepidermal melanocytic variants. Melanoma is
one of the most dangerous forms of skin cancer, with the potential
to metastasise to other parts of the body via the lymphatic system
and blood stream. It accounts for only a small percentage of skin
cancer cases but is responsible for up to 75% of skin cancer deaths
(Boring 1994; Cancer Research UK 2017).
The incidence of melanoma rose to over 200,000 newly diagnosed
cases worldwide in 2012 (Erdmann 2013; Ferlay 2015), with an
estimated 55,000 deaths (Ferlay 2015). The highest incidence is
observed in Australia with 13,134 new cases of melanoma of the
skin in 2014 (ACIM 2017) and in New Zealand with 2341 regis-
tered cases in 2010 (HPA andMelNet NZ 2014). For 2014 in the
USA, the predicted incidence was 73,870 per annum and the pre-
dicted number of deaths was 9940 (Siegel 2015). The highest rates
in Europe are seen in north-western Europe and the Scandinavian
countries, with a highest incidence reported in Switzerland: 25.8
per 100,000 in 2012. Rates in England have tripled from 4.6 and
6.0 per 100,000 inmen and women, respectively, in 1990, to 18.6
and 19.6 per 100,000 in 2012 (EUCAN 2012). Indeed, in the
UK, melanoma has one of the fastest rising incidence rates of any
cancer, and has had the biggest projected increase in incidence be-
tween 2007 and 2030 (Mistry 2011). In the decade leading up to
2013, age-standardised incidence increased by 46%, with 14,500
new cases in 2013 and 2459 deaths in 2014 (Cancer Research UK
2017). Rates are higher in women than in men; however, the rate
of incidence in men is increasing faster than in women (Arnold
2014). This rising incidence is thought to be primarily related to
an increase in recreational sun exposure, tanning bed use and an
increasingly ageing population with higher lifetime recreational
ultraviolet (UV) exposure, in conjunction with possible earlier de-
tection (Belbasis 2016; Linos 2009). Putative risk factors are re-
viewed in detail elsewhere (Belbasis 2016).
A database of over 40,000 US patients from 1998 onwards, which
assisted the development of the 8th American Joint Committee
on Cancer (AJCC) staging system, indicated a five-year survival of
97% to 99% for stage I melanoma, dropping to between 32% and
93% in stage III disease depending on tumour thickness, the pres-
ence of ulceration and number of involved nodes (Gershenwald
2017). While these are substantial increases relative to survival in
1975 (Cho 2014), mortality rates have remained static during the
same period. This observation, coupled with increasing incidence
of localised disease, suggests that improvements in survival may
be due to earlier detection and heightened vigilance (Cho 2014).
New targeted therapies for advanced (stage IV), melanoma (e.g.
BRAF inhibitors), have improved survival, and immunotherapies
are evolving such that long-term survival is being documented
(Pasquali 2018; Rozeman 2017). No new data regarding the sur-
vival prospects for patients with stage IV disease were analysed for
the AJCC 8 staging guidelines due to lack of contemporary data
(Gershenwald 2017).
Treatment
Treatment for BCC and cSCC include surgery, other destructive
techniques such as cryotherapy or electrodesiccation and topical
chemotherapy. A Cochrane Review of 27 randomised controlled
trials (RCTs) of interventions for BCC found very little good
quality evidence for any of the interventions used (Bath-Hextall
2007b). Complete surgical excision of primary BCC has a re-
ported five-year recurrence rate of less than 2% (Griffiths 2005;
Walker 2006), leading to significantly fewer recurrences than treat-
ment with radiotherapy (Bath-Hextall 2007b). After apparent
clear histopathological margins (serial vertical sections) following
standard excision biopsy with 4 mm surgical peripheral margins
taken, reported five-year recurrence rate is around 4% (Drucker
2017). Mohs micrographic surgery, whereby horizontal sections
of the tumour undergo histological analysis, and re-excisions are
made until the margins are tumour-free, can be considered for
high-risk lesions such as on the centre of the face, where stan-
dard wider excision margins might lead to considerable func-
tional impairment (Bath-Hextall 2007b; Lansbury 2010; Motley
2009; Stratigos 2015). Bath-Hextall and colleagues (Bath-Hextall
2007b) found a single trial comparingMohs micrographic surgery
with a 3mm surgical margin excision in BCC (Smeets 2004); the
update of this study showed non-significantly lower recurrence
at 10 years with Mohs micrographic surgery (4.4% compared to
12.2% after surgical excision, P = 0.10) (van Loo 2014).
Destructive techniques other than excisional surgery include elec-
trodesiccation and curettage (ED&C) aswell as cryotherapy (Alam
2001; Bath-Hextall 2007b). Alternatively, non-surgical (or non-
destructive) treatments may be options (Bath-Hextall 2007b; Kim
2014; Drew 2017), including topical chemotherapy such as im-
iquimod (Williams 2017), 5-fluorouracil (Arits 2013), ingenol
mebutate (Nart 2015), and photodynamic therapy (Bath-Hextall
2007b; Roozeboom 2016). These non-surgical approaches are in-
creasingly used for the superficial subtypes of BCC, for multiple
lesions on low-risk sites, where there are relevant comorbidities, or
where surgery would be associated with risk of poor wound heal-
ing or significant scarring (Marsden 2010). However, non-surgi-
cal techniques do not allow histological confirmation of tumour
clearance, and their use is dependent on accurate characterisation
of the histological subtype and depth of tumour. The 2007 sys-
tematic review of BCC interventions found limited evidence from
very small RCTs for these approaches (Bath-Hextall 2007b), which
have only partially been filled by subsequent studies (Bath-Hextall
2014; Kim 2014; Roozeboom 2012). Most BCC trials have com-
pared interventions within the same treatment class, and few have
compared medical versus surgical treatments (Kim 2014).
A systematic review of interventions for primary cSCC found
only one RCT eligible for inclusion (Lansbury 2010). Current
10Exfoliative cytology for diagnosing basal cell carcinoma and other skin cancers in adults (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
practice therefore relies on evidence from observational studies, as
reviewed in Lansbury 2013, for example. Surgical excision with
predetermined margins is usually the first-line treatment (Motley
2009; Stratigos 2015). Observational studies suggest low recur-
rence rates for small, low-risk lesions treated with cryotherapy or
ED&C (recurrence rates of less than 2%). Estimates of recurrence
after Mohs micrographic surgery, surgical excision, or radiother-
apy, which researchers are likely to have evaluated in higher risk
populations, have shown pooled recurrence rates of 3%, 5.4% and
6.4%, respectively, with overlapping confidence intervals; the re-
view authors advise caution when comparing results across treat-
ments (Lansbury 2013).
For primary melanoma, the mainstay of definitive treatment is
wide local excision of the lesion, to remove both the tumour and
any malignant cells that might have spread into the surround-
ing skin (Garbe 2016; Marsden 2010; NICE 2015a; SIGN 2017;
Sladden 2009). Recommended surgical margins vary according to
tumour thickness, as described in Garbe 2016, and by stage of
disease at presentation, as in NICE 2015a. Following histological
confirmation of diagnosis, the lesion is pathologically staged from
0 (referring to melanoma in situ) to IV (indicating the presence of
distant metastasis) according to the AJCC staging system to guide
treatment (Balch 2009). Themain prognostic indicators can be di-
vided into histological and clinical factors. Histologically, Breslow
thickness is the single most important predictor of survival, as it is
a quantitative measure of tumour invasion which correlates with
the propensity for metastatic spread (Balch 2001). Independent
of tumour thickness, prognosis is worse in older people, males,
those with recurrent lesions, and in those with distant lymph node
involvement (micro or macroscopic) and/or metastatic disease at
the time of primary presentation.
Index test(s)
Exfoliative cytology is a non-invasive test that uses the Tzanck
smear technique to identify disease through the examination of
the structure of cells (Tzank 1949). It is also known as ’skin scrape
cytology’, which is perhaps a better description of the technique
than ’exfoliative’ which traditionally refers to the removal of su-
perficial dead cells from the skin surface. Clinicians clean skin le-
sions, remove any surface crust, and then scrape the lesions with
a scalpel or curette to collect cell material and subsequently smear
them onto one or more glass slides (Chandra 2009). They can
then fix the material using alcohol or air-drying, and then they
stain it using one of several methods recommended by the British
Society of Cytopathology, namely the Papanicolaou (Pap) and
May-Grünwald Giemsa (MGG; also called Romanowsky) meth-
ods (Chandra 2009). A cytopathologist or a dermatologist with
experience of the technique can immediately examine the slides
under a microscope to determine the presence of malignant cells
(Bakis 2004). Superficial shave biopsy differs from a cytological
scrape in that it slices off a superficial (largely epidermal) section
from a BCC that protrudes above the skin surface. The specimen
retains the architecture of the part of lesion that is shaved off.
Shave biopsy typically contains only tumour tissue rather than the
interface between BCC and normal tissue, which provides impor-
tant information on the depth and pattern of tumour invasion.
Shave biopsy specimens are processed using normal paraffin block
histopathology; this technique is only suitable for elevated/pro-
truding BCCs and does not provide the immediate results that
cytology can provide (Russell 1999).
Exfoliative cytology may be used for confirming the presence of
clinically diagnosed BCC with a view to definitive treatment such
as radiotherapy. The cellular appearance of BCC is characteristic
(Figure 2), with ’palisade’ arrangements of typically basal cells po-
sitioned around the margins of densely packed masses of larger
and intensely stained cells (Figure 3 and Figure 4) (Ruocco 2011).
Cytological features differ for the detection of cSCC, tending to
show larger cells with less coherence that are more atypical in ap-
pearance with a more varied shape and size (pleomorphic) and ab-
normal nuclei (Bocking 1987; Fortuno-Mar 2013; Ruocco 2011).
The cytological appearance of melanoma ismuchmore varied, but
it can include larger cells than those observed, which are typical
of BCC, with prominent and often multiple large nuclei, large
nuclear inclusions of cytoplasm, and often a presence of melanin
pigment in tumour cells (Bocking 1987; Fortuno-Mar 2013).
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Figure 2. Cytological image of BCC using Papanicoloau stain showing a tissue fragment of BCC on the left
and anucleate squamous cells from the epidermis on the right. Copyright © 2017 Derek Roskell: reproduced
with permission.
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Figure 3. Cytological image of a BCC using Giemsa stain. Focally the nuclei are aligned perpendicular to the
basement edge of the cluster (peripheral palisading), a feature characteristic of BCC. Copyright © 2017 Derek
Roskell: reproduced with permission.
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Figure 4. Cytological image of a BCC using Giemsa stain. The BCC cells are tightly cohesive in a cluster
with a distinct edge to the group. Copyright © 2017 Derek Roskell: reproduced with permission.
Clinical pathway
The diagnosis of melanoma can take place in primary, secondary,
and tertiary care settings by both generalist and specialist health-
care providers. In the UK, people with concerns about a new or
changing lesion will usually present first to their general practi-
tioner (GP) or, less commonly, directly to a specialist in secondary
care, which could include a dermatologist, plastic surgeon, other
specialist surgeon (such as an ear, nose, and throat (ENT) specialist
or maxillofacial surgeon), or ophthalmologist (Figure 5). Current
UK guidelines recommend that GPs should assess all suspicious
pigmented lesions presenting in primary care by taking a clinical
history and visually inspecting them using the revised seven-point
checklist (MacKie 1990). Clinicians should refer those with sus-
pected melanoma or cSCC for appropriate specialist assessment
within two weeks ( Chao 2013; London Cancer Alliance 2013;
Marsden 2010; NICE 2015a). In the UK, low-risk BCCs are usu-
ally recommended for routine referral, with urgent referral for
those in whom a delay could have a significant impact on clini-
cal outcomes, for example due to large lesion size or critical site
(NICE 2015b). Appropriately qualified generalist care providers
increasingly undertake management of low-risk BCCs in the UK,
for example by excising low-risk lesions (NICE 2010). Similar
guidance is in place in Australia (CCAAC Network 2008).
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Figure 5. Current clinical pathway for people with skin lesions.
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For referred lesions, the specialist clinician will use history-tak-
ing, visual inspection of the lesion (in conjunction with other skin
lesions), and often dermoscopy to inform a clinical decision. If
melanoma or cSCC is suspected, then urgent excision is advis-
able. Equivocal lesions for which a definitive diagnosis cannot be
reached may undergo surveillance to identify any lesion changes
that would indicate biopsy or reassurance and discharge for those
that remain stable over a period of time. Low-risk BCC and pre-
malignant skin lesions potentially eligible for non-surgical treat-
ment may undergo a diagnostic biopsy before initiating therapy.
Prior test(s)
The diagnosis of skin cancer is based on history-taking and clinical
examination. In the UK, this is typically undertaken at two deci-
sion points - first in the GP surgery, where a decision is made to re-
fer or not to refer, and then a second time where a dermatologist or
other secondary care clinician makes a decision whether or not to
biopsy or excise. A range of technologies have emerged to aid diag-
nosis to reduce the number of diagnostic biopsies or inappropriate
surgical procedures. Dermoscopy using a hand-held microscope
has become the most widely used tool for clinicians to improve
diagnostic accuracy of pigmented lesions, in particular melanoma,
following visual inspection (Argenziano 1998; Argenziano 2012;
Haenssle 2010; Kittler 2002), although it is less well established
for the diagnosis of BCC or cSCC (Dinnes 2018a). A further
three reviews in this series have evaluated the diagnostic accuracy,
and comparative accuracy, of visual inspection and dermoscopy
(Dinnes 2018a, Dinnes 2018b, Dinnes 2018c).
Visual inspectionof the skin is iterative, using both implicit pattern
recognition (non-analytical reasoning) and more explicit ’rules’
based on conscious analytical reasoning (Norman 2009), the bal-
ance of which will vary according to experience and familiarity
with the diagnostic question. Authors have made various attempts
to formalise themental rules involved in analytical pattern recogni-
tion, ranging from a setting out of lesion characteristics that should
be considered to formal scoring systems or algorithms with ex-
plicit numerical thresholds of skin cancer (Friedman 1985; Sober
1979).
Role of index test(s)
For the diagnosis of BCC, the potential role of exfoliative cytol-
ogy could be to confirm a strong clinical suspicion of malignancy.
If shown to be sufficiently accurate, this simple procedure could
avoid the need for an invasive diagnostic skin biopsy in patients
whose lesions might be more amenable to non-surgical treatment.
In ulcerated lesions (such as BCC), removing the overlying dead
cells or dried exudate is straightforward, and the procedure is there-
fore potentially less invasive than shave or punch biopsy (though
more invasive than dermatoscopic examination). Thus, exfoliative
cytology could replace histology or allow treatment to be initi-
ated prior to biopsy results in some patients. The test might also
be of value to confirm a clinical suspicion of cSCC in recurrent
lesions, or those that are critically located around the eyes, nose,
lips, ears and neck, since these are suitable sites for Mohs micro-
graphic surgery. The potential role for exfoliative cytology to de-
tect melanoma is less clear, given the optimal treatment in these
patients is excision (Murali 2009).Melanomas are frequently solid
skin lesions for which scraping is likely to be more invasive, as re-
moval of the dead layer alone is difficult to achieve. In these cases,
histological biopsy is likely to be equally traumatic and but may
provide more thorough and reliable diagnostic information.
Although skin is the largest and most accessible organ in the body,
cutaneous cytology is not standard practice when diagnosing skin
cancer lesions (NICE 2015a; SIGN 2014; Stratigos 2015; Telfer
2008). Although clinicians occasionally use cytology in practice to
confirm a clinical diagnosis of BCC when planning radiotherapy
or surgery, the nature of the sample obtained lacks the additional
histological information, such as pathological subtype and interac-
tion with surrounding skin and structures, that clinicians need to
decide on best treatment and which is readily available following
biopsy of suspicious lesions (Barr 1984; Ruocco 2011). Nonethe-
less, the simplicity, immediacy and non-invasive nature of exfolia-
tive cytology are clearly desirable attributes, which could benefit
both health services and patients, albeit in a limited number of cir-
cumstances. This is true for confirming a clinical diagnosis of BCC
which can present as multiple lesions, and commonly occur on the
face, head and neck, which are cosmetically critical sites (Powell
2000).Once diagnosed, superficial BCC can be treated using non-
invasive treatments (listed in Target condition being diagnosed).
Excisional surgery and Mohs micrographic surgery are the most
successful treatments for nodular BCC, although smaller nodular
BCCs in low risk areas can also be treated with topical treatments
(Williams 2017); therefore, the ability to confirm a diagnosis in
these patients using a fast and non-invasive approach is attractive
(Ruocco 2011). The test can take place during a consultation,
with negative results in the presence of clinical concerns for malig-
nancy indicating the need to proceed to a definitive biopsy (Ozden
2013). However, such potential benefits may be outweighed by
mistaking more aggressive forms of BCC for a low-risk BCC, and
cytology will never be able to match the additional pathological
information regarding cellular behaviour and interaction with sur-
rounding tissues provided by routine histopathology.
In order for exfoliative cytology to realise its potential in low-risk
BCC, it would need to have a high positive predictive value (from
a high specificity) to be sure that patients receiving positive results
could safely proceed to treatment without biopsy. Any patients
with negative cytology findings would still require biopsy to be
sure that cytology did not miss another malignancy. A delay in the
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diagnosis of a BCC as a result of a false-negative test is usually not
as serious as for melanoma because BCC is typically slow-grow-
ing and very unlikely to metastasise. However, delayed diagnosis
can result in a larger and more complex excision. Very sensitive
tests for BCC, however, are likely to compromise on specificity,
leading to a higher false-positive rate and an enormous burden of
skin surgery. Thus, a balance between sensitivity and specificity is
needed. The situation for cSCC is more similar to melanoma in
that the consequences of falsely reassuring a person that they do
not have skin cancer can be serious and potentially fatal. Thus,
a good diagnostic test for cSCC should demonstrate high sensi-
tivity and a corresponding high negative predictive value. A test
that can reduce false positive diagnoses without missing true cases
of disease has patient and resource benefits. False-positive diag-
noses not only cause unnecessary morbidity from the biopsy but
could lead to initiation of inappropriate therapies and also in-
crease patient anxiety. Notwithstanding these advantages, cytol-
ogy does not allow the diagnostician to observe the tumour’s his-
tologic growth pattern, a characteristic that can influence man-
agement decisions since more aggressive growth patterns require
more aggressive treatment (Oram 1997). For melanoma, high test
sensitivity is a key requirement, as the cost of missing an early, thin
curable lesion can make the difference between life and death.
Alternative test(s)
Standard practice for suspected skin cancer diagnosis in special-
ist settings involves visual and dermatoscopic examination by a
dermatologist, and this review therefore considers these tests to
be the comparators. In suspicious lesions these tests are followed
by histopathologic analysis of biopsy or excision specimens. This
review uses histopathology as the reference standard for defini-
tive diagnosis, and does not review it as an index test. We have
also omitted alternative methods of exfoliative cytology, in par-
ticular imprint or ’touch imprint’ methods, which involve press-
ing cytology slides directly onto the surface of suspicious lesions
(Christensen 2008).
Our series of Cochrane DTA reviews on the diagnosis of skin
cancer also reviews a number of other tests, including visual in-
spection and dermoscopy, teledermatology,mobile phone applica-
tions, reflectance confocal microscopy (RCM), optical coherence
tomography (OCT) and computer-assisted diagnosis techniques
applied to dermoscopic and other types of image (Chuchu 2018a;
Chuchu 2018b; Dinnes 2018a; Dinnes 2018b; Dinnes 2018c;
Dinnes 2018d; Dinnes 2018e; Dinnes 2018f; Ferrante di Ruffano
2018a; Ferrante di Ruffano 2018b). RCM and OCT both pro-
vide depth-resolved optical reflectance imaging and are emerging
as non-invasive adjuncts to dermoscopy in a specialist setting, and
RCM potentially as an alternative to dermoscopy for skin cancer
diagnosis (Edwards 2016). Relative to exfoliative cytology, both
methods are resource intensive, and they require specialist train-
ing. High-frequency ultrasound may prove to be an additional
tool to assist in the diagnosis of melanoma; however, evidence to
date is scarce and generally of poor quality (Dinnes 2018a).
Computer-assisted diagnosis or artificial intelligence-based tech-
niques use predefined algorithms to process and manipulate ac-
quired data to identify the features that discriminate malignant
frombenign lesions, and theymay be applied to any types of image
or spectra (e.g. Wallace 2000; Wallace 2000a). They have most
commonly been applied to digital dermoscopy images (Esteva
2017; Rajpara 2009), with further developments in diffuse re-
flectance spectroscopy such as SIAscopy (Moncrieff 2002; Walter
2012), MelaFind (Hauschild 2014; Monheit 2011; Wells 2012),
and electrical impedance spectroscopy, e.g. the Nevisense system
(Malvehy 2014).
Evidence permitting, the accuracy of available tests will be com-
pared in an overview of reviews, exploiting within-study compar-
isons of tests and allowing the analysis and comparison of com-
monly used diagnostic strategies where tests may be used alone or
in combination.
Rationale
This review is part of a series of reviews of diagnostic tests used
to assist clinical diagnosis that aims to identify the most accurate
approaches to diagnosis and provide clinical and policy decision-
makers with the highest possible standard of evidence on which to
base diagnostic and treatment decisions. With increasing rates of
skin cancer and the push towards the use of dermoscopy and other
high-resolution image analysis in primary care, the anxiety around
missing early cases needs to be balanced against sending too many
people with benign lesions for a specialist opinion. Although its
role for the diagnosis of melanoma is unconvincing because of the
loss of vital additional histological information needed for opti-
mal treatment, exfoliative cytology has the potential to improve
the health of BCC patients through less invasive and more ac-
cessible diagnosis that avoids an additional visit for a skin biopsy
result. These benefits must be weighed carefully against the po-
tential limitations of exfoliative cytology to detect the additional
pathological features seen on histological examination that help to
identify lesions requiring immediate attention. For the subgroup
of patients who will go on to receive non-invasive treatments, the
technique could also enable quicker treatment with the potential
for better cosmetic results - key objectives from patient groups
(NICE 2010) - whilst saving health services the costs of unnec-
essary biopsies. Treatment of BCCs currently requires diagnostic
confirmation using histopathology (NICE 2010), so it is impor-
tant to assess whether these potential benefits could be attained by
comparing the accuracy of exfoliative cytology against that of the
reference standard, histological diagnosis.
Since assessing the appearance of a cytological smear is essentially
a subjective one that depends on adequate material, the diagnostic
performance of exfoliative cytology is likely to be influenced by the
experience and training of the individual collecting the sample, as
well as the diagnostician. Reproducibility is a known issue in other
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areas of cytopathology, for example cervical cytology, where the
ability to make a diagnosis is influenced by the technician’s profi-
ciency in retrieving a sufficient cell sample from scraping (Baena
2017). Evidence arising fromdiagnosticians’ experience with other
tests involving the analysis of visual images, such as histopathol-
ogy, often show variation in diagnosis (Farmer 1996; Shoo 2010),
as well as in the availability of clinical data used at the time of
diagnosis (Ferrara 2009). This review will therefore also aim to
evaluate the impact of clinician experience and training on the
adequate retrieval of cell material for cytopathological analysis, as
well as on the accuracy of diagnosis.
We identified a single meta-analysis published in 2004 which con-
sidered the accuracy of exfoliative cytology for differentiating be-
tween BCC and other conditions (Bakis 2004). Synthesising eight
studies, it incorporated three studies not eligible for our review in-
cluding those conducted on eyelid lesions and evaluating imprint
techniques. It also found no studies evaluating the effect of clini-
cian experience. Given that it only included studies published up
to 2000, there is a need for an up-to-date analysis of the accuracy
of exfoliative cytology for the diagnosis of BCCs as well as cSCCs
and melanoma skin cancer.
This review follows generic protocols which cover the full se-
ries of Cochrane DTA Reviews for the diagnosis of melanoma
(Dinnes 2015a), and for diagnosis of keratinocyte skin cancers
(Dinnes 2015b). The Background and Methods sections of this
review therefore use some text that was originally published in
those protocols, along with text that overlaps some of our other
reviews (Dinnes 2018a; Dinnes 2018b; Dinnes 2018d; Ferrante
di Ruffano 2018a).
O B J E C T I V E S
To determine the diagnostic accuracy of exfoliative cytology for
the detection of basal cell carcinoma in adults, and to compare its
accuracy with that of current standard diagnostic practice (visual
inspection with or without dermoscopy).
Secondary objectives
To determine the diagnostic accuracy of exfoliative cytology for
the detection of cutaneous squamous cell carcinoma, and to com-
pare its accuracy with that of standard diagnostic practice (visual
inspection with or without dermoscopy).
To determine the diagnostic accuracy of exfoliative cytology for
the detection of cutaneous invasive melanoma and atypical in-
traepidermal melanocytic variants, and to compare its accuracy
with that of standard diagnostic practice (visual inspection with
or without dermoscopy).
For each of the target conditions, we aimed:
• to compare the accuracy of exfoliative cytology versus
dermoscopy in direct test comparisons (where the same studies
evaluated both tests);
• to determine the effect of observer experience.
Investigation of sources of heterogeneity
We set out to address a range of potential sources of heterogene-
ity for investigation across our series of reviews, as outlined in
Dinnes 2015a and Dinnes 2015b and described in Appendix 4.
Our ability to investigate these and other sources of heterogeneity
was necessarily limited by the available data on each individual
test reviewed.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included test accuracy studies that allow comparison of the
result of the index test with that of a reference standard, including
the following:
• studies where all participants receive a single index test and
a reference standard;
• studies where all participants receive more than one index
test and reference standard;
• studies where participants are allocated (by any method) to
receive different index tests or combinations of index tests, and
all receive a reference standard (between-person comparative
studies (BPC));
• studies that recruit series of participants unselected by true
disease status (referred to as case series for the purposes of this
review);
• diagnostic case-control studies that separately recruit
diseased and non-diseased groups (see Rutjes 2005); however, we
did not include studies that compared results for malignant
lesions to those for healthy skin (i.e. with no lesion present); and
• both prospective and retrospective studies.
We excluded studies from which we could not extract 2 × 2 con-
tingency data or if they included fewer than five disease-positive
(for each of BCC, cSCC or melanoma) or disease-negative (i.e.
benign) cases. The size threshold of five is arbitrary. However such
small studies are unlikely to add precision to estimate of accuracy.
Studies available only as conference abstracts were excluded; how-
ever, attempts were made to identify full papers for potentially
relevant conference abstracts (Searching other resources).
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Participants
We included studies in adults with lesions suspicious for BCC,
cSCC or melanoma. We excluded studies that recruited only par-
ticipants with malignant diagnoses. We excluded studies con-
ducted in children or where authors clearly reported that more
than 50% of participants were aged 16 years old and under.
Index tests
We included studies evaluating exfoliative cytology alone, or ex-
foliative cytology versus visual inspection and/or dermoscopy. All
techniques involving scraping of skin lesions in vivo and subse-
quent cytological analysis of material were eligible. We excluded
swabbed lesions, tape stripping, use of ex vivo specimens, imprint
cytodiagnosis and fine needle aspiration.
We also excluded studies evaluating the accuracy of subjective as-
sessment of the presence or absence of individual cytomorpholog-
ical features (with no overall diagnosis of malignancy) as well as
those using the test in intraoperative settings, such as for margin
control during excision.
We made no exclusions according to the test observer.
Target conditions
The target condition was basal cell carcinoma (all types).
This decision reflected our assessment that the clearest role of
exfoliative cytology would be to replace histological confirmation
of disease (see Role of index test(s) and Rationale sections above).
In secondary analyses, we considered three additional definitions
of the target condition.
• Cutaneous squamous cell carcinoma.
• Any form of invasive cutaneous melanoma or atypical
melanocytic intraepidermal variants (i.e. including melanoma in
situ, or lentigo maligna, which have a risk of progression to
invasive melanoma).
• Any skin cancer.
Reference standards
The ideal reference standard was histopathological diagnosis of
the excised lesion or biopsy sample in all eligible lesions. All
biopsy methods were eligible. A qualified pathologist or der-
matopathologist should perform histopathology. Ideally, report-
ing should be standardised, detailing a minimum dataset to in-
clude the histopathological features of BCC, cSCC or melanoma
to determine the AJCC staging system (e.g. Slater 2014a; Slater
2014b; Slater 2014c). We did not apply the reporting standard as
a necessary inclusion criterion but extracted any pertinent infor-
mation.
We also accepted clinical follow-up of benign-appearing lesions as
an eligible reference standard, whilst recognising the risk of dif-
ferential verification bias (as misclassification rates of histopathol-
ogy and follow-up will differ) in our quality assessment of studies.
’Expert diagnosis’ of benign lesions with no histology or clinical
follow-up was also acceptable as long as at least 50% of all partici-
pants with benign lesions had a histological diagnosis. We required
all study participants with a final diagnosis of malignancy to have
a histological diagnosis, either subsequent to the application of the
index test or after a period of clinical follow-up.
Search methods for identification of studies
Electronic searches
The Information Specialist (SB) carried out a comprehensive
search for published and unpublished studies. A single large liter-
ature search was conducted to cover all topics in the programme
grant (see Appendix 1 for a summary of reviews included in the
programme grant). This allowed for the screening of search results
for potentially relevant papers for all reviews at the same time.
A search combining disease related terms with terms related to
the test names, using both text words and subject headings was
formulated. The search strategy was designed to capture studies
evaluating tests for the diagnosis or staging of skin cancer. As the
majority of records were related to the searches for tests for stag-
ing of disease, a filter using terms related to cancer staging and
to accuracy indices was applied to the staging test search, to try
to eliminate irrelevant studies, for example, those using imaging
tests to assess treatment effectiveness. A sample of 300 records that
would be missed by applying this filter was screened and the filter
adjusted to include potentially relevant studies. When piloted on
MEDLINE, inclusion of the filter for the staging tests reduced the
overall numbers by around 6000. The final search strategy, incor-
porating the filter, was subsequently applied to all bibliographic
databases as listed below (Appendix 5). The final search result was
cross-checked against the list of studies included in five systematic
reviews; our search identified all but one of the studies, and this
study was not indexed on MEDLINE. The Information Special-
ist devised the search strategy, with input from the Information
Specialist from Cochrane Skin. No additional limits were used.
We searched the following bibliographic databases to 29 August
2016 for relevant published studies:
• MEDLINE via OVID (from 1946);
• MEDLINE In-Process & Other Non-Indexed Citations via
OVID; and
• Embase via OVID (from 1980).
We searched the following bibliographic databases to 30 August
2016 for relevant published studies:
• the Cochrane Central Register of Controlled Trials
(CENTRAL; 2016, Issue 7) in the Cochrane Library;
• the Cochrane Database of Systematic Reviews (CDSR;
2016, Issue 8) in the Cochrane Library;
• Cochrane Database of Abstracts of Reviews of Effects
(DARE; 2015, Issue 2);
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• CRD HTA (Health Technology Assessment) database,
2016, Issue 3;
• CINAHL (Cumulative Index to Nursing and Allied Health
Literature via EBSCO from 1960).
We searched the followingdatabases for relevant unpublished stud-
ies using a strategy based on the MEDLINE search:
• CPCI (Conference Proceedings Citation Index), via Web of
Science™ (from 1990; searched 28 August 2016); and
• SCI Science Citation Index Expanded™ via Web of
Science™ (from 1900, using the ’Proceedings and Meetings
Abstracts’ Limit function; searched 29 August 2016).
We searched the following trials registers using the search terms
’melanoma’, ’squamous cell’, ’basal cell’ and ’skin cancer’ combined
with ’diagnosis’:
• Zetoc (from 1993; searched 28 August 2016).
• The US National Institutes of Health Ongoing Trials
Register ( www.clinicaltrials.gov); searched 29 August 2016.
• NIHR Clinical Research Network Portfolio Database (
www.nihr.ac.uk/research-and-impact/nihr-clinical-research-
network-portfolio/); searched 29 August 2016.
• The World Health Organization International Clinical
Trials Registry Platform ( apps.who.int/trialsearch/); searched 29
August 2016.
We aimed to identify all relevant studies regardless of language
or publication status (published, unpublished, in press, or in
progress). We applied no date limits.
Searching other resources
We had not identified any potentially ongoing studies at the time
of publication. We screened relevant systematic reviews identified
by our searches for their included primary studies and included
any missed by our searches. We checked the reference lists of all
included papers, and subject experts within the author team have
reviewed the final list of included studies. We did not conduct any
citation searching.
Data collection and analysis
Selection of studies
At least one author (JDi or NC or both) screened titles and ab-
stracts, discussing and resolving any queries by consensus. A pi-
lot screen of 539 MEDLINE references showed good agreement
(89% with a kappa of 0.77) between screeners. We included pri-
mary test accuracy studies and test accuracy reviews (for scan-
ning of reference lists) of any test used to investigate suspected
melanoma, BCC, or cSCC at initial screening. Both a clinical re-
viewer (fromone of a teamof 12 clinician reviewers) and amethod-
ologist reviewer (JDi or NC) independently applied inclusion cri-
teria (Appendix 6) to all full-text articles, resolving disagreements
by consensus or in consultation with a third party (JDe, CD, HW
or RM). We contacted authors of eligible studies when studies did
not present enough data to allow for the construction of 2 × 2
contingency tables.
Data extraction and management
One clinical (as detailed above) and one methodologist reviewer
(JDi,NCor LFR) independently extracted data concerning details
of the study design, participants, index test(s) or test combinations
and criteria for index test positivity, reference standards, and data
required to populate a 2 × 2 diagnostic contingency table for each
index test using a piloted data extraction form. Diagnostic thresh-
olds were all qualitative, with cytopathology criteria used to indi-
cate the presence or absence of the target condition. Some studies
used a third diagnostic category for ’possible disease’, extracting
two datasets for these studies: one grouping ’possible’ cases with
index test positives (used for the primary analysis), and another
grouping ’possible’ cases with index test negatives. Disagreements
were resolved by consensus or by a third party (JDe, CD, HW or
RM).
We contacted authors of conference abstracts published from2013
to 2015 to ask whether full data were available. If we could not
locate a full paper, we marked conference abstracts as ’pending’
and will revisit them in a future review update. It was not necessary
to contact authors of included studies due to missing information
regarding the target condition or diagnostic threshold.
Dealing with multiple publications and companion papers
We did not identify multiple publications for any of our included
studies.
Assessment of methodological quality
We assessed risk of bias and applicability of included studies using
the QUADAS-2 checklist (Whiting 2011), tailored to the review
topic (see Appendix 7). We piloted the modified QUADAS-2 tool
on a small number of included full-text articles. One clinical and
one methodologist reviewer (JDi, NC or LFR) independently as-
sessed quality for the remaining studies, resolving any disagree-
ment by consensus or in consultation with a third party where
necessary (JDe, CD, HW or RM).
Statistical analysis and data synthesis
Due to paucity of data and differences in patient populations and
thresholds used to define test positivity, we did not undertake
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meta-analysis for the diagnosis of melanoma or cSCC. However,
we did perform statistical pooling for the diagnosis of BCC.
In these analyses, we considered any other skin cancers (for ex-
ample melanomas or cSCCs) in the ’disease negative’ group that
exfoliative cytology incorrectly identified as BCCs to be false pos-
itive results. We took this decision because the clinical manage-
ment of a lesion considered to be a BCC (for example, initiation of
Mohs micrographic surgery, destructive techniques or non-surgi-
cal treatments) could be quite different to that for a melanoma or
cSCC and could potentially lead to a negative outcome for those
concerned. For the diagnosis of melanoma, however, we consid-
ered any other skin cancers (BCC, cSCC etc) that were incorrectly
identified as melanomas (i.e. positive on exfoliative cytology) to
be true negative test results rather than as false positives, on the
basis that excision of such lesions may still have been appropriate
for the participants concerned.
Our unit of analysis was the lesion rather than the person. This
is because in skin cancer initial treatment is directed to the lesion
rather than systemically (thus it is important to be able to cor-
rectly identify cancerous lesions for each person), and it is also the
most common way in which the primary studies reported data.
Although there is a theoretical possibility of correlations of test
errors when the same people contribute data for multiple lesions,
most studies include very few people with multiple lesions, and
any potential impact on findings is likely to be very small, particu-
larly in comparison with other concerns regarding risk of bias and
applicability. For each analysis, we included only one dataset per
study to avoid multiple counting of lesions. We conducted sepa-
rate analyses according to the definition of the target condition,
i.e. detection of BCC, melanoma or cSCC, and detection of any
skin lesion requiring excision, as defined under Target condition
being diagnosed. We used ReviewManager 5 (RevMan 5) for pre-
liminary analyses of the data by plotting estimates of sensitivity
and specificity on coupled forest plots and in receiver operating
characteristic (ROC) space (RevMan 2014).We used the bivariate
model to obtain summary estimates of sensitivity and specificity
(Macaskill 2013). We fitted the bivariate models using the meqr-
logit command in STATA 15.
We made comparisons with standard diagnostic practice by com-
paring the accuracy of exfoliative cytology with visual inspection
or dermoscopy. We included direct comparisons using data on the
accuracy of visual inspection and/or dermoscopy only if reported
in the included studies of exfoliative cytology due to the known
substantial unexplained heterogeneity in all studies of the accuracy
of dermoscopy (Dinnes 2018b). We did not perform comparative
meta-analysis because of the limited number of studies.
We obtained 95% confidence intervals for sensitivity and speci-
ficity using the delta method and Wald tests, respectively. When
the number of studies was insufficient for meta-analysis, we ex-
amined individual study results and calculated 95% CIs using
the Newcombe-Wilson method without continuity correction
(Newcombe 1998).
Investigations of heterogeneity
We examined heterogeneity between studies by visually inspecting
forest plots and summary ROC plots. Due to the limited number
of studies in each analysis, we were unable to formally assess het-
erogeneity using meta-regression.
Sensitivity analyses
Wewere unable to perform sensitivity analyses due to limited data.
Assessment of reporting bias
Because of uncertainty about the determinants of publication bias
for diagnostic accuracy studies and the inadequacy of tests for
detecting funnel plot asymmetry (Deeks 2005), we did not test
for publication bias.
R E S U L T S
Results of the search
We identified and screened a total of 34,517 unique references
for inclusion. Of these, we reviewed 1051 full-text papers for el-
igibility for any one of the suite of DTA reviews of tests for di-
agnosing melanoma or keratinocyte skin cancer. Figure 6 docu-
ments a PRISMA flow diagram of search and eligibility results.
We tagged 40 full-text publications as potentially eligible for this
review, ultimately including 9. We excluded 9 studies that were
not primary studies, 8 including fewer than five benign lesions, 1
that insufficiently reported test accuracy data, 10 that used an inel-
igible index test (including swabbing (Bocking 1987), tape-strip-
ping (Berardi 1992), imprint cytology (Hering 1970;Melek 1970;
Urbach 1957), and fine needle aspiration (Jakasa 1976; Korabiec
1977; Rojo 1998; vonGizycki-Nienhaus 1992; Yu 2005)), 2 using
exfoliative cytology in an ineligible context (intraoperative care
or margin control), 4 in an ineligible patient population, and 4
using an ineligible reference standard. We excluded three studies
for multiple reasons. A list of the 31 studies excluded from this
review with reasons for exclusion is provided in Characteristics
of excluded studies, with a list of all studies excluded from the
full series of reviews available as a separate pdf (please contact
skin.cochrane.org for a copy of the pdf ).
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Figure 6. PRISMA flow diagram.
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Across all skin cancer DTA reviews, we contacted the correspond-
ing authors of 86 studies, asking 37 to supply further information
to allow study inclusion, 18 to clarify diagnostic thresholds, and
30 to define the target condition. It was not necessary to contact
any authors for the current review.
Included studies
We included nine studies evaluating the use of exfoliative cytology
in participants with lesions suspected of skin cancer, providing 25
datasets (14 for BCC, 2 for cSCC, 1 for melanoma, and 8 for any
malignant condition). One of these also performed a direct com-
parison between exfoliative cytology and dermoscopy (3 datasets:
one each for melanoma, BCC and any malignant condition). A
total of 1697 lesions were examined by the nine studies, of which
42 were excluded from analysis due to the absence of exfoliative
cytology test results (see ’Test failures’ below and Table 1) leaving
1655 lesions for analysis, including 1120 BCCs, 41 cSCCs, and
10 melanomas.
Appendix 8 describes the thresholds used for diagnosis across the
studies, along with summary study details.
Six studies recruited series of lesions with clinically suspected
BCCs that also underwent histological evaluation by excision
or biopsy. Two were prospective (Berner 1999; Gordon 1984),
two retrospective (Powell 2000; Ruocco 1992), and two un-
clear (Brown 1979; Derrick 1994). Two case-control studies,
Christensen 2008 and Nauth 1988, selectively included a mix of
histologically confirmed lesions, while a single prospective case se-
ries, Durdu 2011, was conducted in participants with pigmented
skin lesions considered to be difficult to diagnose on clinical
grounds. No studies provided further details regarding the degree
of investigation prior to receiving exfoliative cytology. Four took
place in the UK (Berner 1999; Brown 1979; Derrick 1994; Powell
2000), one in Italy (Ruocco 1992), one in Norway (Christensen
2008), one in Germany (Nauth 1988), one in Australia (Gordon
1984) and one in Turkey (Durdu 2011). None reported being
funded by manufacturers of diagnostic technology.
The number of participants ranged from 30 to 240 with a median
of 101 (interquartile range (IQR) 73 to 188), but one study did
not report this detail (Ruocco 1992). Studies included amedian of
150 lesions (range 37 to 578, IQR 83 to 224). In the BCC studies,
disease prevalence ranged from 52% in Gordon 1984 to 95% in
Derrick 1994 in the 6 case series, and it was pre-set in the two case-
control studies, at 19% in Nauth 1988 and 64% in Christensen
2008. In the series evaluating pigmented skin lesions, the preva-
lence of melanoma was 5% and of BCC, 17% (Durdu 2011). This
was the only study to include significant numbers of melanocytic
benign lesions (Durdu 2011), whilst the remaining eight stud-
ies included mainly non-melanocytic benign lesions including ac-
tinic keratoses, seborrhoeic keratoses, Bowen’s disease, and ker-
atoacanthoma. Four studies that did not contribute datasets for
the analysis of cSCC included small numbers of cSCCs (Berner
1999; Brown 1979; Derrick 1994; Ruocco 1992). Two studies did
not report specific benign diagnoses (Berner 1999; Nauth 1988).
Appendix 8 lists a full breakdown of differential diagnoses for each
study.
Studies used a variety of staining methods. Three employed Pa-
panicolau (Christensen 2008; Gordon 1984; Nauth 1988), and
three May-Grünwald Giemsa (MGG; Christensen 2008; Derrick
1994; Durdu 2011). One study used Diff-Quick (Berner 1999).
Three studies used more than one technique, but two (Brown
1979; Ruocco 1992) failed to report which they had used in par-
ticular participants, and a fourth failed to report the stain method
(Powell 2000). One study that performed a direct comparison of
diagnoses made using Pap, MGG, and both Pap andMGG inves-
tigated the impact of varying stain methods (Christensen 2008).
All studies based their index diagnoses on cytomorphological find-
ings, though three failed to outline the diagnostic criteria used
(Brown 1979; Christensen 2008; Powell 2000). Features diagnos-
tic for BCC were similar across the remaining studies, except for
Nauth 1988, who clearly implemented a different approach by us-
ing a classification developed from vaginal cytology (the ’Munch-
ener scheme’, a modification of the original Papanicolaou classifi-
cation) to decide whether a lesion was malignant. For the diagnosis
of melanoma, Durdu 2011 provided a basic definition of disease,
defining melanoma as the presence of ’epithelioid or spindle-type
atypical nevoid cells’. Durdu 2011 also reported dermoscopic di-
agnoses for all patients, which followed a two-step method, dif-
ferentiating melanocytic from non-melanocytic lesions before ap-
plying the ABCD algorithm. Appendix 8 lists specific diagnostic
criteria for each study.
The dermatologist performed skin scrapes in one study (Durdu
2011), but the remaining studies did not describe the oper-
ating clinician. Studies described the experience of the clini-
cian performing cytodiagnosis as the cytologist (Gordon 1984),
cytopathologist (Berner 1999; Christensen 2008), pathologist
(Derrick 1994), or dermatologist (Durdu 2011), but four stud-
ies did not report this (Brown 1979; Nauth 1988; Powell 2000;
Ruocco 1992). No study evaluated interobserver variability.
In eight studies the reference standard diagnosis was by histology
alone, while Brown 1979 used expert opinion to overrule the his-
tological diagnosis in two lesions whose clinical and cytological
appearance was ’characteristic’ of BCC.
Test failures
Four studies reported instances of insufficient cellular material
to make a cytological diagnosis (Christensen 2008; Durdu 2011;
Gordon 1984; Nauth 1988), listed in Table 1. Comprising be-
tween 1%and 8%of slides evaluated in each study, these were con-
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sidered as test failures and excluded from analysis of accuracy. One
study excluded inadequate slides at study entry (Berner 1999), and
the remaining four studies did not report the adequacy of cellular
material, suggesting this may have been an implicit eligibility cri-
terion (Brown 1979; Derrick 1994; Powell 2000; Ruocco 1992).
Methodological quality of included studies
Overall study quality was low or unclear, particularly in terms of
the clinical applicability of results (Figure 7 and Figure 8).
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Figure 7. Risk of bias and applicability concerns summary: review authors’ judgements about each domain
for each included study. One study, Durdu 2011, was assessed in the comparative domain as ’unclear’ for both
risk of bias and applicability concerns.
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Figure 8. Risk of bias and applicability concerns graph: review authors’ judgements about each domain
presented as percentages across included studies. One study, Durdu 2011, was assessed in the comparative
domain as ’unclear’ for both risk of bias and applicability concerns.
Three of the nine studies were at low risk of bias for partici-
pant selection (Gordon 1984; Powell 2000; Ruocco 1992); three
were at high risk of bias: two because they recruited non-consec-
utively and selected participants according to histological diagno-
sis (Christensen 2008; Nauth 1988), and one because it excluded
lesions inappropriately (Derrick 1994). Three did not clearly de-
scribe consecutive patient recruitment or exclusions. Concern was
high for the applicability of setting and included participants in
six studies: due to poor reporting regarding the composition of
study populations in five (Christensen 2008;Gordon 1984;Nauth
1988; Powell 2000; Ruocco 1992), inclusion of narrowly defined
study groups in two (Berner 1999; Derrick 1994), and inclusion
of multiple lesions per patient in five (Berner 1999; Christensen
2008;Durdu 2011;Gordon 1984; Powell 2000).We couldnot de-
termine the clinical applicability of participant populations in two
studies due to insufficient reporting of study populations (Nauth
1988; Ruocco 1992).
Risk of bias for the index test was low in two studies (Berner 1999;
Gordon 1984), but we could not determine this in the remaining
seven studies due to poor reporting of diagnostic thresholds and
whether cytology slides were interpreted without knowledge of the
lesion’s histology results.More than half of the studies (5/9) caused
high concern regarding the applicability of the index test, since
examiners did not did have access to the clinical diagnosis during
review of cytology slides (Christensen 2008; Gordon 1984), and
they did not report cytodiagnostic criteria in sufficient detail to
allow replication (Brown 1979; Christensen 2008; Gordon 1984;
Powell 2000; Ruocco 1992); we could not assess two studies due to
poor reporting of the diagnostician’s cytological expertise (Durdu
2011; Nauth 1988). The remaining two studies were of low con-
cern (Berner 1999; Derrick 1994).
All studies reported the use of an acceptable reference standard
with one exception: Nauth 1988 failed to state the reference
standard used to confirm the absence of disease in 14 of 224
included diseased participants (Nauth 1988). Only two studies
clearly blinded the reference standard diagnosis to the cytology
results (Berner 1999; Brown 1979), while in the remaining seven
studies a failure to clearly report this aspect meant that the risk
of bias due to conduct of the reference standard was unclear. We
were also unclear as to whether most studies (7/9) used the refer-
ence standard in a clinically applicable way, largely due to inade-
quate description of the conduct and interpretation of histology;
only one study reported histopathological interpretation by an ex-
perienced dermatopathologist (Derrick 1994). We judged Brown
1979 to be of high concern due to use of expert opinion (discipline
and qualifications not reported) to overrule the reference standard
diagnosis in 2 of 85 cases.
We judged only one study, Durdu 2011, to be at low risk of bias
for the flow and timing domain, while the rest were at high and/or
unclear risk. Brown 1979 andNauth 1988 used different reference
standard tests, and Christensen 2008 excluded slides ’unavailable
for examination’; these aspects conferred a high risk of bias. Seven
studies were unclear in that they failed to report the time interval
between exfoliative cytology and histology examinations (Berner
1999; Christensen 2008; Derrick 1994; Gordon 1984; Nauth
1988; Powell 2000; Ruocco 1992).
The single study comparing exfoliative cytology with dermoscopy,
Durdu 2011, reported blinding the diagnoses of the two index
tests; however, authors did not describe the time interval between
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tests or give sufficient details on their conduct, thus its risk of bias
and applicability in the comparative domain remain unclear.
Findings
Detection of BCC
Seven of the nine studies provided data eligible for pooling. We
did not pool the remaining two studies in the meta-analysis be-
cause Nauth 1988 used a different diagnostic classification system
(the Munchener scheme), and Durdu 2011 evaluated exfoliative
cytology in a distinct patient group (pigmented skin lesions).
The seven pooled studies were in participants with clinically
suspect BCC lesions, and they used standard cytomorphology
to investigate 1264 lesions, 1045 of which were BCCs, using
MGG stain (Derrick 1994), Pap stain (Gordon 1984), Diff-Quick
(Berner 1999), or a mixture of stain techniques (Brown 1979;
Ruocco 1992); Powell 2000 did not report the stain method.
Christensen 2008 used two slides per lesion: one MGG and the
other Pap stain, selecting the slide showing the greatest degree
of cytological atypia for the final diagnosis. These were pooled
regardless of stain method used, giving a summary sensitivity of
97.5% (95% CI 94.5% to 98.9%) with a summary specificity of
90.1% (95% CI 81.1% to 95.1%). Table 2 provides a summary
of all results.
Common diagnoses mistaken for BCC were actinic keratosis in
Christensen 2008 and Gordon 1984 and trichoepithelioma in
Derrick 1994 and Ruocco 1992. Only 3 of the 22 false positive
cases (listed in Table 3) were malignant lesions, and all 3 were
confirmed carcinomas, but it was not possible to classify histolog-
ical type due to insufficient biopsy material (Berner 1999). No
false positive cases were melanomas. Six of the seven false posi-
tive cases in Gordon 1984 were ’possible but not diagnostic for
BCC’ lesions, histologically diagnosed as marked atypia (n = 4)
and seborrhoeic keratosis (n = 2). Consideration of these uncertain
diagnoses as test negatives did not impact on pooled sensitivity
(97.3%, 95% CI 93.5% to 98.9%) but raised the specificity esti-
mate to 94.2% (95%CI 88.7% to 97.1%; Figure 9 Figure 10). All
16 cSCCs were correctly identified as true negative cases (Berner
1999; Brown 1979; Derrick 1994; Gordon 1984; Ruocco 1992);
however, two studies misdiagnosed three BCCs as cSCCs (Brown
1979; Gordon 1984).
Figure 9. Forest plot of exfoliative cytology to detect BCC in patients with suspected BCCs, showing
classification of ’possible BCCs’ as test positives or as test negatives.
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Figure 10. Summary ROC plot of exfoliative cytology to detect BCC in patients with suspected BCCs,
showing classification of ’possible BCCs’ as test positives or as test negatives.
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The study using the Munchener scheme, Nauth 1988, identified
fewer BCCs and incorrectly diagnosed 42 lesions as being BCC,
giving a sensitivity of 80.5% (95% CI 66.0 to 89.8%) and speci-
ficity of 74.6% (95%CI 67.4% to 80.6%). Authors did not report
misdiagnosis by lesion type.
The study in pigmented skin lesions (MGG stain) reported no
false diagnoses amongst slides for 185 lesions, giving a sensitivity
of 100% (95%CI 89.9% to 100%) and specificity of 100% (95%
CI 97.5% to 100%) for the diagnosis of BCC (Durdu 2011);
however, 15 lesionswere excluded from analysis due to the retrieval
of insufficient cell material. Results for dermoscopy, conducted on
the full sample of 200 lesions, demonstrated a lower sensitivity of
94.1% (95% CI 80.9% to 98.4%) and higher specificity 98.2%
(95%CI 94.8% to 99.4%), but the differences could be explained
by chance.
Christensen 2008 found no difference in sensitivity or specificity
between the three stain techniques (Pap versus MGG versus Pap
+ MGG), with each method identifying the same number of false
positive (n = 1) and false negative (n = 2) cases to give a sensitivity
of 96% and specificity of 96%.
Detection of cSCC
Six studies examined cSCC lesions, although those from four stud-
ies (totalling 11 lesions) were excluded from analysis due to each
study having an inadequate number of cSCC cases (fewer than
5 per study). The two remaining studies contributed 41 analysed
cSCC lesions amongst their 347 lesions, however their results were
not pooled due to their use of different diagnostic criteria. Us-
ing standard cytomorphological criteria to diagnose 5 cSCC slides
from 141 lesions, Gordon 1984 report a sensitivity of 100% (95%
CI 56.6% to 100%) and specificity of 98.5% (95% CI 94.8% to
99.6%) with two false positive results, both showing squamous
differentiation with cellular pleomorphism and a histological di-
agnosis of pleomorphic BCC. Nauth 1988’s use of theMunchener
scheme to diagnose 36 cSCC slides from 206 lesions resulted in a
lower sensitivity of 88.9% (95% CI 74.7% to 95.6%) and lower
specificity of 74.7% (95%CI 67.7% to 80.6%), reporting the only
false negative cSCCs of any included study. Two were diagnosed as
’questionable dyskeratoses and/or questionable anaplastic tumour
cells’, one as mild dysplasia and the fourth as severe dysplasia.
No data were available to compare exfoliative cytology for detec-
tion of cSCC with routine diagnostic practice.
Detection of invasive melanoma and atypical
intraepidermal melanocytic variants
The single study evaluating exfoliative cytology for the detection of
10 melanomas in 185 lesions, Durdu 2011, reported sensitivity of
100% (95%CI 72.3% to 100%) and specificity of 100% (95%CI
97.6% to 100%); dermoscopic diagnosis in the full sample (200
lesions, 10 melanomas) produced a sensitivity of 80.0% (95% CI
49.0% to 94.3%) and specificity of 97.4% (95% CI 94.0% to
98.9%). One other study included a single case of melanoma as a
BCC-negative case (Brown 1979).
Detection of any skin cancer
Four studies in 573 clinically suspect BCC lesions provided data
for detection of any skin cancer (Berner 1999; Brown 1979;
Derrick 1994; Gordon 1984); 495 histologically confirmed ma-
lignant lesions were included (476 BCCs, 13 cSCCs, 1melanoma,
4 carcinomas of unspecified histological type (Berner 1999), plus
1 apocrine carcinoma (Derrick 1994)). Pooled sensitivity was es-
timated to be 97.3% (95% CI 93.5% to 98.9%) with a pooled
specificity of 86.0% (95% CI 73.5% to 93.1%). Consideration of
uncertain diagnoses as test negatives did not impact on pooled es-
timates of sensitivity (96.6%, 95% CI 90.3% to 98.9%) or speci-
ficity (94.7%, 95% CI 80.2% to 98.7%; Figure 11; Figure 12;
Berner 1999; Gordon 1984).
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Figure 11. Forest plot of studies pooled for accuracy of exfoliative cytology to detect any skin cancer in
patients with suspected BCCs, comparing: classification of ’possible BCCs’ as test positives versus classification
of ’possible BCCs’ as test negatives.
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Figure 12. Summary ROC plot of pooled studies for accuracy of exfoliative cytology to detect any skin
cancer in patients with suspected BCCs, comparing: classification of ’possible BCCs’ as test positives versus
classification of ’possible BCCs’ as test negatives.
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The Munchener scheme, used in Nauth 1988, was less sensitive
in its detection of 36 cSCCs and 41 BCCs amongst 206 included
cases, with a sensitivity of 84.4% (95% CI 74.7% to 90.9%) and
specificity of 92.3% (95% CI 86.3% to 95.7%).
The study in pigmented skin lesions included 10 melanomas, 34
BCCs, 1 case of pigmented mammary Paget’s disease, and 1 pig-
mented metastatic mammary carcinoma (Durdu 2011). In 185
lesions, exfoliative cytology was able to differentiate between these
and benign conditions with a sensitivity of 100% (95% CI 92.3%
to 100%) and a specificity of 100% (95% CI 97.3% to 100%).
Whilst this was marginally more accurate when compared to der-
moscopy alone (sensitivity 97.8%, 95% CI 88.7% to 99.6%;
specificity 98.1%, 95% CI 94.4% to 99.3%), the difference could
be due to chance. Also, dermoscopy was conducted on the full
sample of 200 lesions (Durdu 2011).
Effect of observer experience
No included studies evaluated the effect of observer experience on
the accuracy of exfoliative cytology in any skin cancer.
Investigations of heterogeneity
We were unable to undertake formal investigations of heterogene-
ity due to insufficient study numbers.
D I S C U S S I O N
Summary of main results
This review aimed to assess the accuracy of exfoliative cytology for
diagnosing BCC, cSCC or melanoma in adults, yet most studies
focus on its use for confirming the clinical diagnosis in lesions with
a high clinical suspicion of BCC. Studies were poorly reported
and of uncertain to poor methodological quality, particularly in
terms of the applicability of their results to the current clinical
setting in the UK, thus limiting the strength of conclusions that
can be drawn. The Summary of findings presents key results for
the primary target condition of BCC.
Pooled results from seven studies with 1264 clinically suspected
BCC lesions that included 1045 BCCs provided a sensitivity of
97.5% (95% CI 94.5% to 98.9%) and specificity of 90.1% (95%
CI 81.1% to 95.1%). The Summary of findings translates these
estimates to a hypothetical cohort of 1000 lesions clinically sus-
pected of being BCC. At the median BCC prevalence of 86%, ex-
foliative cytology wouldmiss 21 BCCs andwould result in 14 false
positive diagnoses. As BCCs are usually relatively slow growing,
delayed treatment of 21 out of 860 BCCs may not have serious
consequences. However, if the test was used as a basis for initia-
tion of non-surgical treatment, and any of the false positive results
were lesions requiring excision, such as melanomas or cSCCs, the
consequences could be potentially fatal. At the lower and upper
quartile prevalence of BCC of 63% and 88%, 16 and 22 BCCs
would be missed, respectively, with 37 and 12 false positive di-
agnoses. While evidence for the ability of exfoliative cytology to
detect cSCC is scarce (with only one study using a clinically rel-
evant application of exfoliative cytology), it is worth noting that
all 17 cSCCs included in the primary analysis were correctly iden-
tified using standard cytomorphology, albeit with some difficulty
in discriminating BCCs from cSCC correctly in the presence of
pleomorphic features. This suggests that in populations with very
high clinical suspicion of BCC, and therefore high prevalence of
disease, exfoliative cytology could have a potential role in guiding
the use of non-surgical therapy and avoiding biopsy. Decisions
to start some non-surgical treatments in patients with superficial
BCC, for example topical imiquimod, are in practice unlikely to
require additional confirmation when clinical suspicion is already
high, and thus cytodiagnosis is likely to have minimal utility in
these cases. Conversely, exfoliative cytology may be most valuable
to the management of patients with BCC lesions considered for
radiotherapy, since a tissue diagnosis is typically required for con-
firmation before the therapy can proceed.
The ’perfect’ results for the detection of both BCC and melanoma
from the single study recruiting only pigmented lesions is likely
to be explained by the unique case-mix of patients (Durdu 2011),
with high proportions of benign melanocytic naevi and of benign
non-melanocytic lesions such as seborrhoeic keratosis, warts and
dermatofibroma (Durdu 2011). The high rate of uninterpretable
benign slides in this study (8%) may also have influenced its speci-
ficity. In the absence of additional studies and greater numbers
of lesions, these data did not provide sufficient evidence on the
performance of exfoliative cytology to detect melanomas, its use
in populations with pigmented skin lesions, or its performance
using other cytological classification approaches.
Observed limitations of primary studies
Studies were limited by universally poor reporting and poor
methodological quality. In addition to scarce reporting of partici-
pant selection, studies failed to outline the prior referral pathway
of eligible patients, including a description of which clinical meth-
ods they had used to arrive at a clinical suspicion of BCC that was
strong enough to make the patients eligible for study inclusion.
For the purposes of our BCC analysis, we have assumed that all
approaches resulted in similar population groups; however, in re-
ality the spectrum of disease in included groups remains unclear
and could differ considerably.
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Similarly, very limited reporting of the diagnostic criteria used
to define the cytomorphologic presence of disease could obscure
actual differences in diagnostic thresholds. Along with missing
descriptions of howhistopathological diagnosesweremade and the
experience of clinicians performing or interpreting scrapes, these
limitations of the primary studies limit the generalisability of our
findings to current clinical practice, as well as our understanding
of the efficacy of exfoliative cytology to distinguish between skin
cancers.
There was a similar lack of clarity in description of most items nec-
essary to determine the risk of bias, including: recruitment meth-
ods, study design, threshold selection, blinding of the reference
standard to the index test result and the time interval between
exfoliative cytology and definitive histology. When these details
were reported, studies were often at high risk of bias, so their accu-
racy estimates may not adequately reflect the true sensitivity and
specificity of exfoliative cytology.
Strengths and weaknesses of the review
The strengths of this review include an in-depth and comprehen-
sive electronic literature search, systematic reviewmethods includ-
ing double extraction of papers by both clinicians and methodol-
ogists, and contact with authors to allow study inclusion or clarify
data. We planned a clear analysis structure to allow estimation of
test accuracy in discrete study populations using only scrape tech-
niques to gather a cell sample for cytopathology. We undertook a
detailed and replicable assessment of methodological quality. This
is the only review we are aware of to have examined the accuracy
of exfoliative cytology for detecting cSCC, melanoma or any skin
cancer.
Published in 2004, Bakis 2004 was an earlier meta-analysis of ex-
foliative cytology based on eight studies including 1261 BCCs.
Reviewers arrived at very similar pooled estimates (97% sensi-
tivity and 86% specificity), despite including three studies that
did not meet our inclusion criteria due to: differing target con-
dition (Barton 1996), ineligible method of exfoliation (Bocking
1987), and insufficient numbers of individuals with benign disease
(Vega-Memije 2000). By comparison, the present review provides
an updated estimate of the accuracy of exfoliative cytology to de-
tect BCC using a larger number of studies (three published after
2004), evaluating the same target conditions, and all of which have
used scrape techniques to gather a cell sample for cytopathology.
Ours has included a non-English language study, Nauth 1988,
which was excluded from the Bakis 2004 review (because the arti-
cle could not be located), so the present review constitutes a more
current and comprehensive summary of the accuracy of exfoliative
cytology to detect BCC.
The main concerns for this review are the small number of stud-
ies and their poor reporting of patients’ prior referral pathways,
criteria used to arrive at cytopathological or histopathological di-
agnoses, observer experience, and other aspects relating to par-
ticipant selection or methods of performing exfoliative cytology.
Some authors have questioned the ability of cytopathology to pro-
vide sufficient discrimination of skin cancer subtypes (Barr 1984);
however, we did not address this topic in the current review. Thus,
echoing the findings of Bakis 2004, the main weakness of this re-
view is the poor reporting of primary studies, which has limited
our appraisal of study quality and, critically, impedes our under-
standing of whether summary estimates are applicable to current
clinical settings.
Applicability of findings to the review question
Not all data included in this review are likely to be generally ap-
plicable to the current clinical setting. In particular, Durdu 2011
used exfoliative cytology in a clearly different population to that
in which the test is likely to be used in clinical practice, whilst
Nauth 1988 used a diagnostic classification used for vaginal cytol-
ogy (the Munchener scheme) to grade the degree of cell dysplasia
from normal to anaplastic, an approach which is clearly different
from the other seven studies that sought to determine whether a
lesion was a BCC, cSCC or melanoma. We pooled the remaining
seven studies, and summary accuracy estimates do appear to show
that exfoliative cytology confirms clinically suspected BCC with
a high sensitivity and specificity; however, poor reporting limits
any more detailed statements regarding which patient populations
these results would be replicated in. Furthermore, the lack of de-
scription in all studies regarding the diagnostic criteria used for
both index test and reference standard may restrict applicability
and transferability of results in practice.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The utility of exfoliative cytology for the primary diagnosis of skin
cancer is unknown, as all included studies have focused on the
use of this technique for confirming strongly suspected clinical
diagnoses. Whilst our review has provided some data regarding the
potential usefulness of confirming the clinical diagnosis of BCC,
the small number of included studies, poor reporting and varying
methodological quality of seven included studies means that we
cannot draw any strong conclusions to guide practice. Bearing this
inmind, for the confirmationof BCC in lesionswith a high clinical
suspicion, there is evidence of high sensitivity and specificity for
exfoliative cytology. As such, the test might be useful for cases
of BCC that can be diagnosed confidently where clinicians are
contemplating treatments that require a tissue diagnosis, such as
radiotherapy. However, as the main potential advantage of the test
would be initiation of non-surgical treatment and avoidance of
unnecessary biopsy in confirmed cases of low-risk BCC, even the
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high rates of specificity observed will lead to a number of false
positive diagnoses, including in populationswith a high prevalence
of BCC.The critical question is whether patients and clinicians are
willing to accept the potential formisdiagnosis of some lesionswith
a worse prognosis that require excision. While none of the false
positive diagnoses in these studiesweremelanomas or cSCCs, three
carcinomas weremisdiagnosed in one study, though unfortunately
their precise type could not be confirmed due to the presence
of inadequate sample sent for histology (Berner 1999). Even if
cytology confirms a clinically suspected BCC, it can never give
the same quality of histological information on parameters such as
lesion architecture and infiltration or perineural invasion as does
an entire skin biopsy. It is possible therefore that some of the true
positives in our studies included more infiltrative forms of BCC
that would have been better treated by wide excision or Mohs
micrographic surgery. Exfoliative cytology poses another potential
limitation in cases that require a subsequent excision, since the
previous scrapingprocess could distortmeasurement of total lesion
depth and because a cytological scrape may induce ulceration,
which would alter the prognostic classification.
Insufficient data are available to provide conclusive comments on
the accuracy of exfoliative cytology to detect melanoma or cSCC.
While only one study reported that exfoliative cytology missed
cSCC diagnoses, not all studies included an adequate range of dif-
ferential diagnoses known to present difficulties in being differen-
tiated from cSCC using cytomorphology. It is therefore unlikely
that the accuracy estimates reflect the true discriminatory power of
exfoliative cytology. As for BCC, superficial scrapings of squama-
tous lesions cannot provide information regarding the lesion’s pat-
tern of invasion, hence the technique is potentially very limited
unless it is used to confirm lesions that already have a very high
clinical suspicion. For similar reasons, exfoliative cytology is very
unlikely to be useful in the diagnosis of melanoma: an absence of
malignant cells would require a biopsy since superficial scrapings
cannot be relied upon to rule out invasion, while the presence
of malignant cells would still require a further biopsy to confirm
the diagnosis of melanoma and to determine depth of invasion
which guides future excision margins for definitive management.
Cytology is unlikely to avert the need for a biopsy of a new lesion
suspected to be melanoma. Conversely, performing an adequate
scrape in these lesions risks introducing inflammation and ulcer-
ation, which would alter the histopathological characteristics of
the lesion that inform prognosis and treatment. On this basis we
caution against the use of exfoliative cytology in non-ulcerated
lesions suspected to be melanoma.
Implications for research
Whilst some (low-quality) evidence exists for evaluating the use
of exfoliative cytology for confirming a BCC that has been diag-
nosed clinically i.e. a confirmatory test, the use of exfoliative cytol-
ogy as a primary diagnostic test for suspected skin cancer at dif-
ferent points in the care pathway remains unknown. Given the
absence of studies that evaluate the diagnostic value of exfoliative
cytology in discriminating between BCC and other skin cancers
and other benign lesions, studies are needed to provide a full and
proper evaluation of the accuracy and ability of the test. Such
studies should prospectively evaluate exfoliative cytology in com-
parison to an alternative diagnostic test such as dermoscopy in a
standard healthcare setting, for which the most rigorous design
would be a multiple test comparison study (Takwoingi 2013), in
which study participants are given both diagnostic tests followed
by an acceptable reference standard. Study participants should be
recruited consecutively from a clearly defined population that is
representative of patients who would receive the test in practice
and should include sufficient numbers of participants with cSCC
as well as key benign differential diagnoses.
There is also scope for further research that adequately reports its
evaluation of exfoliative cytology for confirming the diagnosis of
BCC in whom a clinical diagnosis has indicated a high probability
of BCC in order to plan further treatment such as radiotherapy.
Whether new research examines the use of exfoliative cytology
as a primary diagnostic or confirmatory treatment-planning test,
such studies need to clearly define the target patient group and
should include a full description of the clinical pathway (referral
process), including prior testing. A multi-centred approach would
allow confirmation that results are replicable across centres and
that the technology can be implemented across a health service.
Future studies should also explore patients’ views of the test as well
as costs to the health service. Prospective recruitment of a con-
secutive series of participants, with test interpretation blinded to
the reference standard diagnosis, with pre-specified and clearly de-
fined diagnostic thresholds for determining test positivity, is easily
achieved. Clear identification of qualifications and practitioner/
diagnostician training and experience is also required. Systematic
follow-up of non-excised lesions avoids over-reliance on a histolog-
ical reference standard and allows results to be more generalisable
to routine practice. These studies would benefit from evaluating
standardised techniques for performing and interpreting Tzank
smears, which have yet to be developed. Developing diagnostic
criteria would be useful for clinicians, facilitating ease of inter-
pretation and ensuring that the results of future studies are fully
transferable to clinical practice. Any future research study needs
to be clear about the diagnostic pathway followed by study par-
ticipants prior to study enrolment, and reporting should conform
to the updated Standards for Reporting of Diagnostic Accuracy
(STARD) guideline (Bossuyt 2015).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Berner 1999
Study characteristics
Patient sampling Study design: case series
Data collection: prospective
Period of data collection: NR
Country: Norway
Funding: none declared
Patient characteristics and set-
ting
Inclusion criteria: lesions clinically suspected of being nodular BCCs
Setting: secondary (unspecified)
Prior testing: clinical suspicion of BCC (no further details)
Exclusion criteria: lesions thinner than 2 mm, with inadequate material retrieved for cytological
or histological analysis
Sample size (patients):no. eligible: 90;no. included: 90
Sample size (lesions):no. eligible: 112;no. included: 107
Participant characteristics: none reported
Lesion characteristics: all were nodular lesions, located on the head, thorax or abdomen
Index tests Exfoliative cytology: initial removal of epidermal or keratin layer; scalpel or curette to obtain
sample; stain method Diff-Quick
Diagnostic threshold: qualitative - microscopic appearance of cellular scraping
Diagnosis of BCC was based on a cellular smear with the presence of small dissociated hyperchro-
matic cells in cohesive sheets
Prior test data available: clinical diagnosis (no further details)
Diagnosis based on single or consensus observation: NR (3 examiners)
Observer qualifications: NR - ’cytopathologists’
Experience in practice: NR
Experience with index test: NR
Cases excluded due to insufficient cellular material on slide: 0
Target condition and reference
standard(s)
Type of reference standard: histology (shave biopsy)
Details: minute tumour fragments of sizes 1-3 mm were removed from the lesions with a curette
and placed in a Shandon cytoblock cassette before fixation in 4% buffered formalin. The tumour
fragments were removed without damaging neighbouring skin and without the use of anaesthesia.
The histological specimens were examined by one pathologist (AB). The minute tissue fragments
were fixed in 4% buffered formalin before embedding in paraffin. Sections 5 mm thick were cut at
3 levels and stained with haematoxylin and eosin. The histological diagnosis of BCC was based on
the criteria defined by WHO (study reference #6)
Disease positive: 101;disease negative: 6
Final diagnoses:
• Malignant: 96 BCC; 1 cSCC; 4 carcinoma (type not specified)
• Benign diagnoses: 6 (3 ’benign’; 3 atypical)
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Berner 1999 (Continued)
Flow and timing Index test to reference standard interval: consecutive; quote: “tumour fragments ... were subse-
quently removed from the lesions”
Interval between index tests: NA
Exclusions: none reported
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
No
Unclear High
DOMAIN 2: Index Test Exfoliative cytology
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Was the test applied and inter-
preted in a clinically applicable
manner?
Yes
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Berner 1999 (Continued)
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Were the reference standard re-
sults interpreted with-
out knowledge of the referral di-
agnosis? (DOES NOT CON-
TRIBUTE TO THE REFER-
ENCE STANDARDRISKOF
BIAS JUDGEMENT)
Yes
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
47Exfoliative cytology for diagnosing basal cell carcinoma and other skin cancers in adults (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Berner 1999 (Continued)
Were all patients included in the
analysis?
Yes
Unclear
Brown 1979
Study characteristics
Patient sampling Study design: case series
Data collection: NR
Period of data collection: NR
Country: UK
Funding: none declared
Patient characteristics and set-
ting
Inclusion criteria: localised lesions forwhich a histological diagnosis was required to confirm clinical
diagnosis of BCC, or in a minority to exclude BCC
Setting: secondary (unspecified)
Prior testing: clinical suspicion of BCC (no further details)
Exclusion criteria: none reported
Sample size (patients):no. eligible: NR;no. included: 81
Sample size (lesions):no. eligible: NR;no. included: 85
Participant characteristics: none reported
Lesion characteristics: none reported
Index tests Exfoliative cytology: initial removal of surface crust; scalpel or curette to obtain sample; stain
method short May-Grunwald-Giemsa technique or rapid method (sample treated with 0.1% aque-
ous toluidine blue for 2 minutes followed by brief washing in water)
Diagnostic threshold: NR, presumably based on qualitative appearance of scraping material
Interpretation of smears includes: form of cell clusters, variation in cell size and outline, presence of
squamous differentiation
Prior test data available: clinical diagnosis (no further detail)
Diagnosis based on single or consensus observation: NR
Observer qualifications: NR
Experience in practice: NR
Experience with index test: NR
Cases excluded due to insufficient cellular material on slide: 0
Target condition and reference
standard(s)
Type of reference standard: histology (biopsy) in all, plus expert opinion in 2/85 with discordant
cytological and histological findings
Details: the biopsy tissue was fixed in 10% formalin in normal saline and processed routinely for
histology. When biopsy disagreed with clinical and cytological diagnosis, expert opinion used to
overrule histological diagnosis
Disease positive: 76;disease negative: 9
Final diagnoses:
• Malignant: 73 BCC; 2 cSCC; 1 malignant melanoma
• Benign diagnoses: 9 (5 seborrhoeic keratosis; 4 actinic keratosis)
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Brown 1979 (Continued)
Flow and timing Index test to reference standard interval: consecutive; quote: “biopsy undertaken immediately
after exfoliative cytology”
Interval between index tests: NA
Exclusions: none reported
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
Are the included patients and
chosen study setting appropri-
ate?
Yes
Did the study avoid including
participants with multiple le-
sions?
Yes
Unclear Low
DOMAIN 2: Index Test Exfoliative cytology
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
Was the test applied and inter-
preted in a clinically applicable
manner?
Yes
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Brown 1979 (Continued)
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
Unclear High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Were the reference standard re-
sults interpreted with-
out knowledge of the referral di-
agnosis? (DOES NOT CON-
TRIBUTE TO THE REFER-
ENCE STANDARDRISKOF
BIAS JUDGEMENT)
No
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
No
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Low High
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
No
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Brown 1979 (Continued)
Were all patients included in the
analysis?
Yes
High
Christensen 2008
Study characteristics
Patient sampling Study design: case-control
Data collection: retrospective
Period of data collection: NR
Country: Norway
Funding: none declared
Patient characteristics and set-
ting
Inclusion criteria: histologically confirmed BCC or AK lesions
Setting: secondary (General Dermatology)
Prior testing: NR
Exclusion criteria: none reported
Sample size (patients):no. eligible: NR;no. included: 64
Sample size (lesions):no. eligible: NR;no. included: 78
Participant characteristics: none reported
Lesion characteristics: 10 were recurrences; mean lesion size 9.0 mm (range 2.0-41.0 mm); Mean
BCC tumour thickness (n-30) 1.6 mm (range 0.5-4.0 mm); BCC types: 16 superficial, 23 nodular,
3 micronodular, 2 infiltrating, 2 basosquamous, 4 morphoeic
Lesions located on head or neck (56.72%), trunk (15.19%), extremities (7.10%)
Index tests Exfoliative cytology: curette to obtain sample; 3 smears for each lesion: modified Pap technique,
MGG technique, touch imprint stained with MGG
Diagnostic threshold: qualitative appearance of cell material
Cytological results grouped into 4 categories: BCC, AK, non-BCC/non-AK and non-evaluable
(smears showing only keratin and/or cellular debris or inadequate cellular material). Final diagnosis
for the combined diagnostic result from Pap and MGG stains determined from the slide showing
the greatest degree of cytological atypia
Cytological diagnosis of BCC: quote: “based on fragments of closely packed cells which tend to
present in monolayers or a club-like formations, demonstrating smooth external contours and pe-
ripheral palisading of nuclei. There is little dissociation of cells. The malignant basal cells have small,
oval, hyperchromatic nuclei. The nucleus to cytoplasmic ratio is extremely high. Smears from AK
lesions show greater cellular dissociation and individual as well as clumps of dysplastic keratinocytes,
often with ragged edges. These cells show a polyhedral or spindle-shaped configuration. The nucleus
to cytoplasmic ratio is moderately high ... Each specimen was considered independently even if
taken from the same patient.”
Prior test data available: none; blinded to clinical exam
Diagnosis based on single or consensus observation: NR (2 examiners participated)
Observer qualifications: ’Pathologists’
Experience in practice: NR
Experience with index test: high; extensive experience in cytology without specific training in skin
scrape cytology
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Christensen 2008 (Continued)
Other details: within-patient comparison of stain methods conducted
Cases excluded due to insufficient cellular material on slide: 1 (1 AK)
Target condition and reference
standard(s)
Type of reference standard: histology alone
Details: punch biopsies (2 or 3 mm) fixed in 10% formaldehyde, routinely processed and embed-
ded in paraffin. Sections of 4 microns were cut at 3 levels and stained with haematoxylin-eosin-
saffron. Cases of BCC were subtyped according to the WHO guidelines: superficial type; nodular/
micronodular type; and infiltrating type, basosquamous type or morphoeic type
Disease positive: 50;disease negative: 28
Final diagnoses:
• Malignant: 50 BCC
• Benign diagnosis: 28 actinic keratosis
Flow and timing Index test to reference standard interval: not reported for 50 (67%) cases, consecutive in 28 cases;
quote: “[i]n cases where no former histology report existed, a diagnostic punch biopsy was obtained
approximately 3-5 minutes before cytological sampling”
Interval between index tests: NA
Exclusions: 3 slides ’unavailable for investigation’
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
Was a case-control design
avoided?
No
Did the study avoid inappropri-
ate exclusions?
Unclear
Are the included patients and
chosen study setting appropri-
ate?
Unclear
Did the study avoid including
participants with multiple le-
sions?
No
High High
DOMAIN 2: Index Test Exfoliative cytology
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Christensen 2008 (Continued)
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Unclear High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Were the reference standard re-
sults interpreted with-
out knowledge of the referral di-
agnosis? (DOES NOT CON-
TRIBUTE TO THE REFER-
ENCE STANDARDRISKOF
BIAS JUDGEMENT)
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
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Christensen 2008 (Continued)
Unclear Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
High
Derrick 1994
Study characteristics
Patient sampling Study design: case series
Data collection: NR
Period of data collection: NR
Country: UK
Funding: none declared
Patient characteristics and set-
ting
Inclusion criteria: clinically suspected BCC on head or neck
Setting: secondary (unspecified)
Prior testing: clinical examination (no further details)
Exclusion criteria: none reported
Sample size (patients):no. eligible: NR;no. included: 240
Sample size (lesions): no. eligible: NR;no. included: 240
Participant characteristics: none reported
Lesion characteristics: BCC types: ulcerative (n = 116, 48%), nodulocystic (n = 101, 42%),
morphoeic (n = 19, 8%) and superficial (n = 4, 2%); located on the head or neck
Cases excluded due to insufficient cellular material on slide: 0
Index tests Exfoliative cytology: scalpel to obtain sample; MGG staining method
Diagnostic threshold: qualitative appearance of cell material
Cytological diagnosis of a BCC based on: “the presence or tight groups of uniform small cells and the
presence of pink amorphous material in MGG-stained preparations. Squamous cell lesions showed
less cellular adhesion, much more nuclear pleomorphism and no pink material.”
Prior test data available: clinical diagnosis
Diagnosis based on single or consensus observation: NR
Observer qualifications: consultant pathologists
Experience in practice: NR
Experience with index test: NR
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Derrick 1994 (Continued)
Target condition and reference
standard(s)
Type of reference standard: histology (punch biopsy)
Details: 3-mm biopsy punch, with total surgical excision if cytology and biopsy diagnoses disagreed
(n = 4). Biopsies fixed in formaldehyde, routinely processed, and embedded in paraffin. Sections of
5 microns cut and stained with haematoxylin and eosin
Disease positive: 234;disease negative: 6
Final diagnoses:
• Malignant: 229 BCC; 4 cSCC; 1 apocrine carcinoma
• Benign diagnoses: 6 (1 actinic keratosis, 1 Bowen’s disease, 1 trichoepithelioma, 3 no
abnormality)
Flow and timing Index test to reference standard interval: NR
Interval between index tests: NA
Exclusions: none reported
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Yes
High High
DOMAIN 2: Index Test Exfoliative cytology
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
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Derrick 1994 (Continued)
If a threshold was used, was it
pre-specified?
Unclear
Was the test applied and inter-
preted in a clinically applicable
manner?
Yes
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Unclear Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Were the reference standard re-
sults interpreted with-
out knowledge of the referral di-
agnosis? (DOES NOT CON-
TRIBUTE TO THE REFER-
ENCE STANDARDRISKOF
BIAS JUDGEMENT)
No
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Yes
Unclear Low
DOMAIN 4: Flow and Timing
56Exfoliative cytology for diagnosing basal cell carcinoma and other skin cancers in adults (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Derrick 1994 (Continued)
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Unclear
Durdu 2011
Study characteristics
Patient sampling Study design: case series, within-person comparison
Data collection: prospective
Period of data collection: January 2006 to January 2009
Country: Turkey
Funding: none declared
Patient characteristics and set-
ting
Inclusion criteria: pigmented skin lesions that could not be diagnosed with only dermatologic
physical examination
Setting: secondary (general dermatology)
Prior testing: clinical suspicion of malignancy without dermatoscopic suspicion
Exclusion criteria: none reported
Sample size (patients):no. eligible: NR;no. included: 176
Sample size (lesions):no. eligible: NR;no. included: 200
Participant characteristics: mean age 48 years (range 4-85); 64 (36.4%) males
Lesion characteristics: 100% pigmented; 9% ulcerated; 56% papular; 17%macular; 10% nodular;
8% plaque
Index tests 1. Exfoliative cytology: slit-skin exfoliation using scalpel; MGG stain; evaluated with a light
microscope (310 and 340 magnifications and then 3100 magnification with immersion oil)
Prior test data: clinical examination and/or case notes. Dermoscopy was conducted by a different
dermatologist
Diagnostic threshold: qualitative - microscopic appearance of cellular scraping
Cytologic diagnoses were made according to findings reported previously (several studies referenced
and criteria used were tabulated)
Criteria for BCC: clusters of basaloid cells containing pigment granules (Powell 2000; Vega-Memije
2000)
Criteria for melanoma: epithelioid or spindle-type atypical nevoid cells (Canti 1984).
Diagnosis based on single or consensus observation: single (1 examiner)
Observer qualifications: dermatologist
Experience in practice: NR
Experience with index test: NR
2. Dermoscopy
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Durdu 2011 (Continued)
Method of diagnosis: in-person diagnosis
Prior test data: clinical examination and/or case notes
Diagnostic threshold: NR
2-step process:
1. melanocytic and non melanocytic were differentiated (Braun 2005; Zalaudek 2008)
2. ABCD applied to melanocytic only
Diagnosis based on single or consensus observation: single (1 examiner)
Observer qualifications: dermatologist
Experience in practice: NR
Experience with index test: NR
Cases excluded due to insufficient cellular material on slide: 15 (6 benign melanocytic lesions,
9 benign non-melanocytic lesions)
Target condition and reference
standard(s)
Type of reference standard: histology (excision 166; punch biopsy 34)
Details: biopsy specimens were stained with hematoxylin and eosin. Immunohistochemical (anti-
S-100 and human melanoma black [HMB]-45) and histochemical (Fontana-Masson) stains were
also applied, if necessary
Disease positive: 46;disease negative: 154
Final diagnoses:
• Malignant: 34 BCC; 10 melanoma (in situ and invasive, or not reported); 1 pigmented
mammary Paget’s disease; 1 pigmented metastatic mammary carcinoma; 1 apocrine carcinoma
• Benign diagnoses: 154 (24 seborrhoeic keratosis, 100 benign melanocytic naevus, 30 other
benign melanocytic lesions)
Flow and timing Index test to reference standard interval: consecutive; exact interval not reported
Interval between index tests: consecutive
Exclusions: 15 slides with inadequate material for cytological diagnosis; no exclusions for der-
moscopy
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
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Durdu 2011 (Continued)
Are the included patients and
chosen study setting appropri-
ate?
Yes
Did the study avoid including
participants with multiple le-
sions?
No
Unclear High
DOMAIN 2: Index Test Dermoscopy
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Was the test applied and inter-
preted in a clinically applicable
manner?
Yes
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
Low Unclear
DOMAIN 2: Index Test Exfoliative cytology
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Yes
Was the test applied and inter-
preted in a clinically applicable
manner?
Yes
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Durdu 2011 (Continued)
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
Unclear Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Were the reference standard re-
sults interpreted with-
out knowledge of the referral di-
agnosis? (DOES NOT CON-
TRIBUTE TO THE REFER-
ENCE STANDARDRISKOF
BIAS JUDGEMENT)
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Unclear Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
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Durdu 2011 (Continued)
Were all patients included in the
analysis?
Yes
Low
Gordon 1984
Study characteristics
Patient sampling Study design: case series
Data collection: prospective
Period of data collection: NR
Country: Australia
Funding: none declared
Patient characteristics and set-
ting
Inclusion criteria: patients with cutaneous neoplasms undergoing diagnostic biopsy or definitive
excision at a routine clinic
Setting: secondary (General Dermatology)
Prior testing: selected for excision (no further details)
Exclusion criteria: lesions too small to retrieve adequate material for cytological or histological
analysis, suspected melanomas
Sample size (patients):no. eligible: NR;no. included: 112
Sample size (lesions):no. eligible: NR;no. included: 150
Participant characteristics: none reported
Lesion characteristics: not reported for whole sample; BCCs included 4 pleomorphic BCCs
Index tests Exfoliative cytology: initial removal of ulcerated crust or keratotic surface; scalpel to obtain sample;
stain method Papanicolaou
Diagnostic threshold: qualitative appearance of cell material.
Smears of BCC reported to be characterised by “many cohesive epithelial fragments composed
of tightly packed small cells with uniform, oval, dark nuclei. The nuclear chromatin is dense,
but granular and evenly distributed; nucleoli are small and indistinct. Cytoplasm is scanty and
cyanophilic. Usually, some fragments show the marginal palisading arrangement of tumour cells
familiar to the histopathologist (Figs. I and 2). Squamous differentiationmay be present withinBCC
(keratotic BCC and metatypical epithelioma). When this is prominent and associated with nuclear
enlargement and pleomorphism, the cytologic differentiation between SCC and pleomorphic BCC
is difficult or impossible. Strong cohesiveness, uniformly high nuclear/cytoplasmic ratio, and evenly
distributed nuclear chromatin favour a diagnosis of pleomorphic BCC (Fig. 3).”
Prior test data available: none; blinded to clinical exam
Diagnosis based on single or consensus observation: single
Observer qualifications: NR, ’cytologists’
Experience in practice: NR
Experience with index test: NR
Cases excluded due to insufficient cellular material on slide: 9 (1 BCC, 1 cSCC, 7 AK)
Target condition and reference
standard(s)
Type of reference standard: histology (excisional or incisional biopsy)
Details: biopsy specimens were stained with hematoxylin and eosin. Immunohistochemical (anti-
S-100 and human melanoma black [HMB]-45) and histochemical (Fontana-Masson) stains were
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Gordon 1984 (Continued)
also applied, if necessary
Disease positive: 84;disease negative: 57
Final diagnoses:
• Malignant: 78 BCC; 6 cSCC; severe dysplasia: 4 marked squamous atypia
• Benign diagnoses: 62 (9 seborrhoeic keratosis; 53 actinic keratosis)
Flow and timing Index test to reference standard interval: NR
Interval between index tests: NA
Exclusions: none reported 9 lesions with inadequate material for cytological diagnosis (1 BCC,
1cSCC, 7 AK)
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Are the included patients and
chosen study setting appropri-
ate?
Unclear
Did the study avoid including
participants with multiple le-
sions?
No
Low High
DOMAIN 2: Index Test Exfoliative cytology
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
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Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Low High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Were the reference standard re-
sults interpreted with-
out knowledge of the referral di-
agnosis? (DOES NOT CON-
TRIBUTE TO THE REFER-
ENCE STANDARDRISKOF
BIAS JUDGEMENT)
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Unclear Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
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Gordon 1984 (Continued)
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Unclear
Nauth 1988
Study characteristics
Patient sampling Study design: case control
Data collection: NR
Period of data collection: NR
Country: Germany
Funding: none declared
Patient characteristics and set-
ting
Inclusion criteria: NR
Setting: secondary (unspecified)
Prior testing: NR
Exclusion criteria: NR
Sample size (patients):no. eligible: NR;no. included: 224
Sample size (lesions):no. eligible: NR;no. included: 224
Participant characteristics: age range 11-100 years; 132 (59%) male
Lesion characteristics: NR
Index tests Exfoliative cytology: method of exfoliation not reported; Papanicolaou stain used
Prior test data: NR
Diagnostic threshold: qualitative threshold - assessment of the cell images was based on the findings
andmeasures already obtained in earlier studies on vulva cytology, using theMunchener classification
scheme (study reference #24)
Cut-off of V (malignancy present) used
Diagnosis based on single or consensus observation: NR
Observer qualifications: NR
Experience in practice: NR
Experience with index test: NR
Cases excluded due to insufficient cellular material on slide: 18 (1 BCC, 2 cSCC, 2 Severe
precancerous disease, 6 Mild precancerous disease, 5 Benign tumour, 2 inflammation)
Target condition and reference
standard(s)
Type of reference standard: histology (punch biopsy 210/224), not reported for 14/224 (inflam-
matory conditions)
Details: not described
Disease positive: 145;disease negative: 65
Final diagnoses:
• Malignant: 42 BCC; 38 cSCC; 34 severe dysplasia; 31 moderate dysplasia
• Benign diagnoses: 51 benign (not further specified), 28 inflammatory lesions
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Flow and timing Index test to reference standard interval: NR
Interval between index tests: NA
Exclusions: none reported
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
Was a case-control design
avoided?
No
Did the study avoid inappropri-
ate exclusions?
Unclear
Are the included patients and
chosen study setting appropri-
ate?
Unclear
Did the study avoid including
participants with multiple le-
sions?
Yes
High Unclear
DOMAIN 2: Index Test Exfoliative cytology
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Yes
Was the test applied and inter-
preted in a clinically applicable
manner?
Unclear
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Nauth 1988 (Continued)
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
Unclear Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Were the reference standard re-
sults interpreted with-
out knowledge of the referral di-
agnosis? (DOES NOT CON-
TRIBUTE TO THE REFER-
ENCE STANDARDRISKOF
BIAS JUDGEMENT)
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Unclear
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Unclear Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
No
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Were all patients included in the
analysis?
Yes
High
Powell 2000
Study characteristics
Patient sampling Study design: case series
Data collection: retrospective
Period of data collection: January 1999 to September 1999
Country: UK
Funding: none declared
Patient characteristics and set-
ting
Inclusion criteria: all cytology smears taken over a 9-month period to confirm a diagnosis of BCC
Setting: secondary (unspecified)
Prior testing: clinical suspicion of BCC (no further details)
Exclusion criteria: no histological specimen available
Sample size (patients):no. eligible: 72;no. included: 30
Sample size (lesions):no. eligible: 82;no. included: 37
Participant characteristics: NR
Lesion characteristics: NR
Index tests Exfoliative cytology: scalpel or curette to obtain sample; stain method not reported
Diagnostic threshold: qualitative - microscopic appearance of cellular scraping
Diagnosis of BCC was based on a cellular smear with the presence of small dissociated hyperchro-
matic cells in cohesive sheets
Prior test data available: clinical diagnosis (no further details)
Diagnosis based on single or consensus observation: NR
Observer qualifications: NR - ’histopathologist’
Experience in practice: NR
Experience with index test: NR
Cases excluded due to insufficient cellular material on slide: 0
Target condition and reference
standard(s)
Type of reference standard: histology (excisional or incisional biopsy)
Details: NR - ’routine histological analysis of the lesion’
Disease positive: 22;disease negative: 11
Final diagnoses:
• Malignant: 22 BCC
• Benign diagnoses: 11 (5 actinic keratosis, 1 Bowenoid actinic keratosis, 4 Bowen’s disease, 1
benign lesion (type NR))
Flow and timing Index test to reference standard interval: NR
Interval between index tests: NA
Exclusions: none reported
Comparative
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Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Are the included patients and
chosen study setting appropri-
ate?
Unclear
Did the study avoid including
participants with multiple le-
sions?
No
Low High
DOMAIN 2: Index Test Exfoliative cytology
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Unclear
Was the test applied and inter-
preted in a clinically applicable
manner?
Unclear
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
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Unclear High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Were the reference standard re-
sults interpreted with-
out knowledge of the referral di-
agnosis? (DOES NOT CON-
TRIBUTE TO THE REFER-
ENCE STANDARDRISKOF
BIAS JUDGEMENT)
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Unclear Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Unclear
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Study characteristics
Patient sampling Study design: case series
Data collection: retrospective
Period of data collection: January 1971 to July 1991
Country: Italy
Funding: none declared
Patient characteristics and set-
ting
Inclusion criteria: nodular, papular or erythematous-infiltrative lesions for which the most likely
clinical diagnosis was BCC
Setting: secondary (General Dermatology)
Prior testing: clinical suspicion of BCC without dermatoscopic suspicion
Exclusion criteria: no histology slide or result, insufficient material for histology and cytology, pa-
tient undergoing treatment (diathermal coagulation, cryotherapy, radiotherapy, local chemotherapy
with 5-fluorouracil or interferon a-2b), or patient treated elsewhere
Sample size (patients):no. eligible: NR;no. included: NR
Sample size (lesions):no. eligible: NR;no. included: 578
Participant characteristics: NR
Lesion characteristics: solid (n = 162, 28%), cystic (n = 83, 14%), keratinous (n = 71, 12%),
superficial (n = 63, 11%), pigmented (n = 57, 10%), intermediate (baso-squamous: n = 18, 3%),
morfeiform (n = 12, 2%), aggressive or pleomorphic (n = 6, 1.2%), adamantinoid (n = 1, 0.2%),
other (n = 25, 4%)
Index tests Exfoliative cytology: initial removal of surface crust; scalpel to obtain sample; 3 slides per lesion
stained using the MGG method, and either the Papanicolaou method or with pure undiluted
Giemsa
Diagnostic threshold: qualitative - microscopic appearance of cellular scraping
Characteristics suggestive of BCC: basaloid cells arranged in groups, clumped in the centre and
at times arranged as ’fences/palisades’ around the periphery (as found in histological specimens)
, slightly increased compared to normal epidermal basal keratinocytes, but in a single dimension,
with an elongated shape, oval nucleus, intensely basophilic , occupying 4/5 of the entire cell with
weak/thin cytoplasm, sometimes containing coarse melanin granules
Prior test data available: clinical diagnosis without dermoscopy (no further details)
Diagnosis based on single or consensus observation: NR
Observer qualifications: NR
Experience in practice: NR
Experience with index test: NR
Cases excluded due to insufficient cellular material on slide: 0
Target condition and reference
standard(s)
Type of reference standard: histology (excisional or punch biopsy)
Details: fixed at 10% formalin, initiated to the standard histological method (coloration with
hematoxylin-cosine) and observed at the same microscope
Disease positive: 507;disease negative: 71
Final diagnoses:
• Malignant: 498 BCC; 4 cSCC; 3 cutaneous metastasis from visceral malignancy; 2 Merkel
cell carcinoma
• Benign diagnoses: 67 (19 actinic keratosis, 11 seborrhoeic keratosis, 8 senile sebaceous
hyperplasia, 6 Bowen’s disease, 4 keratoacanthoma, 3 molluscum contagiosum, 3 psoriasis, 3
Trichoepithelioma, 2 Syringocystadenoma papilliferum, 2 lichen planus, 2 localised scleroderma,
1 sebaceous adenoma, 1 cylindroma, 1 pilomatricoma)
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• Other: 4 ’LED’ (abbreviation not defined)
Flow and timing Index test to reference standard interval: NR
Interval between index tests: NA
Exclusions: none reported
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Are the included patients and
chosen study setting appropri-
ate?
Unclear
Did the study avoid including
participants with multiple le-
sions?
Unclear
Low Unclear
DOMAIN 2: Index Test Exfoliative cytology
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Unclear
Was the test applied and inter-
preted in a clinically applicable
manner?
Unclear
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Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
No
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
Unclear High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Were the reference standard re-
sults interpreted with-
out knowledge of the referral di-
agnosis? (DOES NOT CON-
TRIBUTE TO THE REFER-
ENCE STANDARDRISKOF
BIAS JUDGEMENT)
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Unclear Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
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Ruocco 1992 (Continued)
Were all patients included in the
analysis?
Unclear
Unclear
ABCD: asymmetry/border/colour/diameter; AK: actinic keratosis; BCC: basal cell carcinoma; cSCC: cutaneous squamous cell carci-
noma;H/N: head and neck; LED: disease type, acronym not provided by study;MGG: May-Grünwald Giemsa stain technique;NA:
not applicable;NR: not reported;Pap: Papanicolaou stain technique; SK: seborrhoeic keratosis;WHO: WorldHealthOrganization.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Baba 2010 Index test - margin control; study population - confirmed BCC cases only
Bakis 2004 Not primary study - systematic review and meta-analysis
Barton 1996 Target condition - periocular suspected BCCs
Berardi 1992 Index test - tape stripping cytology
Bilen 2000 sample size - < 5 benign lesions
Bocking 1987 Index test - ineligible method: use of swabbing
David 1971 Target condition - intraocular tumours
Eryilmaz 2014 Reference standard - unclear if all disease positive based on histology
Hajdu 1973 Study population - metastatic melanoma
Hatvani 1974 Study population - includes intra-ocular disease
Hering 1970 Index test - imprint cytology
Jakasa 1976 Index test - includes data for FNA; unclear whether data disaggregated by type of test
Korabiec 1977 Index test - includes FNA as well as scrape cytology; results cannot be differentiated
Melek 1970 Index test - imprint cytology
Norris 2008 Not primary study
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Oram 1997 Sample size - < 5 benign cases
Ozden 2013 Sample size - < 5 benign cases
Rojo 1998 Index test - fine needle aspiration
Scanagatta 1981 Study population - only confirmed BCCs included
Schmid-Wendtner 1999 Not primary study
Sharifi 2007 Sample size - < 5 benign cases
Spinowitz 1986 Not primary study
Strokowska 1981 Reference standard - unclear if all disease positive based on histology
Tzanck 1951 Not primary study
Urbach 1957 Index test - exfoliative cytology from ex vivo biopsy samples
Vakhturova 1995 Index test - intraoperative use of cytology
Vega-Memije 2000 Sample size - < 5 benign cases
Veselovskaia 1984 Reference standard - no reference standard for index test negatives
Viglioglia 1955 Not primary study
von Gizycki-Nienhaus 1992 Index test - fine needle aspiration; Study population - includes recurrences
Yu 2005 Index test - three different cytological tests used, cannot disaggregate
BCC: basal cell carcinoma; FNA: fine needle aspiration.
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Presented below are all the data for all of the tests entered into the review.
Tests. Data tables by test
Test
No. of
studies
No. of
participants
1 Exfoliative cytology - BCC
(possible BCCs classified as test
positives)
7 1264
2 Exfoliative cytology - BCC
(possible BCCs classified as test
negatives)
7 1264
3 Exfoliative cytology - BCC
(pigmented lesion population)
1 185
4 Dermoscopy - BCC (pigmented
lesion population)
1 200
5 Exfoliative cytology - BCC
(mixed population, Munchener
diagnostic criteria)
1 206
6 Exfoliative cytology - cSCC
(suspected BCC population)
1 141
7 Exfoliative cytology - cSCC
(mixed population, Munchener
diagnostic criteria)
1 206
8 Exfoliative cytology - melanoma
(pigmented lesion population)
1 185
9 Dermoscopy - melanoma
(pigmented lesion population)
1 200
10 Exfoliative cytology - any
skin cancer (suspected BCC
population, possible BCCs
classified as test positives)
4 573
11 Exfoliative cytology - any
skin cancer (suspected BCC
population, possible BCCs
classified as test negatives)
4 573
12 Exfoliative cytology - any
skin cancer (pigmented lesion
population)
1 185
13 Dermoscopy - any skin cancer
(pigmented lesion population)
1 200
14 Exfoliative cytology - any skin
cancer (mixed population,
Munchener diagnostic criteria)
1 206
15 Exfoliative cytology
(Papanicolaou + MGG stain) -
BCC (stain comparison)
1 76
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16 Exfoliative cytology (MGG
stain) - BCC (stain comparison)
1 73
17 Exfoliative cytology
(Papanicolaou stain) - BCC
(stain comparison)
1 77
Test 1. Exfoliative cytology - BCC (possible BCCs classified as test positives).
Review: Exfoliative cytology for diagnosing basal cell carcinoma and other skin cancers in adults
Test: 1 Exfoliative cytology - BCC (possible BCCs classified as test positives)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Berner 1999 94 5 2 6 0.98 [ 0.93, 1.00 ] 0.55 [ 0.23, 0.83 ]
Brown 1979 68 0 5 12 0.93 [ 0.85, 0.98 ] 1.00 [ 0.74, 1.00 ]
Christensen 2008 48 1 2 25 0.96 [ 0.86, 1.00 ] 0.96 [ 0.80, 1.00 ]
Derrick 1994 228 1 1 10 1.00 [ 0.98, 1.00 ] 0.91 [ 0.59, 1.00 ]
Gordon 1984 72 7 5 57 0.94 [ 0.85, 0.98 ] 0.89 [ 0.79, 0.95 ]
Powell 2000 20 2 2 13 0.91 [ 0.71, 0.99 ] 0.87 [ 0.60, 0.98 ]
Ruocco 1992 494 6 4 74 0.99 [ 0.98, 1.00 ] 0.93 [ 0.84, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 2. Exfoliative cytology - BCC (possible BCCs classified as test negatives).
Review: Exfoliative cytology for diagnosing basal cell carcinoma and other skin cancers in adults
Test: 2 Exfoliative cytology - BCC (possible BCCs classified as test negatives)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Berner 1999 94 3 2 8 0.98 [ 0.93, 1.00 ] 0.73 [ 0.39, 0.94 ]
Brown 1979 68 0 5 12 0.93 [ 0.85, 0.98 ] 1.00 [ 0.74, 1.00 ]
Christensen 2008 48 1 2 25 0.96 [ 0.86, 1.00 ] 0.96 [ 0.80, 1.00 ]
Derrick 1994 228 1 1 10 1.00 [ 0.98, 1.00 ] 0.91 [ 0.59, 1.00 ]
Gordon 1984 68 1 9 63 0.88 [ 0.79, 0.95 ] 0.98 [ 0.92, 1.00 ]
Powell 2000 20 2 2 13 0.91 [ 0.71, 0.99 ] 0.87 [ 0.60, 0.98 ]
Ruocco 1992 494 6 4 74 0.99 [ 0.98, 1.00 ] 0.93 [ 0.84, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 3. Exfoliative cytology - BCC (pigmented lesion population).
Review: Exfoliative cytology for diagnosing basal cell carcinoma and other skin cancers in adults
Test: 3 Exfoliative cytology - BCC (pigmented lesion population)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Durdu 2011 34 0 0 151 1.00 [ 0.90, 1.00 ] 1.00 [ 0.98, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 4. Dermoscopy - BCC (pigmented lesion population).
Review: Exfoliative cytology for diagnosing basal cell carcinoma and other skin cancers in adults
Test: 4 Dermoscopy - BCC (pigmented lesion population)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Durdu 2011 32 3 2 163 0.94 [ 0.80, 0.99 ] 0.98 [ 0.95, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 5. Exfoliative cytology - BCC (mixed population, Munchener diagnostic criteria).
Review: Exfoliative cytology for diagnosing basal cell carcinoma and other skin cancers in adults
Test: 5 Exfoliative cytology - BCC (mixed population, Munchener diagnostic criteria)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Nauth 1988 33 42 8 123 0.80 [ 0.65, 0.91 ] 0.75 [ 0.67, 0.81 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 6. Exfoliative cytology - cSCC (suspected BCC population).
Review: Exfoliative cytology for diagnosing basal cell carcinoma and other skin cancers in adults
Test: 6 Exfoliative cytology - cSCC (suspected BCC population)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Gordon 1984 5 2 0 134 1.00 [ 0.48, 1.00 ] 0.99 [ 0.95, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 7. Exfoliative cytology - cSCC (mixed population, Munchener diagnostic criteria).
Review: Exfoliative cytology for diagnosing basal cell carcinoma and other skin cancers in adults
Test: 7 Exfoliative cytology - cSCC (mixed population, Munchener diagnostic criteria)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Nauth 1988 32 43 4 127 0.89 [ 0.74, 0.97 ] 0.75 [ 0.67, 0.81 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 8. Exfoliative cytology - melanoma (pigmented lesion population).
Review: Exfoliative cytology for diagnosing basal cell carcinoma and other skin cancers in adults
Test: 8 Exfoliative cytology - melanoma (pigmented lesion population)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Durdu 2011 10 0 0 175 1.00 [ 0.69, 1.00 ] 1.00 [ 0.98, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 9. Dermoscopy - melanoma (pigmented lesion population).
Review: Exfoliative cytology for diagnosing basal cell carcinoma and other skin cancers in adults
Test: 9 Dermoscopy - melanoma (pigmented lesion population)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Durdu 2011 8 5 2 185 0.80 [ 0.44, 0.97 ] 0.97 [ 0.94, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 10. Exfoliative cytology - any skin cancer (suspected BCC population, possible BCCs classified as test
positives).
Review: Exfoliative cytology for diagnosing basal cell carcinoma and other skin cancers in adults
Test: 10 Exfoliative cytology - any skin cancer (suspected BCC population, possible BCCs classified as test positives)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Berner 1999 98 2 3 4 0.97 [ 0.92, 0.99 ] 0.67 [ 0.22, 0.96 ]
Brown 1979 72 0 4 9 0.95 [ 0.87, 0.99 ] 1.00 [ 0.66, 1.00 ]
Derrick 1994 233 1 1 5 1.00 [ 0.98, 1.00 ] 0.83 [ 0.36, 1.00 ]
Gordon 1984 79 7 5 50 0.94 [ 0.87, 0.98 ] 0.88 [ 0.76, 0.95 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 11. Exfoliative cytology - any skin cancer (suspected BCC population, possible BCCs classified as test
negatives).
Review: Exfoliative cytology for diagnosing basal cell carcinoma and other skin cancers in adults
Test: 11 Exfoliative cytology - any skin cancer (suspected BCC population, possible BCCs classified as test negatives)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Berner 1999 97 1 4 5 0.96 [ 0.90, 0.99 ] 0.83 [ 0.36, 1.00 ]
Brown 1979 72 0 4 9 0.95 [ 0.87, 0.99 ] 1.00 [ 0.66, 1.00 ]
Derrick 1994 233 1 1 5 1.00 [ 0.98, 1.00 ] 0.83 [ 0.36, 1.00 ]
Gordon 1984 75 1 9 56 0.89 [ 0.81, 0.95 ] 0.98 [ 0.91, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 12. Exfoliative cytology - any skin cancer (pigmented lesion population).
Review: Exfoliative cytology for diagnosing basal cell carcinoma and other skin cancers in adults
Test: 12 Exfoliative cytology - any skin cancer (pigmented lesion population)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Durdu 2011 46 0 0 139 1.00 [ 0.92, 1.00 ] 1.00 [ 0.97, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 13. Dermoscopy - any skin cancer (pigmented lesion population).
Review: Exfoliative cytology for diagnosing basal cell carcinoma and other skin cancers in adults
Test: 13 Dermoscopy - any skin cancer (pigmented lesion population)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Durdu 2011 45 3 1 151 0.98 [ 0.88, 1.00 ] 0.98 [ 0.94, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 14. Exfoliative cytology - any skin cancer (mixed population, Munchener diagnostic criteria).
Review: Exfoliative cytology for diagnosing basal cell carcinoma and other skin cancers in adults
Test: 14 Exfoliative cytology - any skin cancer (mixed population, Munchener diagnostic criteria)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Nauth 1988 65 10 12 119 0.84 [ 0.74, 0.92 ] 0.92 [ 0.86, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 15. Exfoliative cytology (Papanicolaou + MGG stain) - BCC (stain comparison).
Review: Exfoliative cytology for diagnosing basal cell carcinoma and other skin cancers in adults
Test: 15 Exfoliative cytology (Papanicolaou + MGG stain) - BCC (stain comparison)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Christensen 2008 48 1 2 25 0.96 [ 0.86, 1.00 ] 0.96 [ 0.80, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 16. Exfoliative cytology (MGG stain) - BCC (stain comparison).
Review: Exfoliative cytology for diagnosing basal cell carcinoma and other skin cancers in adults
Test: 16 Exfoliative cytology (MGG stain) - BCC (stain comparison)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Christensen 2008 47 1 2 23 0.96 [ 0.86, 1.00 ] 0.96 [ 0.79, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 17. Exfoliative cytology (Papanicolaou stain) - BCC (stain comparison).
Review: Exfoliative cytology for diagnosing basal cell carcinoma and other skin cancers in adults
Test: 17 Exfoliative cytology (Papanicolaou stain) - BCC (stain comparison)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Christensen 2008 48 1 2 26 0.96 [ 0.86, 1.00 ] 0.96 [ 0.81, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
A D D I T I O N A L T A B L E S
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Table 1. Test failures due to insufficient cellular material
Study Stain technique Slides with inadequate material n (%) Histological diagnosis
Gordon 1984 Papanicolaou 9 (6) BCC: 1
cSCC: 1
Actinic keratosis: 7
Christensen 2008a Papanicolaou 1 (1) Actinic keratosis: 1
MGG 3 (4) BCC: 1
Actinic keratosis: 2
Durdu 2011 MGG 15 (8) Melanocytic benign: 6
Non-melanocytic benign: 9
Nauth 1988 Papanicolaou 18 (8) BCC: 1
cSCC: 2
Severe precancerous disease: 2
Mild precancerous disease: 6
Benign tumour: 5
Inflammation: 2
BCC: basal cell carcinoma; cSCC: cutaneous squamous cell carcinoma;MGG: May-Grünwald Giemsa stain technique.
aWhen diagnosis was made using both Papanicolaou and MGG stained slides, all lesions could be diagnosed cytologically
Table 2. Summary of main results
Analysis Target
condition
Test
No. studies Lesions with cy-
tology results (n)
Diseased lesions
(n)
Sensitivity (95%
CI)
Specificity (95%
CI)
Detection of basal cell carcinoma (BCC)
All studies Studies with
cases of BCC
9 1655 1120 - -
Pooled studies Standard
cytological crite-
ria used to con-
firm disease in
participants with
clinical suspicion
of BCC (’possi-
ble BCC’ cases
classified as BCC
test positive)
7 1264 1045a 97.5 (94.5 to 98.
9)
90.1 (81.1 to 95.
1)
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Table 2. Summary of main results (Continued)
- Standard
cytological crite-
ria used to con-
firm disease in
participants with
clinical suspicion
of BCC (’possi-
ble BCC’ cases
classified as BCC
test negative)
7 1264 1045a 97.3 (93.5 to 98.
9)
94.2 (88.7 to 97.
1)
Studies not pooled 2 391 75 - -
- Nauth 1988: dif-
ferent diagnostic
crite-
ria - Munchener
scheme (class V =
malignant)
1 206 41b 80.5 (66.0 to 89.
8)
74.6 (67.4 to 80.
6)
- Durdu
2011: different
patient group -
pigmented skin
lesions (exfolia-
tive cytology)
1 185c 34 100 (89.9 to 100) 100 (97.5 to 100)
- Durdu
2011: different
patient group -
pigmented
skin lesions (der-
moscopy)
1 200 34 94.1 (80.9 to 98.
4)
98.2 (94.8 to 99.
4)
Detection of cutaneous squamous cell carcinoma (cSCC)
All studies Studies with
cases of cSCC
6 1357 52 - -
Studies not pooled 2 401 41d - -
- Gordon
1984: standard
cytological crite-
ria used to con-
firm disease in
participants with
clinical suspicion
1 141 5e 100 (56.6 to 100) 98.5 (94.8 to 99.
6)
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Table 2. Summary of main results (Continued)
of BCC
- Nauth 1988: dif-
ferent diagnostic
crite-
ria - Munchener
scheme (class V =
malignant)
1 206 36f 88.9 (74.7 to 95.
6)
74.7 (67.7 to 80.
6)
Studies not in-
cluded in dataset
< 5 cSCC cases 4 1010 11 - -
Detection of invasive melanoma and atypical intraepidermal melanocytic variants (MM)
All studies Studies with
cases of MM
2 270 11 - -
Studies not pooled 1 185c 10 - -
- Durdu
2011: different
patient group -
pigmented skin
lesions (exfolia-
tive cytology)
1 185c 10 100 (72.3 to 100) 100 (97.6 to 100)
- Durdu
2011: different
patient group -
pigmented
skin lesions (der-
moscopy)
1 200 10 80.0 (49.0 to 94.
3)
97.4 (94.0 to 98.
9)
Studies not in-
cluded in dataset
< 5 MM cases 1 85 1 - -
Detection of any potential skin cancer (BCC or other skin cancer)
All studies Studies with any
skin cancer le-
sions
9 1655 1200 - -
Pooled studies Standard
cytological crite-
ria used to con-
firm disease in
participants with
clinical suspicion
of BCC (’possi-
4 573 495 97.3 (93.5 to 98.
9)
86.0 (73.5 to 93.
1)
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Table 2. Summary of main results (Continued)
ble BCC’ cases
classified as BCC
test positive)
- Standard
cytological crite-
ria used to con-
firm disease in
participants with
clinical suspicion
of BCC (’possi-
ble BCC’ cases
classified as BCC
test negative)
4 573 495 96.6 (90.3 to 98.
9)
94.7 (80.2 to 98.
7)
Studies not pooled 2 391 123 - -
- Nauth 1988: dif-
ferent diagnostic
crite-
ria - Munchener
scheme (class V =
malignant)
1 206 77g 84.4 (74.7 to 90.
9)
92.3 (86.3 to 95.
7)
- Durdu
2011: different
patient group -
pigmented skin
lesions (exfolia-
tive cytology)
1 185c 46 100 (92.3 to 100) 100 (97.3 to 100)
- Durdu
2011: different
patient group -
pigmented
skin lesions (der-
moscopy)
1 200 46 97.8 (88.7 to 99.
6)
98.1 (94.4 to 99.
3)
Studies not in-
cluded in dataset
No skin cancer
other than BCC
(Christensen
2008; Powell
2000)
2 113 72 - -
- Data not re-
ported (Ruocco
1992)
1 578 507 - -
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BCC: basal cell carcinoma; CI: confidence interval; cSCC: cutaneous squamous cell carcinoma; MM: invasive melanoma and atypical
intraepidermal melanocytic variants.
aTwo additional BCC lesions could not be analysed by exfoliative cytology, due to insufficient cell material.
b1/42 BCC lesions could not be analysed by exfoliative cytology, due to insufficient cell material.
cFrom a total population of 200 lesions (15 excluded from exfoliative cytology analysis due to insufficient cell material, all 200 examined
by dermoscopy).
d3/44 cSCC lesions could not be analysed by exfoliative cytology, due to insufficient cell material.
e1/6 cSCC lesions could not be analysed by exfoliative cytology, due to insufficient cell material.
f 2/38 cSCC lesions could not be analysed by exfoliative cytology, due to insufficient cell material.
g3/80 lesions could not be analysed by exfoliative cytology, due to insufficient cell material.
Table 3. Exfoliative cytology for the detection of BCC: false positive diagnoses
Study False positive n (%) Histological diagnosis
Berner 1999 5 (4.6) Carcinoma, type not specified: 3
atypia: 2
Brown 1979 0 (0) -
Christensen 2008a 1 (1.3) Actinic keratosis: 1
Derrick 1994 1 (0.4) Trichoepithelioma: 2
Durdu 2011 0 (0) -
Gordon 1984 7 (5.0) Actinic keratosis: 1
Marked atypia: 4
Sebhorroeic keratosis: 2
Nauth 1988 18 (8) BCC: 1
cSCC: 2
Severe precancerous disease: 2
Mild precancerous disease: 6
Benign tumour: 5
Inflammation: 2
Powell 2000 2 (5.4) Bowenoid actinic keratosis: 1
Bowen’s disease: 1
Ruocco 1992 6 (1) Trichoepithelioma: 3
Syringocystadenoma papilliferum: 2
Pilomatricoma: 1
BCC: basal cell carcinoma; CI: confidence interval; cSCC: cutaneous squamous cell carcinoma.
aDiagnosis made using both Papanicolaou and May-Grünwald Giemsa stained slides
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A P P E N D I C E S
Appendix 1. Current content and structure of the Programme Grant
LIST OF REVIEWS Number of studies
Diagnosis of melanoma
1 Visual inspection 49
2 Dermoscopy +/- visual inspection 104
3 Teledermatology 22
4 Smartphone applications 2
5a Computer-assisted diagnosis - dermoscopy-based techniques 42
5b Computer-assisted diagnosis - spectroscopy-based techniques Review amalgamated into 5a
6 Reflectance confocal microscopy 18
7 High-frequency ultrasound 5
Diagnosis of keratinocyte skin cancer (BCC and cSCC)
8 Visual inspection +/- Dermoscopy 24
5c Computer-assisted diagnosis - dermoscopy-based techniques Review amalgamated into 5a
5d Computer-assisted diagnosis - spectroscopy-based techniques Review amalgamated into 5a
9 Optical coherence tomography 5
10 Reflectance confocal microscopy 10
11 Exfoliative cytology 9
Staging of melanoma
12 Imaging tests (ultrasound, CT, MRI, PET-CT) 38
13 Sentinel lymph node biopsy 160
Staging of cSCC
Imaging tests review Review dropped; only one study identified
89Exfoliative cytology for diagnosing basal cell carcinoma and other skin cancers in adults (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
13 Sentinel lymph node biopsy Review amalgamated into 13 above (n = 15 studies)
Appendix 2. Glossary of terms
Term Definition
Acantholytic subtypes An uncommon squamous cell carcinoma variant characterised by acantholy-
sis, which is the marked disruption of intercellular connections and resulting
separation of epidermal cells
Arborizing blood vessels Blood vessels in the skin that form a tree-like branching appearance. They can
be a sign of basal cell carcinomas
Atypical honeycombing This pattern arises from variation in size and shape of keratinocytic nuclei
and irregular cell borders of keratinocytes in the spinous-granular epidermal
layer. It is a feature of actinic keratosis and squamous cell carcinoma on optical
coherence tomography and on reflective confocal microscopy examination
Atypical intraepidermal melanocytic variant Unusual area of darker pigmentation contained within the epidermis that may
progress to an invasive melanoma; includes melanoma in situ and lentigo ma-
ligna
Atypical naevi Unusual looking but noncancerous mole or area of darker pigmentation of the
skin
Atypical pleomorphic keratinocytes Abnormal skin cells of different shapes and sizes, a feature visible on
histopathology
Axial resolution Axial resolution describes the ability of an OCT system to distinguish between
two points in space that lie in the direction parallel to the light beam
Basaloid cells Cells in the skin that look like those in epidermal basal layer
BRAF V600 mutation BRAF is a human gene that makes a protein called B-Raf which is involved in
the control of cell growth. BRAF mutations (damaged DNA) occur in around
40% of melanomas, which can then be treated with particular drugs
BRAF inhibitors Therapeutic agents which inhibit the serine-threonine protein kinase BRAF
mutated metastatic melanoma
Breslow thickness A scale for measuring the thickness of melanomas by the pathologist using a
microscope, measured in mm from the top layer of skin to the bottom of the
tumour
Congenital naevi A type of mole found on infants at birth
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(Continued)
Dermoscopy Whereby a handheld microscope is used to allow more detailed, magnified,
examination of the skin compared to examination by the naked eye alone
Dermo-epidermal junction The area where the lower part of the epidermis and top layer of the dermis
meet
Dermal nests Collections of pigment cells that are bunched together in the dermis
Dermal papilla Small projections of the dermis into the overlying epidermis giving an undu-
lating pattern and visible as ”fingerprints“ in hands and feet
Dermis Layer of skin below the epidermis, composed of living tissue and containing
blood capillaries, nerve endings, sweat glands, hair follicles and other structures
Desmoplastic subtypes of SCC An aggressive squamous cell carcinoma variant characterised by a proliferation
of fibroblasts and formation of fibrous connective tissue
Electrodessication The use of high-frequency electric currents to cut, destroy or cauterise tissue.
It is performed with the use of a fine needle-shaped instrument
Epidermis Outer layer of the skin
False negative An individual who is truly positive for a disease, but whom a diagnostic test
classifies them as disease-free
False positive An individual who is truly disease-free, but whom a diagnostic test classifies
them as having the disease
Fibrotic septa Excess fibrous connective tissue formation separating other parts of tissue
Grey-blue ovoid nests and globules Grey-blue coloured oval shaped areas seen under dermoscopy that may repre-
sent basal cell carcinomas
Histopathology/Histology The study of tissue, usually obtained by biopsy or excision, for example under
a microscope
Hypertrophic actinic keratosis Precancerous scaly patches of skin that are particularly thickened
Hypoechogenic Displaying lower echogenicity reflecting and appears darker on ultrasonogra-
phy
Incidence The number of new cases of a disease in a given time period.
Index test A diagnostic test under evaluation in a primary study
Inflammatory dermatoses Skin conditions where the main disease process is inflammatory, often involv-
ing immune cells, as apposed to malignant or infectious processes. The inflam-
matory process may be due to internal or external factors
91Exfoliative cytology for diagnosing basal cell carcinoma and other skin cancers in adults (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
Interferometry The measurement of waves of light or sound after interference in order to
extract information
Interfollicular epidermis The part of the epidermis that lies in between the hair follicles
Junctional nests Collections of pigment cells bunched up around the junction between the
epidermis and dermis
Lateral resolution Lateral resolutiondescribes the ability of anOCTsystem todistinguish between
two points in space that lie in a perpendicular direction to the light beam
Lentigo maligna Unusual area of darker pigmentation contained within the epidermis which
includes malignant cells but with no invasive growth. May progress to an
invasive melanoma
Lymph node Lymph nodes filter the lymphatic fluid (clear fluid containingwhite blood cells)
that travels around the body to help fight disease; they are located throughout
the body often in clusters (nodal basins)
Melanocytic naevus An area of skin with darker pigmentation (or melanocytes) also referred to as
‘moles’
Meta-analysis A form of statistical analysis used to synthesise results from a collection of
individual studies
Metastases/metastatic disease Spread of cancer away from the primary site to somewhere else through the
bloodstream or the lymphatic system
Micrometastases Micrometastases are metastases so small that they can only be seen under a
microscope
Mitotic activity Relates to the presence of proliferating cells and used as an index of tumour
aggressiveness
Mitotic rate Microscopic evaluation of number of cells actively dividing in a tumour
Morbidity Detrimental effects on health
Mortality Either (1) the condition of being subject to death; or (2) the death rate, which
reflects the number of deaths per unit of population in relation to any specific
region, age group, disease, treatment or other classification, usually expressed
as deaths per 100, 1000, 10,000 or 100,000 people
Multidisciplinary team A team with members from different healthcare professions and specialties (e.
g. urology, oncology, pathology, radiology, and nursing). Cancer care in the
National Health Service (NHS) uses this system to ensure that all relevant
health professionals are engaged to discuss the best possible care for that patient
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(Continued)
Naevus A mole or collection of pigment cells (plural: naevi or nevi)
Nuclear dysplasia and mitoses A histopathological term referring to abnormal nuclei with increased mitotic
activity and nuclear size associated with disordered nuclear dysplasia and mi-
toses cell growth
Nucleated The presence of a nuclei within a cell, which contain most of the cell’s genetic
material
Pagetoid cells Abnormal pigment cells that spread upwards through the epidermis
Papillary dermis Also called the ’upper dermis’, this is the uppermost layer of the dermis that
connects to the dermal-epidermal junction
Peripheral palisading A histopathological term referring to the wall-like appearance of cells around
a central focus
Pleomorphic Variability in size or shape
Polygonal cells Skin cells that appear to have many sides, such as taking up a pentagonal,
hexagonal or octagonal appearance
Prevalence The proportion of a population found to have a condition.
Prognostic factors/indicators Specific characteristics of a cancer or the person who has it which might affect
the patient’s prognosis
Receiver operating characteristic (ROC) plot A plot of the sensitivity and 1 minus the specificity of a test at the different
possible thresholds for test positivity; represents the diagnostic capability of a
test with a range of binary test results
Receiver operating characteristic (ROC) analysis The analysis of a ROC plot of a test to select an optimal threshold for test
positivity
Recurrence Recurrence is when new cancer cells are detected following treatment. This
can occur either at the site of the original tumour or at other sites in the body
Reference Standard A test or combination of tests used to establish the final or ‘true’ diagnosis of
a patient in an evaluation of a diagnostic test
Reflectance confocal microscopy (RCM) A microscopic technique using infrared light (either in a handheld device or a
static unit) that can create images of the deeper layers of the skin
Resolution Resolution in an imaging system refers to its ability to distinguish two points
in space as being separate points; resolution is measured in two directions: axial
and lateral
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(Continued)
Rete ridges Also called ’epidermal ridges’ or ’epidermal pegs’, they represent downward
projections of the epidermis into underlying connective tissue
Reticular dermis Also called the ’lower dermis’, the reticular dermis is the lower layer of the
dermis, located under the papillary dermis
Sensitivity In this context the term is used to mean the proportion of individuals with a
disease who have that disease correctly identified by the study test
Specificity The proportion of individuals without the disease of interest (in this case with
benign skin lesions) who have that absence of disease correctly identified by
the study test
Spindle subtypes of SCC A squamous cell carcinoma variant characterised by poorly differentiated spin-
dle cells surrounded by collagenous stroma
Spinous-granular layer One of several layers of the epidermis, which is the outermost layer of skin.
The nuclei of keratinocytes, which contain most of the cell’s genetic material
are found here
Staging Clinical description of the size and spread of a patient’s tumour, fitting into
internationally agreed categories
Stratum corneum The outermost layer of the epidermis. This layer is the most superficial layer
of skin, which is composed of flattened skin cells organised like a brick wall.
In normal conditions cells are not nucleated at this layer
Stromal reaction Change in connective tissue microenvironment
Subclinical (disease) Disease that is usually asymptomatic and not easily observable, e.g. by clinical
or physical examination
Superficial fine telangiectasia Fine dilated blood vessels of small/varying diameter located in the superficial
dermis
Targetoid hair follicles The presence of yellow keratotic follicular plugs surrounded by a white rim
on dermoscopy, more frequently known as “white circle”, which can be a
characteristic of squamous cell carcinoma
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Appendix 3. Table of Acronyms
7PCL seven point checklist
ABCD(E) asymmetry, border, colour, differential structures (enlargement)
AHM amelanotic or hypomelanotic melanoma
AK actinic keratosis
AMN atypical melanocytic naevi
AUC Area under the curve
BCC basal cell carcinoma
BD Bowen’s disease
BN benign naevi
BNM benign non-melanocytic
BPC between person comparison (of tests)
CAD computer assisted diagnosis
CCS case control study
CD compact disc
CM cutaneous melanoma
CMM cutaneous malignant melanoma
CS case series
cSCC cutaneous squamous cell carcinoma
D- disease negative
D+ disease positive
DF dermatofibroma
Dx diagnosis
ELM epiluminescence microscopy
FN false negative
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(Continued)
FP false positive
FU follow- up
GP general practitioner
H&E haematoxylin and eosin stain
LPLK lichen planus- like keratosis
LS lentigo simplex
MiS melanoma in situ (or lentigo maligna)
MM malignant melanoma
MN melanocytic naevi
N/A not applicable
NC non comparative
NMLs non melanocytic lesions
NPV negative predictive value
NR not reported
P prospective
PCPs primary care providers
PLC pigmented lesion clinic
PPV positive predictive value
PSL pigmented skin lesion
R retrospective
RCM reflectance confocal microscopy
RCT randomised controlled trial
SCC squamous cell carcinoma
SD standard deviation
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(Continued)
SDDI Short term sequential digital dermoscopy imaging
se sensitivity
sp specificity
SK seborrhoeic keratosis
SN Spitz nevi
SSM superficial spreading melanoma
TD teledermatology
TN true negative
TWR two week rule
VI visual inspection
WPC within person comparison (of tests)
WPC-algs within person comparison (of algorithms)
Appendix 4. Proposed sources of heterogeneity
i. Population characteristics
• general versus higher risk populations
• patient population: primary /secondary / specialist unit
• degree of prior clinical suspicion (highly suspicious vs. challenging/equivocal lesions)
• disease prevalence (high vs low)
• inclusion of multiple lesions per participant
• ethnicity
ii. Index test characteristics
• the nature of and definition of criteria for test positivity
• observer experience with the index test
iii. Reference standard characteristics
• whether histology-reporting meets pathology-reporting guidelines
• use of excisional versus diagnostic biopsy
• whether two independent dermatopathologists reviewed histological diagnosis
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iv. Study quality
• consecutive or random sample of participants recruited
• index test interpreted blinded to the reference standard result
• index test interpreted blinded to the result of any other index test
• use of an adequate reference standard
• overall risk of bias
Appendix 5. Final search strategies
Melanoma search strategies to August 2016
Database: Ovid MEDLINE(R) 1946 to August week 3 2016
Search strategy:
1 exp melanoma/
2 exp skin cancer/
3 exp basal cell carcinoma/
4 basalioma$1.ti,ab.
5 ((basal cell or skin) adj2 (cancer$1 or carcinoma$1 or mass or masses or tumour$1 or tumor$1 or neoplasm$1 or adenoma$1 or
epithelioma$1 or lesion$1 or malignan$ or nodule$1)).ti,ab.
6 (pigmented adj2 (lesion$1 or mole$ or nevus or nevi or naevus or naevi or skin)).ti,ab.
7 (melanom$1 or nonmelanoma$1 or non-melanoma$1 or melanocyt$ or non-melanocyt$ or nonmelanocyt$ or keratinocyt$).ti,ab.
8 nmsc.ti,ab.
9 (squamous cell adj2 (cancer$1 or carcinoma$1 or mass or masses or tumor$1 or tumour$1 or neoplasm$1 or adenoma$1 or
epithelioma$1 or epithelial or lesion$1 or malignan$ or nodule$1) adj2 (skin or epiderm$ or cutaneous)).ti,ab.
10 (BCC or CSCC or NMSC).ti,ab.
11 keratinocy$.ti,ab.
12 Keratinocytes/
13 or/1-12
14 dermoscop$.ti,ab.
15 dermatoscop$.ti,ab.
16 photomicrograph$.ti,ab.
17 exp epiluminescence microscopy/
18 (epiluminescence adj2 microscop$).ti,ab.
19 (confocal adj2 microscop$).ti,ab.
20 (incident light adj2 microscop$).ti,ab.
21 (surface adj2 microscop$).ti,ab.
22 (visual adj (inspect$ or examin$)).ti,ab.
23 ((clinical or physical) adj examin$).ti,ab.
24 3 point.ti,ab.
25 three point.ti,ab.
26 pattern analys$.ti,ab.
27 ABCD$.ti,ab.
28 menzies.ti,ab.
29 7 point.ti,ab.
30 seven point.ti,ab.
31 (digital adj2 (dermoscop$ or dermatoscop$)).ti,ab.
32 artificial intelligence.ti,ab.
33 AI.ti,ab.
34 computer assisted.ti,ab.
35 computer aided.ti,ab.
36 neural network$.ti,ab.
37 exp diagnosis, computer-assisted/
38 MoleMax.ti,ab.
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39 image process$.ti,ab.
40 automatic classif$.ti,ab.
41 image analysis.ti,ab.
42 SIAscop$.ti,ab.
43 Aura.ti,ab.
44 (optical adj2 scan$).ti,ab.
45 MelaFind.ti,ab.
46 SIMSYS.ti,ab.
47 MoleMate.ti,ab.
48 SolarScan.ti,ab.
49 VivaScope.ti,ab.
50 (high adj3 ultraso$).ti,ab.
51 (canine adj2 detect$).ti,ab.
52 ((mobile or cell or cellular or smart) adj ((phone$1 adj2 app$1) or application$1)).ti,ab.
53 smartphone$.ti,ab.
54 (DermoScan or SkinVision or DermLink or SpotCheck).ti,ab.
55 Mole Detective.ti,ab.
56 Spot Check.ti,ab.
57 (mole$1 adj2 map$).ti,ab.
58 (total adj2 body).ti,ab.
59 exfoliative cytolog$.ti,ab.
60 digital analys$.ti,ab.
61 (image$1 adj3 software).ti,ab.
62 (teledermatolog$ or tele-dermatolog$ or telederm or tele-derm or teledermoscop$ or tele-dermoscop$ or teledermatoscop$ or tele-
dermatoscop$).ti,ab.
63 (optical coherence adj (technolog$ or tomog$)).ti,ab.
64 (computer adj2 diagnos$).ti,ab.
65 exp sentinel lymph node biopsy/
66 (sentinel adj2 node).ti,ab.
67 nevisense.mp. or HFUS.ti,ab.
68 electrical impedance spectroscopy.ti,ab.
69 history taking.ti,ab.
70 patient history.ti,ab.
71 (naked eye adj (exam$ or assess$)).ti,ab.
72 (skin adj exam$).ti,ab.
73 physical examination/
74 ugly duckling.mp. or UD.ti,ab.
75 ((physician$ or clinical or physical) adj (exam$ or triage or recog$)).ti,ab.
76 ABCDE.mp. or VOC.ti,ab.
77 clinical accuracy.ti,ab.
78 Family Practice/ or Physicians, Family/ or clinical competence/
79 (confocal adj2 microscop$).ti,ab.
80 diagnostic algorithm$1.ti,ab.
81 checklist$.ti,ab.
82 virtual imag$1.ti,ab.
83 volatile organic compound$1.ti,ab.
84 dog$1.ti,ab.
85 gene expression analy$.ti,ab.
86 reflex transmission imag$.ti,ab.
87 thermal imaging.ti,ab.
88 elastography.ti,ab.
89 or/14-88
90 (CT or PET).ti,ab.
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91 PET-CT.ti,ab.
92 (FDG or F18 or Fluorodeoxyglucose or radiopharmaceutical$).ti,ab.
93 exp Deoxyglucose/
94 deoxy-glucose.ti,ab.
95 deoxyglucose.ti,ab.
96 CATSCAN.ti,ab.
97 exp Tomography, Emission-Computed/
98 exp Tomography, X-ray computed/
99 positron emission tomograph$.ti,ab.
100 exp magnetic resonance imaging/
101 (MRI or fMRI or NMRI or scintigraph$).ti,ab.
102 exp echography/
103 Doppler echography.ti,ab.
104 sonograph$.ti,ab.
105 ultraso$.ti,ab.
106 doppler.ti,ab.
107 magnetic resonance imag$.ti,ab.
108 or/90-107
109 (stage$ or staging or metasta$ or recurrence or sensitivity or specificity or false negative$ or thickness$).ti,ab.
110 “Sensitivity and Specificity”/
111 exp cancer staging/
112 or/109-111
113 108 and 112
114 89 or 113
115 13 and 114
Database: Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations 29 August 2016
Search strategy:
1 basalioma$1.ti,ab.
2 ((basal cell or skin) adj2 (cancer$1 or carcinoma$1 or mass or masses or tumour$1 or tumor$1 or neoplasm$1 or adenoma$1 or
epithelioma$1 or lesion$1 or malignan$ or nodule$1)).ti,ab.
3 (pigmented adj2 (lesion$1 or mole$ or nevus or nevi or naevus or naevi or skin)).ti,ab.
4 (melanom$1 or nonmelanoma$1 or non-melanoma$1 or melanocyt$ or non-melanocyt$ or nonmelanocyt$ or keratinocyt$).ti,ab.
5 nmsc.ti,ab.
6 (squamous cell adj2 (cancer$1 or carcinoma$1 or mass or masses or tumor$1 or tumour$1 or neoplasm$1 or adenoma$1 or
epithelioma$1 or epithelial or lesion$1 or malignan$ or nodule$1) adj2 (skin or epiderm$ or cutaneous)).ti,ab.
7 (BCC or CSCC or NMSC).ti,ab.
8 keratinocy$.ti,ab.
9 or/1-8
10 dermoscop$.ti,ab.
11 dermatoscop$.ti,ab.
12 photomicrograph$.ti,ab.
13 (epiluminescence adj2 microscop$).ti,ab.
14 (confocal adj2 microscop$).ti,ab.
15 (incident light adj2 microscop$).ti,ab.
16 (surface adj2 microscop$).ti,ab.
17 (visual adj (inspect$ or examin$)).ti,ab.
18 ((clinical or physical) adj examin$).ti,ab.
19 3 point.ti,ab.
20 three point.ti,ab.
21 pattern analys$.ti,ab.
22 ABCD$.ti,ab.
23 menzies.ti,ab.
24 7 point.ti,ab.
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25 seven point.ti,ab.
26 (digital adj2 (dermoscop$ or dermatoscop$)).ti,ab.
27 artificial intelligence.ti,ab.
28 AI.ti,ab.
29 computer assisted.ti,ab.
30 computer aided.ti,ab.
31 neural network$.ti,ab.
32 MoleMax.ti,ab.
33 image process$.ti,ab.
34 automatic classif$.ti,ab.
35 image analysis.ti,ab.
36 SIAscop$.ti,ab.
37 Aura.ti,ab.
38 (optical adj2 scan$).ti,ab.
39 MelaFind.ti,ab.
40 SIMSYS.ti,ab.
41 MoleMate.ti,ab.
42 SolarScan.ti,ab.
43 VivaScope.ti,ab.
44 (high adj3 ultraso$).ti,ab.
45 (canine adj2 detect$).ti,ab.
46 ((mobile or cell or cellular or smart) adj ((phone$1 adj2 app$1) or application$1)).ti,ab.
47 smartphone$.ti,ab.
48 (DermoScan or SkinVision or DermLink or SpotCheck).ti,ab.
49 Mole Detective.ti,ab.
50 Spot Check.ti,ab.
51 (mole$1 adj2 map$).ti,ab.
52 (total adj2 body).ti,ab.
53 exfoliative cytolog$.ti,ab.
54 digital analys$.ti,ab.
55 (image$1 adj3 software).ti,ab.
56 (teledermatolog$ or tele-dermatolog$ or telederm or tele-derm or teledermoscop$ or tele-dermoscop$ or teledermatoscop$ or tele-
dermatoscop$).ti,ab.
57 (optical coherence adj (technolog$ or tomog$)).ti,ab.
58 (computer adj2 diagnos$).ti,ab.
59 (sentinel adj2 node).ti,ab.
60 nevisense.mp. or HFUS.ti,ab.
61 electrical impedance spectroscopy.ti,ab.
62 history taking.ti,ab.
63 patient history.ti,ab.
64 (naked eye adj (exam$ or assess$)).ti,ab.
65 (skin adj exam$).ti,ab.
66 ugly duckling.mp. or UD.ti,ab.
67 ((physician$ or clinical or physical) adj (exam$ or triage or recog$)).ti,ab.
68 ABCDE.mp. or VOC.ti,ab.
69 clinical accuracy.ti,ab.
70 (Family adj (Practice or Physicians)).ti,ab.
71 (confocal adj2 microscop$).ti,ab.
72 clinical competence.ti,ab.
73 diagnostic algorithm$1.ti,ab.
74 checklist$.ti,ab.
75 virtual imag$1.ti,ab.
76 volatile organic compound$1.ti,ab.
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77 dog$1.ti,ab.
78 gene expression analy$.ti,ab.
79 reflex transmission imag$.ti,ab.
80 thermal imaging.ti,ab.
81 elastography.ti,ab.
82 or/10-81
83 (CT or PET).ti,ab.
84 PET-CT.ti,ab.
85 (FDG or F18 or Fluorodeoxyglucose or radiopharmaceutical$).ti,ab.
86 deoxy-glucose.ti,ab.
87 deoxyglucose.ti,ab.
88 CATSCAN.ti,ab.
89 positron emission tomograph$.ti,ab.
90 (MRI or fMRI or NMRI or scintigraph$).ti,ab.
91 Doppler echography.ti,ab.
92 sonograph$.ti,ab.
93 ultraso$.ti,ab.
94 doppler.ti,ab.
95 magnetic resonance imag$.ti,ab.
96 or/83-95
97 (stage$ or staging or metasta$ or recurrence or sensitivity or specificity or false negative$ or thickness$).ti,ab.
98 96 and 97
99 82 or 98
100 9 and 99
Database: Embase 1974 to 29 August 2016
Search strategy:
1 *melanoma/
2 *skin cancer/
3 *basal cell carcinoma/
4 basalioma$.ti,ab.
5 ((basal cell or skin) adj2 (cancer$1 or carcinoma$1 or mass or masses or tumour$1 or tumor$1 or neoplasm$ or adenoma$ or
epithelioma$ or lesion$ or malignan$ or nodule$)).ti,ab.
6 (pigmented adj2 (lesion$1 or mole$ or nevus or nevi or naevus or naevi or skin)).ti,ab.
7 (melanom$1 or nonmelanoma$1 or non-melanoma$1 or melanocyt$ or non-melanocyt$ or nonmelanocyt$ or keratinocyt$).ti,ab.
8 nmsc.ti,ab.
9 (squamous cell adj2 (cancer$1 or carcinoma$1 or mass or tumor$1 or tumour$1 or neoplasm$1 or adenoma$1 or epithelioma$1 or
epithelial or lesion$1 or malignan$ or nodule$1) adj2 (skin or epiderm$ or cutaneous)).ti,ab.
10 (BCC or cscc).mp. or NMSC.ti,ab.
11 keratinocyte.ti,ab.
12 keratinocy$.ti,ab.
13 or/1-12
14 dermoscop$.ti,ab.
15 dermatoscop$.ti,ab.
16 photomicrograph$.ti,ab.
17 *epiluminescence microscopy/
18 (epiluminescence adj2 microscop$).ti,ab.
19 (confocal adj2 microscop$).ti,ab.
20 (incident light adj2 microscop$).ti,ab.
21 (surface adj2 microscop$).ti,ab.
22 (visual adj (inspect$ or examin$)).ti,ab.
23 ((clinical or physical) adj examin$).ti,ab.
24 3 point.ti,ab.
25 three point.ti,ab.
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26 pattern analys$.ti,ab.
27 ABCD$.ti,ab.
28 menzies.ti,ab.
29 7 point.ti,ab.
30 seven point.ti,ab.
31 (digital adj2 (dermoscop$ or dermatoscop$)).ti,ab.
32 artificial intelligence.ti,ab.
33 AI.ti,ab.
34 computer assisted.ti,ab.
35 computer aided.ti,ab.
36 neural network$.ti,ab.
37 MoleMax.ti,ab.
38 exp diagnosis, computer-assisted/
39 image process$.ti,ab.
40 automatic classif$.ti,ab.
41 image analysis.ti,ab.
42 SIAscop$.ti,ab.
43 (optical adj2 scan$).ti,ab.
44 Aura.ti,ab.
45 MelaFind.ti,ab.
46 SIMSYS.ti,ab.
47 MoleMate.ti,ab.
48 SolarScan.ti,ab.
49 VivaScope.ti,ab.
50 confocal microscop$.ti,ab.
51 (high adj3 ultraso$).ti,ab.
52 (canine adj2 detect$).ti,ab.
53 ((mobile or cell$ or cellular or smart) adj ((phone$1 adj2 app$1) or application$1)).ti,ab.
54 smartphone$.ti,ab.
55 (DermoScan or SkinVision or DermLink or SpotCheck).ti,ab.
56 Spot Check.ti,ab.
57 Mole Detective.ti,ab.
58 (mole$1 adj2 map$).ti,ab.
59 (total adj2 body).ti,ab.
60 exfoliative cytolog$.ti,ab.
61 digital analys$.ti,ab.
62 (image$1 adj3 software).ti,ab.
63 (optical coherence adj (technolog$ or tomog$)).ti,ab.
64 (teledermatolog$ or tele-dermatolog$ or telederm or tele-derm or teledermoscop$ or tele-dermoscop$ or teledermatoscop$).mp. or
tele-dermatoscop$.ti,ab.
65 (computer adj2 diagnos$).ti,ab.
66 *sentinel lymph node biopsy/
67 (sentinel adj2 node).ti,ab.
68 nevisense.ti,ab.
69 HFUS.ti,ab.
70 electrical impedance spectroscopy.ti,ab.
71 history taking.ti,ab.
72 patient history.ti,ab.
73 (naked eye adj (exam$ or assess$)).ti,ab.
74 (skin adj exam$).ti,ab.
75 *physical examination/
76 ugly duckling.ti,ab.
77 UD sign$.ti,ab.
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78 ((physician$ or clinical or physical) adj (exam$ or recog$ or triage)).ti,ab.
79 ABCDE.ti,ab.
80 clinical accuracy.ti,ab.
81 *general practice/
82 (confocal adj2 microscop$).ti,ab.
83 clinical competence/
84 diagnostic algorithm$.ti,ab.
85 checklist$1.ti,ab.
86 virtual image$1.ti,ab.
87 volatile organic compound$1.ti,ab.
88 VOC.ti,ab.
89 dog$1.ti,ab.
90 gene expression analys$.ti,ab.
91 reflex transmission imaging.ti,ab.
92 thermal imaging.ti,ab.
93 elastography.ti,ab.
94 dog$1.ti,ab.
95 gene expression analys$.ti,ab.
96 reflex transmission imaging.ti,ab.
97 thermal imaging.ti,ab.
98 elastography.ti,ab.
99 or/14-93
100 PET-CT.ti,ab.
101 (CT or PET).ti,ab.
102 (FDG or F18 or Fluorodeoxyglucose or radiopharmaceutical$).ti,ab.
103 exp Deoxyglucose/
104 CATSCAN.ti,ab.
105 deoxyglucose.ti,ab.
106 deoxy-glucose.ti,ab.
107 *positron emission tomography/
108 *computer assisted tomography/
109 positron emission tomograph$.ti,ab.
110 *nuclear magnetic resonance imaging/
111 (MRI or fMRI or NMRI or scintigraph$).ti,ab.
112 *echography/
113 Doppler.ti,ab.
114 sonograph$.ti,ab.
115 ultraso$.ti,ab.
116 magnetic resonance imag$.ti,ab.
117 or/100-116
118 (stage$ or staging or metasta$ or recurrence or sensitivity or specificity or false negative$ or thickness$).ti,ab.
119 “Sensitivity and Specificity”/
120 *cancer staging/
121 or/118-120
122 117 and 121
123 99 or 122
124 13 and 123
Database: Cochrane Library (Wiley) 2016 searched 30 August 2016 CDSR Issue 8 of 12 2016 CENTRAL Issue 7 of 12 2016
HTA Issue 3 of 4 July 2016 DARE Issue 3 of 4 2015
Search strategy:
#1 melanoma* or nonmelanoma* or non-melanoma* or melanocyt* or non-melanocyt* or nonmelanocyt* or keratinocyte*
#2 MeSH descriptor: [Melanoma] explode all trees
#3 “skin cancer*”
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#4 MeSH descriptor: [Skin Neoplasms] explode all trees
#5 skin near/2 (cancer* or carcinoma* or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or epithelioma* or lesion*
or malignan* or nodule*)
#6 nmsc
#7 “squamous cell” near/2 (cancer* or carcinoma* or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or epithelioma*
or lesion* or malignan* or nodule*) near/2 (skin or epiderm* or cutaneous)
#8 “basal cell” near/2 (cancer* or carcinoma* or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or epithelioma* or
lesion* or malignan* or nodule*)
#9 pigmented near/2 (lesion* or nevus or mole* or naevi or naevus or nevi or skin)
#10 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9
#11 dermoscop*
#12 dermatoscop*
#13 Photomicrograph*
#14 MeSH descriptor: [Dermoscopy] explode all trees
#15 confocal near/2 microscop*
#16 epiluminescence near/2 microscop*
#17 incident next light near/2 microscop*
#18 surface near/2 microscop*
#19 “visual inspect*”
#20 “visual exam*”
#21 (clinical or physical) next (exam*)
#22 “3 point”
#23 “three point”
#24 “pattern analys*”
#25 ABDC
#26 menzies
#27 “7 point”
#28 “seven point”
#29 digital near/2 (dermoscop* or dermatoscop*)
#30 “artificial intelligence”
#31 “AI”
#32 “computer assisted”
#33 “computer aided”
#34 AI
#35 “neural network*”
#36 MoleMax
#37 “computer diagnosis”
#38 “image process*”
#39 “automatic classif*”
#40 SIAscope
#41 “image analysis”
#42 “optical near/2 scan*”
#43 Aura
#44 MelaFind
#45 SIMSYS
#46 MoleMate
#47 SolarScan
#48 Vivascope
#49 “confocal microscopy”
#50 high near/3 ultraso*
#51 canine near/2 detect*
#52 Mole* near/2 map*
#53 total near/2 body
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#54 mobile* or smart near/2 phone*
#55 cell next phone*
#56 smartphone*
#57 “mitotic index”
#58 DermoScan or SkinVision or DermLink or SpotCheck
#59 “Mole Detective”
#60 “Spot Check”
#61 mole* near/2 map*
#62 total near/2 body
#63 “exfoliative cytolog*”
#64 “digital analys*”
#65 image near/3 software
#66 teledermatolog* or tele-dermatolog* or telederm or tele-derm or teledermoscop* or tele-dermoscop* or teledermatoscop* or tele-
dermatolog*
#67 “optical coherence” next (technolog* or tomog*)
#68 computer near/2 diagnos*
#69 sentinel near/2 node*
#70 #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28
or #29 or #30 or #31 or #32 or #33 or #34 or #35 or #36 or #37 or #38 or #39 or #40 or #41 or #42 or #43 or #44 or #45 or #46 or
#47 or #48 or #49 or #50 or #51 or #52 or #53 or #54 or #55 or #56 or #57 or #58 or #59 or #60 or #61 or #62 or #63 or #64 or #
65 or #66 or #67 or #68 or #69
#71 ultraso*
#72 sonograph*
#73 MeSH descriptor: [Ultrasonography] explode all trees
#74 Doppler
#75 CT or PET or PET-CT
#76 “CAT SCAN” or “CATSCAN”
#77 MeSH descriptor: [Positron-Emission Tomography] explode all trees
#78 MeSH descriptor: [Tomography, X-Ray Computed] explode all trees
#79 MRI
#80 MeSH descriptor: [Magnetic Resonance Imaging] explode all trees
#81 MRI or fMRI or NMRI or scintigraph*
#82 “magnetic resonance imag*”
#83 MeSH descriptor: [Deoxyglucose] explode all trees
#84 deoxyglucose or deoxy-glucose
#85 “positron emission tomograph*”
#86 #71 or #72 or #73 or #74 or #75 or #76 or #77 or #78 or #79 or #80 or #81 or #82 or #83 or #84 or #85
#87 stage* or staging or metasta* or recurrence or sensitivity or specificity or “false negative*” or thickness*
#88 MeSH descriptor: [Neoplasm Staging] explode all trees
#89 #87 or #88
#90 #89 and #86
#91 #70 or #90
#92 #10 and #91
#93 BCC or CSCC or NMCS
#94 keratinocy*
#95 #93 or #94
#96 #10 or #95
#97 nevisense
#98 HFUS
#99 “electrical impedance spectroscopy”
#100 “history taking”
#101 “patient history”
#102 naked next eye near/1 (exam* or assess*)
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#103 skin next exam*
#104 “ugly duckling” or (UD sign*)
#105 MeSH descriptor: [Physical Examination] explode all trees
#106 (physician* or clinical or physical) near/1 (exam* or recog* or triage*)
#107 ABCDE
#108 “clinical accuracy”
#109 MeSH descriptor: [General Practice] explode all trees
#110 confocal near microscop*
#111 “diagnostic algorithm*”
#112 MeSH descriptor: [Clinical Competence] explode all trees
#113 checklist*
#114 “virtual image*”
#115 “volatile organic compound*”
#116 dog or dogs
#117 VOC
#118 “gene expression analys*”
#119 “reflex transmission imaging”
#120 “thermal imaging”
#121 elastography
#122 #97 or #98 or #99 or #100 or #101 or #102 or #103 or #104 or #105 or #106 or #107 or #108 or #109 or #110 or #111 or #
112 or #113 or #114 or #115 or #116 or #117 or #118 or #119 or #120 or #121
#123 #70 or #122
#124 #96 and #123
#125 #96 and #90
#126 #125 or #124
#127 #10 and #126
Database : CINAHL Plus (EBSCO) 1937 to 30 August 2016
Search strategy:
S1 (MH “Melanoma”) OR (MH “Nevi and Melanomas+”)
S2 (MH “Skin Neoplasms+”)
S3 (MH “Carcinoma, Basal Cell+”)
S4 basalioma*
S5 (basal cell) N2 (cancer* or carcinoma* or mass or masses or tumor* or tumour* or neoplasm* or adenoma* or epithelioma* or
lesion* or malignan* or nodule*)
S6 (pigmented) N2 (lesion* or mole* or nevus or nevi or naevus or naevi or skin)
S7 melanom* or nonmelanoma* or non-melanoma* or melanocyt* or non-melanocyt* or nonmelanocyt*
S8 nmsc
S9 TX BCC or cscc or NMSC
S10 (MH “Keratinocytes”)
S11 keratinocyt*
S12 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11
S13 dermoscop* or dermatoscop* or photomicrograph* or (3 point) or (three point) or ABCD* or menzies or (7 point) or (seven
point) or AI or Molemax or SIASCOP* or Aura or MelaFind or SIMSYS or MoleMate or SolarScan or smartphone* or DermoScan
or SkinVision or DermLink or SpotCheck
S14 (epiluminescence or confocal or incident or surface) N2 (microscop*)
S15 visual N1 (inspect* or examin*)
S16 (clinical or physical) N1 (examin*)
S17 pattern analys*
S18 (digital) N2 (dermoscop* or dermatoscop*)
S19 (artificial intelligence)
S20 (computer) N2 (assisted or aided)
S21 (neural network*)
S22 (MH “Diagnosis, Computer Assisted+”)
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S23 (image process*)
S24 (automatic classif*)
S25 (image analysis)
S26 SIAScop*
S27 (optical) N2 (scan*)
S28 (high) N3 (ultraso*)
S29 elastography
S30 (mobile or cell or cellular or smart) N2 (phone*) N2 (app or application*)
S31 (mole*) N2 (map*)
S32 total N2 body
S33 exfoliative cytolog*
S34 digital analys*
S35 image N3 software
S36 teledermatolog* or tele-dermatolog* or telederm or tele-derm or teledermoscop* or tele-dermoscop* or teledermatoscop* or tele-
dermatoscop* teledermatolog* or tele-dermatolog* or telederm or tele-derm or teledermoscop*
S37 (optical coherence) N1 (technolog* or tomog*)
S38 computer N2 diagnos*
S39 sentinel N2 node
S40 (MH “Sentinel Lymph Node Biopsy”)
S41 nevisense or HFUS or checklist* or VOC or dog*
S42 electrical impedance spectroscopy
S43 history taking
S44 “Patient history”
S45 naked eye
S46 skin exam*
S47 physical exam*
S48 ugly duckling
S49 UD sign*
S50 (physician* or clinical or physical) N1 (exam*)
S51 clinical accuracy
S52 general practice
S53 (physician* or clinical or physical) N1 (recog* or triage)
S54 confocal microscop*
S55 clinical competence
S56 diagnostic algorithm*
S57 checklist*
S58 virtual image*
S59 volatile organic compound*
S60 gene expression analys*
S61 reflex transmission imag*
S62 thermal imaging
S63 S13 or S14 or S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR S22 OR S23 OR S24 OR S25 OR S26 OR S27 OR
S28 OR S29 OR S30 OR S31 OR S32 OR S33 OR S34 OR S35 OR S36 OR S37 OR S38 OR S39 OR S40 OR S41 OR S42 OR
S43 OR S44 OR S45 OR S46 OR S47 OR S48 OR S49 OR S50 OR S51 OR S52 OR S53 OR S54 OR S55 OR S56 OR S57 OR
S58 OR S59 OR S60 OR S61 OR S62
S64 CT or PET
S65 PET-CT
S66 FDG or F18 or Fluorodeoxyglucose or radiopharmaceutical*
S67 (MH “Deoxyglucose+”)
S68 deoxy-glucose or deoxyglucose
S69 CATSCAN
S70 CAT-SCAN
S71 (MH “Deoxyglucose+”)
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S72 (MH “Tomography, Emission-Computed+”)
S73 (MH “Tomography, X-Ray Computed”)
S74 positron emission tomograph*
S75 (MH “Magnetic Resonance Imaging+”)
S76 MRI or fMRI or NMRI or scintigraph*
S77 echography
S78 doppler
S79 sonograph*
S80 ultraso*
S81 magnetic resonance imag*
S82 S64 OR S65 OR S66 OR S67 OR S68 OR S69 OR S70 OR S71 OR S72 OR S73 OR S74 OR S75 OR S76 OR S77 OR S78
OR S79 OR S80 OR S81
S83 stage* or staging or metasta* or recurrence or sensitivity or specificity or (false negative*) or thickness
S84 (MH “Neoplasm Staging”)
S85 S83 OR S84
S86 S82 AND S85
S87 S63 OR S86
S88 S12 AND S87
Database: Science Citation Index SCI Expanded (Web of Science) 1900 to 30 August 2016
Conference Proceedings Citation Index (Web of Science) 1900 to 1 September 2016
Search strategy:
#1 (melanom* or nonmelanom* or non-melanoma* or melanocyt* or non-melanocyt* or nonmelanocyt* or keratinocyt*)
#2 (basalioma*)
#3 ((skin) near/2 (cancer* or carcinoma or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or epithelioma* or lesion*
or malignan* or nodule*))
#4 ((basal) near/2 (cancer* or carcinoma* or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or epithelioma* or
lesion* or malignan* or nodule*))
#5 ((pigmented) near/2 (lesion* or mole* or nevus or nevi or naevus or naevi or skin))
#6 (nmsc or BCC or NMSC or keratinocy*)
#7 ((squamous cell (cancer* or carcinoma* or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or epithelioma* or
lesion* or malignan* or nodule*))
#8 (skin or epiderm* or cutaneous)
#9 #8 AND #7
#10 #9 OR #6 OR #5 OR #4 OR #3 OR #2 OR #1
#11 ((dermoscop* or dermatoscop* or photomicrograph* or epiluminescence or confocal or “incident light” or “surface microscop*”
or “visual inspect*” or “physical exam*” or 3 point or three point or pattern analy* or ABCDE or menzies or 7 point or seven point
or dermoscop* or dermatoscop* or AI or artificial or computer aided or computer assisted or neural network* or Molemax or image
process* or automatic classif* or image analysis or siascope or optical scan* or Aura or melafind or simsys or molemate or solarscan or
vivascope or confocal microscop* or high ultraso* or canine detect* or cellphone* or mobile* or phone* or smartphone or dermoscan
or skinvision or dermlink or spotcheck or spot check or mole detective or mole map* or total body or exfoliative psychology or digital
or image software or optical coherence or teledermatology or telederm* or teledermoscop* or teledermatoscop* or computer diagnos*
or sentinel))
#12 ((nevisense or HFUS or impedance spectroscopy or history taking or patient history or naked eye or skin exam* or physical exam*
or ugly duckling or UD sign* or physician* exam* or physical exam* or ABCDE or clinical accuracy or general practice or confocal
microscop* or clinical competence or diagnostic algorithm* or checklist* or virtual image* or volatile organic or VOC or dog* or gene
expression or reflex transmission or thermal imag* or elastography))
#13 #11 or #12
#14 ((PET or CT or FDG or deoxyglucose or deoxy-glucose or fluorodeoxy* or radiopharma* or CATSCAN or positron emission or
computer assisted or nuclear magnetic or MRI or FMRI or NMRI or scintigraph* or echograph* or Doppler or sonograph* or ultraso*
or magnetic reson*))
#15 ((stage* or staging or metast* or recurrence or sensitivity or specificity or false negative* or thickness*))
#16 #14 AND #15
#17 #16 OR #13
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#18 #10 AND #17
Refined by: DOCUMENT TYPES: (MEETING ABSTRACT OR PROCEEDINGS PAPER)
Appendix 6. Full text inclusion criteria
The table below summarises the inclusion criteria applied to each study.
Criterion Inclusion Exclusion
Study design For diagnostic and staging reviews
• Any study for which a 2×2 contingency table
can be extracted, e.g.
◦ diagnostic case control studies
◦ ’cross-sectional’ test accuracy study with
retrospective or prospective data collection
◦ studies where estimation of test accuracy
was not the primary objective but test results for
both index and reference standard were available
◦ RCTs of tests or testing strategies where
participants were randomised between index tests
and all undergo a reference standard (i.e. accuracy
RCTs)
• < 5 melanoma cases (diagnosis reviews)
• < 10 participants (staging reviews)
• Studies developing new criteria for diagnosis
unless a separate ’test set’ of images were used to
evaluate the criteria (mainly digital dermoscopy)
• Studies using ’normal’ skin as controls
• Letters, editorials, comment papers, narrative
reviews
• Insufficient data to construct a 2×2 table
Target condition • Melanoma
• Keratinocyte skin cancer (or non-melanoma
skin cancer)
◦ BCC or epithelioma
◦ cSCC
• Studies exclusively conducted in children
• Studies of non-cutaneous melanoma or SCC
Population For diagnostic reviews
• Adults with a skin lesion suspicious for
melanoma, BCC, or cSCC (other terms include
pigmented skin lesion/nevi, melanocytic,
keratinocyte, etc.)
• Adults at high risk of developing melanoma
skin cancer, BCC, or cSCC
For staging reviews
• Adults with a diagnosis of melanoma or cSCC
undergoing tests for staging of lymph nodes or
distant metastases or both
• People suspected of other forms of skin cancer
• Studies conducted exclusively in children
Index tests For diagnosis
• Visual inspection/clinical examination
• Dermoscopy/dermatoscopy
• Teledermoscpoy
• Smartphone/mobile phone applications
• Digital dermoscopy/artificial intelligence
• Confocal microscopy
• Ocular coherence tomography
• Exfoliative cytology
• Sentinel lymph biopsy for therapeutic rather
than staging purposes
• Tests to determine melanoma thickness
• Tests to determine surgical margins/lesion
borders
• Tests to improve histopathology diagnose
• LND
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(Continued)
• High-frequency ultrasound
• Canine odour detection
• DNA expression analysis/gene chip analysis
• Other
For staging
• CT
• PET
• PET-CT
• MRI
• Ultrasound +/fine needle aspiration cytology
FNAC
• SLNB +/high-frequency ultrasound
• Other
Any test combination and in any order
Any test positivity threshold
Any variation in testing procedure (e.g. radioisotope
used)
Reference standard For diagnostic studies
• Histopathology of the excised lesion
• Clinical follow-up of non-excised/benign
appearing lesions with later histopathology if
suspicious
• Expert diagnosis (studies should not be
included if expert diagnosis is the sole reference
standard)
For studies of imaging tests for staging
• Histopathology (via LND or SLMB)
• Clinical/radiological follow-up
• A combination of the above
For studies of SLNB accuracy for staging
• LND of both SLN+ and SLn participants to
identify all diseased nodes
• LND of SLN+ participants and follow-up of
SLN participants to identify a subsequent nodal
recurrence in a previously investigated nodal basin
For diagnostic studies
• Exclude if any disease positive participants have
diagnosis unconfirmed by histology
• Exclude if > 50% of disease negative
participants have diagnosis confirmed by expert
opinion with no histology or follow-up
• Exclude studies of referral accuracy, i.e.
comparing referral decision with expert diagnosis,
unless evaluations of teledermatology or mobile
phone applications
BCC: basal cell carcinoma; cSCC: cutaneous squamous cell carcinoma; CT: computed tomography; FNAC: fine needle aspiration
cytology; LND: lymph node dissection; MRI: magnetic resonance imaging; PET: positron emission tomography; PET-CT: positron
emission tomography computed tomography; RCT: randomised controlled trial; SCC: squamous cell carcinoma; SLN+: positive
sentinel lymph node; SLn: negative sentinel lymph node; SLNB: sentinel lymph node biopsy
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Appendix 7. Quality assessment (based on QUADAS-2)
We tailored the QUADAS-2 checklist to the review topic as follows below (Whiting 2011).
Patient selection domain (1)
Selective recruitment of study participants can be a key influence on test accuracy. In general terms, all participants eligible to undergo
a test should be included in a study, allowing for the intended use of that test within the context of the study. We considered studies that
separately sampled malignant and benign lesions to have used a case-control design; and those that supplemented a series of suspicious
lesions with additional malignant or benign lesions to be at unclear risk of bias.
In terms of exclusions, we considered studies that excluded particular lesion types, particular lesion sites, or that excluded lesions on
the basis of image quality or lack of observer agreement (e.g. on histopathology) to be at high risk of bias.
In judging the applicability of patient populations to the review question, we considered restriction to particular lesion populations,
such as melanocytic, nodular, high risk or restrictions by size to be of high concern for applicability.
Given that diagnosis of skin cancer is primarily lesion-based, there is the potential for study participants with multiple lesions to
contribute disproportionately to estimates of test accuracy, especially if they are at particular risk of having skin cancer. We considered
studies that include a high number of lesions in relation to the number of study to be less representative than studies conducted in a
more general population participants (i.e. if the difference between the number of included lesions and number of included participants
is greater than 5%).
Index test domain (2)
Given the potential for subjective differences in test interpretation, the interpretation of the index test blinded to the result of the
reference standard is a key means of reducing bias. For prospective studies and retrospective studies that used the original index test
interpretation, the diagnosis will by nature be interpreted and recorded before the result of the reference standard is known; however,
studies using previously acquired images could be particularly susceptible to information bias. For these studies to be at low risk of bias,
we required a clear indication that observers were unaware of the reference standard diagnosis at time of test interpretation. An item
was also added to assess the presence of blinding between interpretations of different algorithms; however, this item was not included
in the overall assessment of risk of bias.
Pre-specification of the index test threshold was considered present if the study clearly reported that the threshold used was not data
driven, i.e. was not based on study results. We considered studies that did not clearly describe the threshold used but required clinicians
to record a diagnosis or management decision for a lesion to be unclear on this criterion. We deemed studies reporting accuracy
for multiple numeric thresholds, where ROC analysis was used to select the threshold, or that reported accuracy for the presence of
independently significant lesion characteristics with no separate test set of lesions to be at high risk of bias.
In terms of applicability of the index test to the review question, we required exfoliative cytology to be applied and interpreted as it
would be in a clinical practice setting.
• Sample obtained by dragging scalpel/curette across lesion, possibly after removal of crust.
• Material spread directly on to a slide and wet-fixed or air-dried.
• At least one slide stained with either Pap or MGG (Romanowsky) stain
Rapid staining methods were also acceptable; however, studies were considered to be of high concern for clinical applicability if
interpretation of cytology slides was made without access to the clinical referral information.
Despite the often subjective nature of test interpretation, it is also important for study authors to outline the particular lesion character-
istics that were considered to be indicative of skin cancer, particularly where established algorithms or checklists were not used. Studies
were considered of low concern if the threshold used was established in a prior study or sufficient threshold details were presented to
allow replication.
The experience of the examiner will also impact on the applicability of study results. We required studies to describe the test interpreter
as ’experienced’ or ’expert’ in exfoliative cytology to have low concern about applicability.
Reference standard domain (3)
In an ideal study, consecutively recruited participants should all undergo incisional or excisional biopsy of the skin lesion regardless of
level of clinical suspicion. In reality, both partial and differential verification bias are likely. Partial verification bias may occur where
histology is the only reference standard used, and only those participants with a certain degree of suspicion of malignancy based on
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the result of the index test undergo verification, the others either being excluded from the study or defined as being disease-negative
without further assessment or follow-up, as discussed above.
Differential verification bias will be present where other reference standards are used in addition to histological verification of suspicious
lesions. A typical example of verification bias in skin cancer occurs when investigators do not biopsy people with benign-appearing
lesions but instead follow them up for a period of time to determine whether any malignancy subsequently develops (these would be
false negatives on the index test). We defined an ’adequate’ reference standard as: all disease-positive individuals having a histological
reference standard either at the time of application of the index test or after a period of clinical follow-up; and at least 80% of disease-
negative participants have received a histological diagnosis, with up to 20% undergoing at least three months’ follow-up of benign-
appearing lesions.
A further challenge is the potential for incorporation bias, i.e. where the result of the index test is used to help determine the reference
standard diagnosis. It is normal practice for the clinical diagnosis (usually by visual inspection or dermoscopy) to be included on
pathology request forms and for the histopathologist to use this diagnosis to help with the pathology interpretation. Although inclusion
of such clinical information on the histopathology request form is theoretically a form of incorporation bias, blinded interpretation
of the histopathology reference standard is not normal practice, and enforcement of such conditions would significantly limit the
generalisability of the study results. For studies evaluating exfoliative cytology, this item was divided into two questions, firstly whether
the reference standard was blinded to the index test result (exfoliative cytology), and secondly whether it was blinded to the clinical
diagnosis. Only the response to the first part (i.e. blinding to exfoliative cytology) was included in our overall assessment of risk of bias
for the reference standard domain.
In judging the applicability of the reference standard to our review question, scored studies as high concern around applicability if
they used expert diagnosis (with no follow-up) as a reference standard in any patient, or did not report histology interpretation by a
dermatopathologist.
Flow and timing domain (4)
In the ideal study, the diagnosis based on the index test and reference standard should be made consecutively or as near to each other in
time as possible to avoid changes in lesion over time. For lesions with a histological reference standard, we have defined a one-month
period as an appropriate interval between application of the index test and the reference standard. For studies using clinical follow-up,
a minimum three-month follow-up period has been defined as at low risk of bias for detecting false negatives.
In assessing whether all patients were included in the analysis, we considered studies at high risk of bias if participants were excluded
following recruitment for any reason other than due to inadequate collection of cellular material for cytological analysis (’test failures’).
Comparative domain
Acomparative domainwas added to theQUADAS-2 checklist for studies comparing the accuracy of exfoliative cytology anddermoscopy.
Items were included to assess the presence blinding of interpretation between tests, and to specify a maximum of one month interval
between application of index tests, as intervals greater than these may be accompanied by changes in tumour characteristics. As it would
not be normal practice for exfoliative cytology to be interpreted blinded to the clinical or dermoscopic diagnosis, the scoring of this
item did not contribute to our overall assessment of risk of bias. We also considered whether both tests were applied and interpreted
in a clinically applicable manner.
The following tables use text that was originally published in the QUADAS-2 tool by Whiting and colleagues (Whiting 2011).
Item Response (delete as required)
PARTICIPANT SELECTION (1) RISK OF BIAS
1) Was a consecutive or random sample of participants or images
enrolled?
Yes - if paper states consecutive or random
No - if paper describes other method of sampling
Unclear - if participant sampling not described
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(Continued)
2) Was a case-control design avoided? Yes - if consecutive or random or case-control design clearly not
used
No - if study described as case-control or describes sampling spe-
cific numbers of participants with particular diagnoses
Unclear - if not described
3) Did the study avoid inappropriate exclusions, e.g.
• ’difficult to diagnose’ lesions not excluded
• lesions not excluded on basis of disagreement between
evaluators
Yes if inappropriate exclusions were avoided
No - if lesions were excluded that might affect test accuracy, e.
g. ’difficult to diagnose’ lesions, or where disagreement between
evaluators was observed
Unclear - if not clearly reported but there is suspicion that difficult
to diagnose lesions may have been excluded
4) For between-person comparative studies only (i.e. allocating
different tests to different study participants):
• A) were the same participant selection criteria used for
those allocated to each test?
• B) was the potential for biased allocation between tests
avoided through adequate generation of a randomised sequence?
• C) was the potential for biased allocation between tests
avoided through concealment of allocation prior to assignment?
For A)
• Yes - if same selection criteria were used for each index test,
• No - if different selection criteria were used for each index
test
• Unclear - if selection criteria per test were not described,
NA - if only 1 index test was evaluated or all participants
received all tests
For B)
• Yes - if adequate randomisation procedures are described
• No - if inadequate randomisation procedures are described
• Unclear - if the method of allocation to groups is not
described (a description of ’random’ or ’randomised’ is
insufficient), NA - if only 1 index test was evaluated or all
participants received all tests
For C)
• Yes - if appropriate methods of allocation concealment are
described
• No - if appropriate methods of allocation concealment are
not described,
• Unclear - if the method of allocation concealment is not
described (sufficient detail to allow a definite judgement is
required), NA - if only 1 index test was evaluated
Could the selection of participants have introduced bias?
For non-comparative and within person-comparative studies
1. If answers to all of questions 1), 2), and 3) ’Yes’
2. If answers to any 1 of questions 1), 2), or 3) ’No’
3. If answers to any 1 of questions 1), 2), or 3) ’Unclear’
For between-person comparative studies
1. If answers to all of questions 1), 2), 3), and 4) ’Yes’
2. If answers to any 1 of questions 1), 2), 3), or 4) ’No’
3. If answers to any 1 of questions 1), 2), 3), or 4) ’Unclear’
For non-comparative and within person-comparative studies
1. Risk is low
2. Risk is high
3. Risk unclear
For between-person comparative studies
1. Risk is low
2. Risk is high
3. Risk unclear
PARTICIPANT SELECTION (1) CONCERNS REGARDING APPLICABILITY
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(Continued)
1) Are the included participants and chosen study setting appro-
priate to answer the review question, i.e. are the study results gen-
eralisable?
• This item is not asking whether exclusion of certain
participant groups might bias the study’s results (as in ’Risk of
bias’ above), but is asking whether the chosen study participants
and setting are appropriate to answer our review question.
Because we are looking to establish test accuracy in both primary
presentation and referred participants, a study could be
appropriate for 1 setting and not for the other, or it could be
unclear as to whether the study can appropriately answer either
question
• For each study assessed, please consider whether it is more
relevant for A) participants with a primary presentation of a skin
lesion or B) referred participants, and respond to the questions
in either A) or B) accordingly. If the study gives insufficient
details, please respond Unclear to both parts of the question
A) For studies that will contribute to the analysis of partic-
ipants with a primary presentation of a skin lesion (i.e. test
naive)
Yes - if participants included in the study appear to be generally
representative of those who might present in a usual practice set-
ting
No - if study participants appear to be unrepresentative of usual
practice, e.g. in terms of severity of disease, demographic features,
presence of differential diagnosis or comorbidity, setting of the
study, and previous testing protocols
Unclear - if insufficient details are provided to determine the
generalisability of study participants
B) For studies that will contribute to the analysis of referred
participants (i.e. who have already undergone some form of
testing)
Yes - if study participants appear to be representative of those who
might be referred for further investigation. If the study focuses
only on those with equivocal lesions, for example, we would sug-
gest that this is not representative of the wider referred population
No - if study participants appear to be unrepresentative of usual
practice, e.g. if a particularly high proportion of participants have
been self-referred or referred for cosmetic reasons. Other factors
to consider include severity of disease, demographic features, pres-
ence of differential diagnosis or comorbidity, setting of the study,
and previous testing protocols
Unclear - if insufficient details are provided to determine the
generalisability of study participants
2) Did the study avoid including participants with multiple le-
sions?
Yes - if the difference between the number of included lesions and
number of included participants is less than 5%
No - if the difference between the number of included lesions and
number of included participants is greater than 5%
Unclear - if it is not possible to assess
Is there concern that the included participants do not match the
review question?
1. If the answer to question 1) or 2) ’Yes’
2. If the answer to question 1) or 2) ’No’
3. If the answer to question 1) or 2) ’Unclear’
1. Concern is low
2. Concern is high
3. Concern is unclear
INDEX TEST (2) RISK OF BIAS (to be completed per test evaluated)
1) Was the index test or testing strategy result interpreted without
knowledge of the results of the reference standard?
Yes - if index test described as interpreted without knowledge of
reference standard result or, for prospective studies, if index test is
always conducted and interpreted prior to the reference standard
No - if index test described as interpreted in knowledge of reference
standard result
Unclear - if index test blinding is not described
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(Continued)
2) Was the diagnostic threshold at which the test was considered
positive prespecified?
Yes - if threshold was prespecified (i.e. prior to analysing study
results)
No - if threshold was not prespecified
Unclear - if not possible to tell whether or not diagnostic threshold
was prespecified
3) For within-person comparisons of index tests or testing strate-
gies (i.e. > 1 index test applied per participant): was each index
test result interpreted without knowledge of the results of other
index tests or testing strategies?
Yes - if all index tests were described as interpreted without knowl-
edge of the results of the others
No - if the index tests were described as interpreted in the knowl-
edge of the results of the others
Unclear - if it is not possible to tell whether knowledge of other
index tests could have influenced test interpretation
NA - if only 1 index test was evaluated
Could the conduct or interpretation of the index test have intro-
duced bias?
For non-comparative and between-person comparison studies
1. If answers to questions 1) and 2) ’Yes’
2. If answers to either questions 1) or 2) ’No’
3. If answers to either questions 1) or 2) ’Unclear’
For within-person comparative studies
1. If answers to all questions 1), 2), for any index test and 3)
’Yes’
2. If answers to any 1 of questions 1) or 2) for any index test
or 3) ’No’
3. If answers to any 1 of questions 1) or 2) for any index test
or 3) ’Unclear’
For non-comparative and between-person comparison studies
1. Risk is low
2. Risk is high
3. Risk is unclear
For within-person comparative studies
1. Risk is low
2. Risk is high
3. Risk is unclear
INDEX TEST (2) CONCERN ABOUT APPLICABILITY
1) Was the test applied and interpreted in a clinically applicable
manner?
Yes - sample of cells was obtained by dragging a scalpel/curette
across the lesion, after removal of any crust, material was spread
directly onto a slide andwet-fixed or air-dried, at least one slidewas
stained using either Pap or MGG technique, or a rapid staining
method
No - not all of the above were carried out OR interpretation was
blinded to clinical diagnosis
Unclear - if insufficient information was reported
2) Were thresholds or criteria for diagnosis reported in sufficient
detail to allow replication?
Study results can only be reproduced if the diagnostic threshold is
described in sufficient detail. This item applies equally to studies
using pattern recognition and those using checklists or algorithms
to aid test interpretation
Yes - If the criteria for diagnosis were reported in sufficient detail
to allow replication
No - if the criteria for diagnosis were not reported in sufficient
detail to allow replication
Unclear - If some but not sufficient information on criteria for
diagnosis to allow replication were provided
3) Was the test interpretation carried out by an experienced ex-
aminer?
Yes - if the test was interpreted by 1 or more speciality-accredited
dermatologists, or by examiners of any clinical background with
special interest in dermatology and with any formal training in
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the use of the test
No - if the test was not interpreted by an experienced examiner
(see above)
Unclear - if the experience of the examiner(s) was not reported in
sufficient detail to judge or if examiners were described as ’Expert’
with no further detail given
NA - if system-based diagnosis, i.e. no observer interpretation
Is there concern that the index test, its conduct, or interpretation
differ from the review question?
1. If answers to questions 1), 2), and 3) ’Yes’
2. If answers to questions 1), 2), or 3) ’No’
3. If answers to questions 1), 2), or 3) ’Unclear’
1. Concern is low
2. Concern is high
3. Concern is unclear
REFERENCE STANDARD (3) RISK OF BIAS
1) Is the reference standard likely to correctly classify the target
condition?
A) Disease-positive - 1 or more of the following:
• histological confirmation of malignancy following biopsy
or lesion excision
• clinical follow-up of benign-appearing lesions for at least 3
months following the application of the index test, leading to a
histological diagnosis of skin cancer
B) Disease-negative - 1 or more of the following:
• histological confirmation of absence of malignancy
following biopsy or lesion excision in at least 80% of disease-
negative participants
• clinical follow-up of benign-appearing lesions for a
minimum of 3 months following the index test in up to 20% of
disease-negative participants
A) Disease-positive
Yes - if all participants with a final diagnosis of malignancy un-
derwent 1 of the listed reference standards
No - If a final diagnosis of malignancy for any participant was
reached without histopathology
Unclear - if themethod of final diagnosis was not reported for any
participant with a final diagnosis of malignancy or if the length
of clinical follow-up used was not clear or if a clinical follow-up
reference standard was reported in combination with a partici-
pant-based analysis and it was not possible to determine whether
the detection of a malignant lesion during follow-up is the same
lesion that originally tested negative on the index test
B) Disease-negative
Yes - If at least 80% of benign diagnoses were reached by histology
and up to 20% were reached by clinical follow-up for a minimum
of 3 months following the index test
No - ifmore than20%of benigndiagnoseswere reachedby clinical
follow-up for a minimum of 3 months following the index test or
if clinical follow-up period was less than 3 months
Unclear - if the method of final diagnosis was not reported for
any participant with benign or non-melanoma diagnosis
2) Were the reference standard results interpreted without knowl-
edge of the results of the index test?
Please score this item for all studies even though histopathology
interpretation is usually conducted with knowledge of the clinical
diagnosis (from visual inspection or dermoscopy or both).We will
deal with this by not including the response to this item in the
’Risk of bias’ assessment for these tests. For reviews of all other
tests, this item will be retained
Yes - if the reference standard diagnosis was reached blinded to
the index test result
No - if the reference standard diagnosis was reached with knowl-
edge of the index test result
Unclear - if blinded reference test interpretation was not clearly
reported
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Could the reference standard, its conduct, or its interpretation
have introduced bias?
For visual inspection/dermoscopy evaluations
1. If answer to question 1) ’Yes’
2. If answer to question 1) ’No’
3. If answer to question 1) ’Unclear’
For all other tests
1. If answers to questions 1) and 2) ’Yes’
2. If answers to questions 1) or 2) ’No’
3. If answers to questions 1) or 2) ’Unclear’
For visual inspection/dermoscopy evaluations
1. Risk is low
2. Risk is high
3. Risk is unclear
For all other tests
1. Risk is low
2. Risk is high
3. Risk is unclear
REFERENCE STANDARD (3) CONCERN ABOUT APPLICABILITY
1) Expert opinion (with no histological confirmation) was not
used as a reference standard
’Expert opinion’ means diagnosis based on the standard clinical
examination, with no histology or lesion follow-up
Yes - if expert opinion was not used as a reference standard for
any participant
No - if expert opinion was used as a reference standard for any
participant
Unclear - if not clearly reported
2) Was histology interpretation carried out by an experienced
histopathologist or by a dermatopathologist?
Yes - if histology interpretation was reported to be carried out by
an experienced histopathologist or dermatopathologist
No - if histology interpretation was reported to be carried out by
a less experienced histopathologist
Unclear - if the experience/qualifications of the pathologist were
not reported
Is there concern that the target condition as defined by the refer-
ence standard does not match the review question?
1. If answers to both questions 1), 2), ’Yes’:
2. If answers to any 1 of questions 1), 2), ’No’:
3. If answers to any 1 of questions 1), 2), ’Unclear’:
1. Concern is low
2. Concern is high
3. Concern is unclear
FLOW AND TIMING (4): RISK OF BIAS
1) Was there an appropriate interval between index test and ref-
erence standard?
A) For histopathological reference standard, was the interval be-
tween index test and reference standard ≤ 1 month?
B) If the reference standard includes clinical follow-up of border-
line/benign-appearing lesions, was there at least 3 months’ follow-
up following application of index test(s)?
A)
Yes - if study reports ≤ 1 month between index and reference
standard
No - if study reports > 1 month between index and reference
standard
Unclear - if study does not report interval between index and
reference standard
B)
Yes - if study reports ≥ 3 months’ follow-up
No - if study reports < 3 months’ follow-up
Unclear - if study does not report the length of clinical follow-up
2) Did all participants receive the same reference standard? Yes - if all participants underwent the same reference standard
No - if more than 1 reference standard was used
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Unclear - if not clearly reported
3) Were all participants included in the analysis? Yes - if all participants were included in the analysis
No - if some participants were excluded from the analysis
Unclear- if not clearly reported
4) For within-person comparisons of index tests
Was the interval between application of index tests ≤ 1 month?
Yes - if study reports ≤ 1 month between index tests
No - if study reports > 1 month between index tests
Unclear - if study does not report the interval between index tests
Could the participant flow have introduced bias?
For non-comparative and between-person comparison studies
1. If answers to questions 1), 2), and 3) ’Yes’
2. If answers to any 1 of questions 1), 2), or 3) ’No’
3. If answers to any 1 of questions 1), 2), or 3) ’Unclear’
For within-person comparative studies
1. If answers to all questions 1), 2), 3), and 4) ’Yes’
2. If answers to any 1 of questions 1), 2), 3), or 4) ’No’
3. If answers to any 1 of questions 1), 2), 3), or 4) ’Unclear’
For non-comparative and between-person comparison studies
1. Risk is low
2. Risk is high
3. Risk is unclear
For within-person comparative studies
1. Risk is low
2. Risk is high
3. Risk is unclear
BCC: basal cell carcinoma; cSCC: cutaneous squamous cell carcinoma
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Inclu-
sion cri-
teria
Exclu-
sions
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tients (le-
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Lesion
site
Stain
tech-
nique
Cy-
topatho-
logical
criteria
Uncer-
tain
cytolog-
ical diag-
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qualifi-
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(n)
Test ex-
perience
Test fail-
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Refer-
ence
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Final di-
agnosis
Berner
1999
BCC
Any
NC
P-CS
Norway
Lesions
clin-
ically sus-
pected of
being
nodular
BBCs, lo-
cated on
the head,
thorax or
abdomen
Ex-
cluded:
90 (107) Head,
face, tho-
rax,
abdomen
(%s NR)
Diff-
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Presence
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dissoci-
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The cells
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ogy alone
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Thick-
ness < 2
mm, in-
ade-
quate cel-
lular ma-
terial
for cyto-
logical or
histolog-
ical evalu-
ation
indistinct
cell
borders
and the
cohesive
sheets
often
demon-
strate pal-
isading
Brown
1979
BCC
Any
NC
NR-CS
UK
Localised
lesions
for which
a histo-
logical di-
agno-
sis was re-
quired to
con-
firm clini-
cal di-
agnosis of
BCC, or
in a mi-
nority to
exclude
BCC
Exclu-
sions not
reported
81 (85) NR MGG or
rapid
stain with
aque-
ous tolui-
dine blue
BCC:
tumour
cells
occur
dispersed
and in
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clusters
and large
clusters
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lobulated
outline;
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size and
shape,
having
very little
cyto-
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an oval
nucleus
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outline,
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evenly
dis-
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dotted
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0 NR (n =
NR)
NR
0 Histology
(biopsy)
plus other
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(expert
opinion,
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2; MM 1;
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4
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matin,
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with one
or two
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distinct
nucleoli;
The squa-
mous
tumour
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in size to
prickle
layer
cells and
typically
are uni-
form in
size and
occur as
irregular
clusters
or as
small
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distinct
from the
squa-
mous
cells of
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dermis;
most
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uniform
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and
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ical detail
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very large
or
very small
forms.
cSCC:
cells are
larger
though
more
varied in
size and
outline;
nuclear
chro-
matin
shows
irregular
clump-
ing,
nucleoli
are often
very con-
spicuous,
while
some
heavily
kera-
tinised
cells
retain a
densely
staining,
pyknotic
nucleus
Chris-
tensen
2008
BCC
NC
CCS
Norway
Histolog-
i-
cally con-
firmed
BCC
or AK le-
sions
Ex-
cluded:
other di-
agnoses
64 (78) H/N (56,
72%),
trunk
(15,
19%), ex-
tremities
(7, 9%)
3
slides per
lesion:
Pap
MGG
Touch
Imprint
(not eval)
Frag-
ments of
closely
packed
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layers
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like for-
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0 Patholo-
gist (n=2)
“Exten-
sive expe-
rience in
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but no
specific
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in skin
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Pap - 1
MGG - 3
Histology
(punch
biopsy)
BCC 50
AK 28
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smooth
external
contours
and pe-
ripheral
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nuclei.
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dissoci-
ation of
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lignant
basal
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perchro-
matic nu-
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nucleus
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AK
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shaped
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nucleus
to cyto-
plasmic
ratio
Derrick
1994
BCC
NC
NR-CS
UK
Lesion on
the head
or
neck clin-
ically sus-
pected of
being
BCC
Ex-
cluded:
lesions on
the trunk
or ex-
tremities
240 (240) H/N (%
NR)
MGG Presence
of tight
groups of
uniform
small
cells;
pink
amor-
phous
material
in MGG-
stained
prepa-
rations.
Squa-
mous cell
lesions
showed
less
cellular
adhesion,
much
more
nuclear
pleomor-
phism
and no
pink
material
0 Consul-
tant
patholo-
gist (NR)
NR
0 Histology
(punch
biopsy +
excision
when
cytology
and
histopathol-
ogy dis-
cordant,
n = 4)
BCC 229
cSCC 4;
AC 1; AK
1; BD 1;
trichoep-
ithelioma
1; No ab-
normality
3
Gordon
1984
BCC
cSCC
Any
NC
P-CS
Australia
Cuta-
neous
neoplasm
requiring
diagnos-
tic biopsy
or defini-
tive exci-
sion at a
112 (150) NR Pap BCC
charac-
teristics:
cohesive
epithelial
frag-
ments
com-
posed of
10
4 BCC
4 m-
atypia
2 SK
Cytolo-
gist (1)
NR
9
1 BCC
1 cSCC
7 benign
Histology
(biopsy or
excision)
BCC 78
cSCC
6;marked
squa-
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routine
clinic.
Exclu-
sions:
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malig-
nant
melanomas
or lesions
that
were ’too
small’
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both
cytologic
and
histopatho-
logic as-
sessment
tightly
packed
small
cells with
uniform,
oval, dark
nuclei.
The
nuclear
chro-
matin is
dense,
but gran-
ular and
evenly
dis-
tributed;
nucleoli
are small
and in-
distinct.
Cyto-
plasm is
scanty
and
cyanophilic.
Usually,
some
frag-
ments
show the
marginal
pal-
isading
arrange-
ment of
tumor
cells
familiar
to the
histopathol-
ogist.
Squa-
mous
differen-
mous
atypia
4; AK 53;
SK 9
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within
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(keratotic
BCC and
metatyp-
ical
epithe-
lioma)
. When
this is
promi-
nent and
associ-
ated with
nuclear
enlarge-
ment and
pleomor-
phism,
the cy-
tologic
differen-
tiation
between
cSCC
and pleo-
morphic
BCC is
difficult
or im-
possible.
Strong
cohesive-
ness, uni-
formly
high
nuclear/
cyto-
plasmic
ratio, and
evenly
dis-
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tributed
nuclear
chro-
matin
favor a
diagnosis
of pleo-
morphic
BCC
Powell
2000
BCC
NC
R-CS
UK
All cytol-
ogy
smears
taken
over a 9-
month
period
Ex-
cluded:
no histo-
logical
specimen
available
30 (37) NR NR Not
described
0 NR (NR)
NR
0 Histol-
ogy (type
NR)
Ruocco
1992
NC
R-CS
Italy
Patients
with a
suspected
clinical
di-
agnosis of
BCC, for
whom cy-
tology
and
histology
test
results
available.
Exclu-
sions: in-
sufficient
material
for his-
tology or
cytology
diagnosis,
patient
NR (578) NR MGG
and Pap
or pure
Giemsa
Charac-
teristics
sugges-
tive of
BCC:
basaloid
cells ar-
ranged in
groups,
clumped
in the
centre
and at
times
arranged
as ’fences/
palisades’
around
the pe-
riphery
(as found
in histo-
logical
0 NR (NR)
NR
Ex-
cluded at
study en-
try
Histol-
ogy (exci-
sion or
biospy)
BCC 498
cSCC 4;
5
other ma-
lignant: 3
cuta-
neous
metas-
tasis from
vis-
ceral ma-
lignancy,
2 Merkel
cell carci-
noma
Benign
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under-
going
treatment
(diather-
mal coag-
ulation,
cryother-
apy, ra-
diother-
apy, local
chemo-
therapy
with 5-
fluo-
rouracil
or inter-
feron a-
2b) or
treated
elsewhere
speci-
mens),
slightly
increased
com-
pared to
normal
epider-
mal basal
ker-
atinocytes,
but in a
single di-
mension,
with an
elongated
shape,
oval
nucleus,
intensely
ba-
sophilic,
occupy-
ing 4/5 of
the entire
cell with
weak/
thin cy-
toplasm,
some-
times
contain-
ing coarse
melanin
granules
diag-
noses:
11 SK; 4
LED, 3
trichoep-
ithe-
lioma, 2
syringo-
cystade-
noma
papil-
liferum,
19 AK,
8 senile
sebaceous
hyper-
plasia, 6
Bowen’s
disease,
4 kera-
toacan-
thoma,
3 mol-
luscum
contagio-
sum, 3
psoriasis,
2 lichen
planus, 2
localised
sclero-
derma, 1
sebaceous
adenoma,
1 cylin-
droma,
1 pilo-
matri-
coma, 1
nevocytic
nevus
Durdu
2011
BCC
MM
alone
Any
WPC
P-CS
Turkey
Pig-
mented
skin le-
sions that
could
not be di-
agnosed
176 (200) NR MGG Cytologic
diagnoses
were
made ac-
cording
to
findings
0 Derma-
tol-
ogist (n =
1) single
observer
15 Histol-
ogy (exci-
sion-166,
or punch
biopsy-
34)
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with only
dermato-
logic
physi-
cal exami-
nation
No exclu-
sions re-
ported
reported
previ-
ously:
Pig-
mented
BCC:
clusters of
basaloid
cells con-
taining
pigment
granules.
Melanoma:
epithe-
lioid or
spindle-
type
atypical
nevoid
cells.
Pig-
mented
mam-
mary
Paget’s
disease:
clusters of
round to
ovoid
Paget
cells
Metastatic
carci-
noma:
atypical
(non-ker-
atinocytic
and non-
nevoid)
cells
Melanocytic
naevi:
BCC 34
Melanoma
10;
2 other
malig-
nant:
1 pig-
mented
mam-
mary
Paget’s
disease;
1 pig-
mented
metastatic
mam-
mary car-
cinoma;
SK 24;
benign
melanocytic
nevus
100;
other
benign
non-
melanocytic
lesions 30
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epider-
mal and
dermal-
type
nevoid
cells.
Sebor-
rhoeic
keratosis:
horny
cysts, pig-
mented
ker-
atinocytes.
Warts:
koilo-
cytes
Der-
matofi-
broma:
spindle-
shaped fi-
broblasts
with col-
lagenised
stroma
Nauth
1988
BCC
cSCC
Any
NC
CCS
Germany
NR
No exclu-
sions re-
ported
224 (224) NR Pap (A) Or-
thoker-
atosis cell:
small, ho-
moge-
neous of
polygonal
shape
(B)
Paraker-
atosis cell:
nuclear
polygonal
horn cell,
about
twice as
large as an
orthoker-
atosis cell
(C)
Slightly
13
BCC and
18 cSCC
classified
as anapla-
sia
NR (NR)
NR
18 Histology
(punch
biospy, n-
210) or
other
(NR-14
lesions
with in-
flamma-
tory con-
ditions)
BCC: 42
cSCC:
38; severe
dys-
plasia 34;
marked
dyspla-
sia 31; in-
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dyskera-
totic cell:
slightly
poly-
morphic
nucleated
horn cell,
about
three
times the
size of an
orthok-
eratosis
cell with
a cell
nucleus
of about
twice the
size of a
parak-
eratosis
cell.
Slightly
elevated
nuclear
plasma
ratio
(D)
Massively
dysker-
atotic
cell: poly-
morphic
nucleated
horny
cell,
some-
what
smaller
than a
paraker-
atosis cell
with a
nucleus
three
flamma-
tion 28;
be-
nign (not
reported)
51
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times the
size of a
paraker-
atose cell.
Signif-
icantly
increased
core-
plasma
ratio.
(E)
Severely
dyskera-
totic cell:
highly
poly-
morphic
horny
cell,
approx.
as large
as an
orthok-
eratose
cell, with
a cell
nucleus
approx-
imately
the same
size as
a mod-
erately
dysker-
atotic
cell. As
a result,
only
slightly
or not
increased
core
plasma
ratio
(F)
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Anaplas-
tic tumor
cells:
small
degraded,
mostly
ba-
sophilic
or chro-
mopho-
bic cell
with
roundish
plasma
and a
large
round
nucleus
that
has an
atypical
chro-
matin
structure
and often
a promi-
nent
nucleolus
AC: apocrine carcinoma; AK: actinic keratosis; BCC: basal cell carcinoma; ?BCC: possible basal cell carcinoma; BD: Bowen’s disease;
CCS: case-control study; cSCC: cutnaeous squamous cell carcinoma; H/N: head and neck; LED: disease type, acronym not provided
by study; m-atypia: marked squamous atypia; MGG: May-Grünwald Giemsa stain technique; MM: invasive melanoma and atypical
intraepidermal melanocytic variants;NC: non-comparative study design; NR: not reported;NR-CS: case series data collection method
not reported; NS: not specified; Pap: Papanicolaou stain technique; P-CS: prospective case series; R-CS: restrospective case series; SK:
seborrhoeic keratosis; WPC: within-person comparison study design.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Reviews on the accuracy of gene expression testing and volatile organic compounds could not be performed as planned due to an
absence of relevant studies.
We changed the primary target condition and primary objective from the detection of BCC and cSCC (as per our generic protocol
for the detection of keratinocyte skin cancer (Dinnes 2015b) to the detection of BCC, since exfoliative cytology has a clearer potential
role for this condition.
We added secondary target conditions, including cSCC, and cutaneous invasive melanoma and atypical intraepidermal melanocytic
variants (from our generic protocol for the detection of melanoma (Dinnes 2015a)).
We have tailored secondary objectives to the individual test, with two objectives added for each primary and secondary target condition:
to compare the accuracy of exfoliative cytology to dermoscopy where both tests have been evaluated in the same studies; and to determine
the effect of observer experience. Sources of heterogeneity that could be investigated were restricted due to lack of data.
We amended the text to clarify that studies available only as conference abstracts would be excluded from the review unless full
papers could be identified; studies available only as conference abstracts do not allow a comprehensive assessment of study methods or
methodological quality.
We proposed to supplement the database searches by searching the annual meetings of appropriate organisations (e.g. British Association
of Dermatologists Annual Meeting, American Academy of Dermatology Annual Meeting, European Academy of Dermatology and
Venereology Meeting, Society for Melanoma Research Congress, World Congress of Dermatology, European Association of Dermato
Oncology); however, due to the volume of evidence retrieved from database searches and time restrictions, we were unable to do this.
For quality assessment, we further tailored the QUADAS-2 tool according to the review topic. In terms of analysis, we did not restrict
analysis to per patient data due to lack of data. For the same reason, we did not perform the planned sensitivity analyses.
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